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HHV-8 seropositivity was associated with prevalent prostate cancer among African-Caribbean 
Tobago men (Odds ratio [O.R.] = 2.24; 95% confidence interval [C.I.], 1.29-3.90). To understand this 
association, HHV-8 seropositivity among African-Caribbean Tobago women, modes of HHV-8 sexual 
transmission, the natural history of HHV-8 seropositivity, and the relationship between HHV-8 and 
incident prostate cancer were examined.   
A cross-sectional study was conducted in 213 Tobago women, ages 18-65 years. Age-specific 
rates were compared to those previously observed in men. Logistic regression analyses were performed to 
determine the association between HHV-8 seropositivity and sexual behaviors among women. A 9-year 
prospective cohort study was conducted among 407 Tobago men at risk for incident prostate cancer, ages 
40-81 years. HHV-8 seroconversion and seroreversion rates and their 95% C.I. were calculated using a 
Poisson distribution. A case-cohort study was conducted among 90 and 407 Tobago men, ages 40-81 
years, with incident prostate cancer and at risk for incident prostate cancer, respectively. Cox proportional 
hazards modeling for case-cohort design was used to examine the association between baseline HHV-8 
seropositivity and incident prostate cancer. All serum/plasma were tested for HHV-8 seropositivity by 
immunofluorescence assay.  
Among women, HHV-8 seroprevalence was 14.1%, with no difference with men of similar age 
(p-value = .741).  There was a significant but minimal association between HHV-8 seropositivity and age 
< 17 years at first sexual intercourse among women (O.R. = 2.51, 95% C.I. = 1.09-5.78). Among men at 
risk for incident prostate cancer, HHV-8 seroconversion and seroreversion rates were 0.5 (95% C.I., 0.22-
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0.99) and 2.52 (95% C.I., 1.09-4.96) per 100 person-years, respectively. There were inverse associations 
between baseline HHV-8 seropositivity and screen-detected incident prostate cancer when age and 
baseline prostate cancer screening results (Hazard ratio [H.R.] = 0.454, 95% C.I., 0.221 – 0.933) and age 
(H.R. = 0.517, 95% C.I., 0.262 – 1.020) were considered. 
Sexual activity may not be the predominant mode of HHV-8 transmission among women. HHV-8 
is probably acquired at younger ages, < 40 years among men. HHV-8 seropositivity may not be related to 
prostate cancer incidence. The public health significance of these studies is to reduce HHV-8 infection 
and prostate cancer in Tobago.  
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1.0  INTRODUCTION/SPECIFIC AIMS 
Human herpesvirus 8 (HHV-8) is the causal agent of the vascular tumor Kaposi’s sarcoma (KS) 
and primary effusion lymphoma and has been associated with multicentric Castleman’s disease1. The 
seroprevalence of HHV-8 infection varies geographically and is considered endemic in African and 
Mediterranean countries where KS is relatively common. African countries have the highest overall 
HHV-8 seroprevalence and KS incidence, followed by Mediterranean countries2-7. North America, 
Northern Europe, and Asia have the lowest HHV-8 seroprevalence with little to no KS8. For the 
Caribbean island of Tobago, a high seroprevalence of HHV-8 infection was detected in prostate cancer 
free African-Caribbean men, > 
In HHV-8 endemic populations, sexual and non-sexual transmission have been shown to be 
modes of transmitting this virus. In hyper-endemic KS areas like Sub-Saharan Africa, non-sexual 
exchange (for example, saliva exchange) has been shown to be the predominant mode of HHV-8 
tranmission12. In Tobago, the predominate mode of HHV-8 transmission is unknown, as well as the 
seroprevalence in Tobago women is unknown. The knowledge of women seroprevalence at various ages 
may shed light on the route of transmission of the virus in Tobago. We propose to conduct a cross-
sectional study in 213 Tobago women, 18-65 years of age, in order to examine HHV-8 seropositivity rates 
40 years of age (22.9%), and this value was even higher when men with 
prostate cancer were considered (39.9%)9. The reasons behind these high rates of HHV-8 infection 
observed in Tobago men, particularly men with prostate cancer, are not known, considering that this 
country reports a low to no incidence of known HHV-8 malignancies such as KS10, 11. The study of the 
epidemiology of HHV-8 infections may help explain the high prevalence of prostate cancer (15% of men 
aged 50-79) observed in this Tobago population, as well the etiologic mechanisms. 
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in this population. We hypothesize that age-specific HHV-8 seropositivity rates will be similar to Tobago 
men’s rates due to similar environmental exposures. We want to explore in this study population whether 
certain sexual practices are associated with increased risk for acquiring this herpes virus. We hypothesize 
that HHV-8 seropositivity rates will be higher in women who have many sexual partners, have been 
previous diagnosed with a sexually transmitted disease, sexually active at a younger age, participate in 
oral sex activities, and use no barrier methods for protection during sexual activity. HHV-8 infection by 
sero-status will be determined by a modified serological assay HHV-8 monoclonal antibody-enhanced 
immunofluorescence assay (IFA)13 which has been reported to have a sensitivity of 89.9% and specificity 
of 97.5% in comparison to other serological assays based on a latent-class analysis14. Sexual activity was 
ascertained from The Centers for Disease Control and Prevention’s Sexual Lifestyle Questionnaire that 
was administered to study participants in a private setting. 
In order to better understand possible relationships between HHV-8 and prostate cancer, the 
natural of history of HHV-8 infection should be investigated. Therefore, we propose to conduct a 9-year 
prospective cohort study that examines patterns of change in HHV-8 sero-status (seroconversion and 
seroreversion) and the frequency of persistent HHV-8 seropositivity among 501 Tobago men, ages 40-81 
years, at risk for incident prostate cancer. We hypothesize low seroconversion rates, ~ 3%, due to low 
HHV-8 exposure after the age of 40; and, we hypothesize even lower seroreversion rates, ~ 1%, due to 
the virus’ life-long infection. HHV-8 seroconversion is defined as HHV-8 seronegative at baseline visit to 
HHV-8 seropositive at subsequent visits. HHV-8 seroreversion is defined as HHV-8 seropositive at 
baseline visit to HHV-8 seronegative at subsequent visits. HHV-8 seropositivity will be determined by the 
modified IFA described in the previous paragraph. The examination of HHV-8 seroconversion, 
seroreversion, persistent seropositivity rates in men at risk for incident prostate cancer will provide 
knowledge of the pattern of HHV-8 infection in the Tobago population. 
In HHV-8 infected individuals, HHV-8 may contribute to the inflammatory process in the 
prostate. This virus has been shown to infect prostatic epithelial cells15. The expression of HHV-8 
proteins (LANA-1, vIL-6, and K8.1), as well as evidence of local inflammation (macrophage/monocyte 
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marker and B-cell marker), have been found in the prostate16. Because of its presence in the prostate, 
HHV-8 may contribute to prostate cancer through chronic inflammation, a persistent inflammatory 
response to the virus. Therefore, it is important to examine whether HHV-8 seropositivity is associated 
with prostate cancer risk, especially in a population where 11% prostate cancer prevalence was detected at 
initial screening17. We propose to conduct a case-cohort study among 501 men at risk for incident prostate 
cancer (sub-cohort, the controls) and 116 screen-detected incident prostate cancer men (the cases) in order 
to determine whether baseline HHV-8 seropositivity is associated with incident prostate cancer. Based on 
Hoffman et al. study results, we hypothesize screen-detected incident prostate cancer cases are 2-fold 
more likely to be HHV-8 seropositive at baseline visit than men at risk for incident prostate cancer (the 
sub-cohort). Examining possible relationships between HHV-8 seropositivity and incident prostate cancer 
will provide information on whether HHV-8 infection plays a role in the progression of prostate cancer.   
In conclusion, examining HHV-8 seropositivity among Tobago women, identifying possible 
modes of sexual transmission of HHV-8, studying the natural history of HHV-8 seropositivity, and 
investigating the relationship between HHV-8 and incident prostate cancer will allow us to evaluate 
HHV-8 infection and its possible relationship with prostate cancer in Tobago. These aims will help us to 
determine whether further studies are needed in examining relationships among HHV-8 infection, 
inflammation, and prostate cancer. 
 
Specific Aims 
Aim 1 (Paper 1): To examine HHV-8 infections among African-Caribbean women living in 
Tobago 
From a Tobago Cervical and Oral Cancer Screening Study, specimens were collected 
from 213 healthy African-Caribbean Tobago women 18 to 65 years old. We propose to conduct a 
cross-sectional study that will examine the following items: 
a) To examine age-specific rates of HHV-8 seroprevalence in Tobago women 18-65 years of 
age. 
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- Hypothesis: We hypothesize that HHV-8 seropositivity will increase with age due to 
cumulative exposure to sexual practices and possibly other environmental factors.   
b) To compare age-specific HHV-8 seroprevalence rates in African-Caribbean Tobago women 
with rates in African-Caribbean Tobago men, aged 40-65 years. 
- Hypothesis: We hypothesize that HHV-8 seroprevalence will be similar in older men and 
women due to similar environmental exposure (for example, childhood exposure).  
c) To determine if HHV-8 seropositivity in African-Caribbean Tobago women is associated 
with sexual behavior. 
- Hypothesis: We hypothesize that seropositivity will be higher in women who have many 
sexual partners, have been previous diagnosed with a sexually transmitted disease, 
sexually active at a younger age, participate in oral sex activities, and use no barrier 
methods for protection during sexual activity than women who do not participate in these 
activities.  
 
Aim 2 (Paper 2): To measure the incidence of HHV-8 seroconversion and seroreversion, 
and to examine persistent HHV-8 seropositivity in African-Caribbean men at risk for incident 
prostate cancer in Tobago. 
From the Tobago Prostate Cancer Screening Survey of African-Caribbean Tobago men, 
aged 40-81 years, we propose to conduct a prospective cohort study among 501 men at risk for 
incident prostate cancer in order to examine the following items:  
a) To measure the incidence of HHV-8 seroconversion in seronegative men at baseline visit to 
subsequent visits (wave 2 visit or wave 3 visit). 
- Hypothesis: We hypothesize low seroconversion rate, 3%, due to low HHV-8 exposure 
after the age of 40. 
b) To measure the incidence of HHV-8 seroreversion in seropositive men at baseline visit to 
subsequent visits (wave 2 visit or wave 3 visit). 
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- Hypothesis: We hypothesize low seroreversion rate, 1%, due to the virus’ life-long 
infection. 
c) To measure the rate of persistent HHV-8 seropositivity in men from baseline visit to 
subsequent visits (wave 2 visit and/or wave 3 visit). 
- Hypothesis: We hypothesize high persistent seropositivity rate due to the virus’ lifelong 
infection. 
 
Aim 3 (Paper 3): To examine baseline HHV-8 seropositivity in screen-detected incident 
prostate cancer men (cases) in comparison to men at risk for incident prostate cancer (sub-cohort, 
the controls) in Tobago. 
From the Tobago Prostate Cancer Screening Survey of African-Caribbean Tobago men, 
aged 40-81 years, we propose to conduct a case-cohort study in 116 screen-detected incident 
prostate cancer cases in comparison to 501 men at risk for incident prostate cancer to examine the 
following: 
a) To test the association between baseline HHV8 seropositivity and incident prostate cancer in 
men from Tobago  
- Hypothesis: We hypothesize prostate cancer incident cases are 2 times more likely to be 
HHV-8 seropositive at the baseline visit than men at risk for incident prostate cancer. 
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2.0  BACKGROUND 
 
2.1 HERPESVIRIDAE 
The family Herpesviridae consists of viruses that affect humans and animals such as primates, 
various mammals, bony fishes, and invertebrates. Herpesviridae has three subfamilies of common 
ancestry that are grouped on biological properties: Alphaherpesvirinae, Betaherpesvirinae, and 
Gammaherpesvirinae (see Table 1). The subfamily Alphaherpesvirinae affects a wide range of hosts, has 
a short reproductive cycle, destroys infected cells efficiently, spreads rapidly in culture, and can establish 
latent infection in the sensory ganglia18. The alphaherpesviruses that affect humans include herpes 
simplex virus 1 (e.g., oral cold sores), herpes simplex virus 2 (e.g., genital herpes), and varicella-zoster 
viruses (e.g., chicken pox and shingles).  
The subfamily Betaherpesvirinae, affects a restricted range of hosts, has a long reproductive 
cycle, grows slowly in culture, and can establish latent infection in secretory gland, lymphoreticular cells, 
kidneys, and other tissues18. The betaherpesviruses that affect humans are cytomegalovirus and human 
herpesviruses 6 (e.g., exanthema subitum) and human herpesvirus 7.   
The subfamily Gammaherpesvirinae infection occurs primarily in T and B lymphocytes and to a 
lesser extent in epithelial and endothelial cells. Latency is usually established in lymphoid tissue18. The 
gammaherpesviruses that affect humans are divided into the genera Lymphocryptovirus (Epstein Barr 
virus) and Rhadinovirus (human herpesvirus 8, also known as Kaposi’s sarcoma associated herpesvirus). 
HHV-8 has commonly been compared to Epstein-Barr virus (EBV) because they both cause 
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lymphoproliferative diseases and tumors1, 19-22 as well as have similar tropism for B cells, endothelial 
cells, macrophages, and keratinocytes23-25. However, HHV-8’s homology is closest to the 
gammaherpesvirus, herpesvirus saimiri, a virus that affects squirrel monkeys8, 26. 
Table 1. Family Herpesviridae's Human Associated Diseases 
Alphaherpesvirinae 
Herpes simplex 1 
(HSV-1) 
Orolabial infections, gingivostomatitis, encephalitis 
Herpes simplex 2 
(HSV-2) 
Genital infections, encephalitis 
Varicella-zoster 
(HHV-3) 
Chicken pox & Shingles 
Betaherpesvirinae 
Human Herpesvirus 5 
(HHV-5) 
Cytomegalovirus infection  
Human Herpesvirus 6 
(HHV-6A & 6B) 
Exanthema subitum 
Human Herpesvirus 7 
(HHV-7) 
Sub-clinical infection; occasionally exanthema 
subitum & febrile convulsions 
Gammaherpesvirinae 
Epstein-Barr virus 
(HHV-4) 
Mononucleosis,  Hodgkin’s lymphoma, 
nasopharyngeal carcinoma, Burkitt’s lymphoma, 
gastric carcinoma, T & natural killer (NK) lymphoma, 
and Leiomyosarcoma 
Human Herpesvirus 8 
(HHV-8) 
Kaposi’s sarcoma (KS), primary effusion lymphoma 
(PEL), and multicentric Castleman’s disease (MCD) 
 
2.1.1 Seroprevalence of Human Herpes Viruses 
The seroprevalence of common human herpes viruses and herpes-associated diseases varies 
geographically (Table 2). In the U.S., the alphaherpesviruses human herpes simplex 1 and 2 (HSV-1 and -
2) have a seroprevalence of 80% in individuals < 40 years of age and 21.9% in adults, respectively 
(NHANES II & III)27. In some northern European, Mediterranean, Caribbean, African, and Asian 
countries, HSV-1 seroprevalence has been reported to be over 95% in the population27. As for the 
varicella-zoster virus, a 4 million yearly incidence of the chicken pox infection has been reported in the 
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U.S.; however, this incidence has recently declined due to the introduction of the varicella vaccine in 
199527.  
With the betaherpesviruses, cytomegalovirus has a U.S. seroprevalence of 58.9% compared to 
Mediterranean, Asian, and South American countries’ seroprevalence ranging from 77% to 99% in the 
population27. As for the gammaherpesviruses, HHV-8 has been reported to have a seroprevalence ranging 
from 3% to 5.2% in U.S. healthy individuals4, 14 in comparison to Mediterranean and African countries 
having a significantly higher seroprevalence, ranging from 11.5% in West Sicily, Italy to 87% in 
Botswana, Africa2-7. Epstein Barr virus has a seroprevalence of 90% worldwide.  
Table 2. Human Herpes Viruses Seroprevalence in General Population 
 U.S. Seroprevalence 
(overall) 
Non-U.S. 
Seroprevalence 
Herpes simplex 1 (HSV-1) 80% > 95% 
Herpes simplex 2 (HSV-2) 21.9%  
Varicella-zoster (HHV-3) ~80%  
Human Herpesvirus 5 (HHV-5) 58.9% 52% - 99% (Grenoble, France – 
Ankara, Turkey) 
Epstein-Barr virus (HHV-4) 90.0% 90% 
Human Herpesvirus 8 (HHV-8) 3.0% - 5.2% 11.5% - 87% (West Sicily, Italy 
- Botswana, Africa) 
 
2.1.2 Malignancies of Human Herpes Viruses 
Some herpes viruses have been associated with human malignancies and/or cancer-causing 
diseases, in particular, the subfamily Gammaherpesvirinae (Table 1). For example, Epstein Barr virus, a 
gammaherpesvirus that causes mononucleosis, has been associated with Hodgkin’s lymphoma, 
nasopharyngeal carcinoma, Burkitt’s lymphoma, gastric carcinoma, T & natural killer (NK) lymphoma, 
and Leiomyosarcoma27. HHV-8, also a gammaherpesvirus, has been associated with Kaposi’s sarcoma 
(KS), primary effusion lymphoma (PEL), and the cancer-causing multicentric Castleman’s disease 
(MCD).  
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As for other subfamily herpes viruses, studies have suggested that the betaherpesvirus HHV-6 
may play a possible co-factorial role in cancer development for the following cancers and cancer-causing 
diseases: non-Hodgkin’s lymphoma, Hodgkin’s disease, S100-positive, T-cell chronic 
lymphoproliferative disease, oral salivary gland carcinoma tissue, and other neoplasia18, 27-29. However, 
the subfamily Gammaherpesvirinae contain the only known herpes viruses that cause malignancies in 
humans. 
2.2 HISTORY OF HHV-8 
In 1872, a Hungarian dermatologist Moritz Kaposi described an “idiopathic multiple pigmented 
sarcoma” of the skin that affected men of Mediterranean descent30; this KS was later called “classical 
KS.” In 1920’s, more KS cases with an aggressive form were identified in central and eastern African 
populations31, 32; this form was later called “endemic KS.” In 1972, Giraldo et al. identified a herpes-like 
particle in KS lesions which was thought to be cytomegalovirus (CMV)32, 33. CMV DNA was never 
identified32; however, the Giraldo et al. study led to the hypothesis that KS might have a viral etiology33. 
Decades later, an increase incidence of KS cases was observed worldwide, including in the U.S., among 
homosexual men during the 1980’s human immunodeficiency virus (HIV) pandemic34-36, a new emerging 
sexually transmitted disease that causes acquired immunodeficiency disease syndrome (AIDS). KS cases 
that resulted from this sexually transmitted disease were called “AIDS-associated KS.” In 1994, Moore 
and Chang discovered an unknown herpes virus from KS lesions of AIDS patients using representational 
differences analysis1. This new herpes virus was called Kaposi’s sarcoma associated herpesvirus or 
human herpes virus 8 (HHV-8). Later in 1995, HHV-8 was found to be associated with two 
lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric Castleman’s disease 
(MCD).  
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2.3 BIOLOGY OF HHV-8 
2.3.1 Genetic Structure of HHV-8 
HHV-8 is an envelope, double-strand, DNA virus that structurally has a DNA containing 
nucleocapsid core, a middle proteinaceous tegument, and an outer lipid bi-layer envelope. The lipid bi-
layer envelope has many glycoproteins attached to its outer layer that are responsible for functions such as 
viral cell entry and replication as well as assembly, maturation, migration, and release of viral particles8, 
18, 37. The conserved structural glycoproteins (common for all herpes viruses) are glycoproteins B (gB), H 
(gH), L (gL), M (gM) and N (gN) which encode open reading frames (ORFs) 8, 22, 47, 39, and 53, 
respectively20, 37, 38. Open reading frames (ORFs) are part of the HHV-8 genome that contains sequences 
of bases (A,G,C,T) that can encode a protein. The glycoproteins unique to HHV-8 are K8.1A, K8.1B, K1, 
K14, and K15 which are expressed during lytic replication20, 37. HHV-8-encoded virion envelope 
glycoproteins B and K8.1A are important for viral entry in target cells through their interaction with 
heparan sulfate, a binding receptor on the target cell24. 
HHV-8’s DNA is approximately 165 kbps (kilobase pairs).  The genome consists of a long 
unique region (approximately 140 kbps) flanked by terminal repeat sequences.  The long unique region 
contains the open reading frames.  There are 81 to more than 90 open reading frames (ORFs) of which 
sixty-six to sixty-eight have similar homology to the non-human, gammaherpesvirus herpesvirus saimiri8, 
19, 20, 39-41. The terminal repeat regions consist of multiple copies of an 801 bp sequence that is 
approximately 85% G+C content.  The terminal repeats vary in number at each end of the genome and 
contain packaging and cleavage signal sequences8, 20, 39. 
 11 
2.3.2 HHV-8 Specific Genes 
HHV-8 has been reported to have more than 90 separate ORFs each one encoding for a separate 
protein.  Majority of these genes are homologues with other herpesviruses and are therefore described as 
conserved genes. HHV-8 genes that do not have a herpesvirus homologue have been  given a “K” prefix 
(i.e., ORF K1 to ORF K15) in order to identify genes unique to HHV-8. These unique HHV-8 genes have 
been found to consist primarily of cellular homologues for genes such as IL-6, bcl-2, macrophage 
inhibitory proteins, cyclin-D, IL-8 receptor, etc.20, 40, 42.  
HHV-8’s gene expression is dependent on whether the virus in latency (virus is not replicating) or 
in a lytic cycle (virus is replicating producing infectious progeny). Latent and lytic stages are common in 
all herpes viruses and these stages contribute to the virus’s long-life infection. With HHV-8, there are 
genes that are expressed in either the latent and lytic cycle and contribute to the survival of the virus 
and/or the progression to cancers like Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL). 
However for cancer progression, individuals who are immunodeficient who usually acquire HHV-8 
associated diseases and malignancies8, 40. 
During latency, there are a few genes that are expressed once HHV-8 is well-established in the 
infected B cell, macrophage, endothelial cell, spindle cell, epithelial cell, or keratinocytes nucleus as a 
circular DNA episome19, 23-25. In individuals with KS, these latent gene expressions increase with KS 
lesion stage indicating an increase in HHV-8 latently-infected cells43. For both non-KS and KS persons, 
no viral particles are produced during latency39, 44.  
Even though latent genes’ expression is minimized during latency, they play an important role in 
the progression of lymphoproliferative malignancies and diseases through their growth and/or anti-
apoptotic signaling43. The major latent genes (proteins) are the following: ORF73 (LANA-1), ORF72 
(viral cyclin D), ORF K13 (viral FLIP protein), ORF K12 (Kaposin A), ORF K11.5 (viral IRF2), ORF 
K10.5 (LANA-2), and ORF K15 (LAMP). Latency-associated nuclear antigen (LANA) and v-FLIP 
proteins are responsible for preventing programmed cell death (apoptosis); and, viral cyclin D, Kaposin 
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A, and LAMP proteins are responsible for stimulating cellular growth. Both these processes allow the 
survival of HHV-8 infected cells. In addition, viral interferon regulatory factor 2 (v-IRF-2) prevents 
transcription factors, like nuclear factor kappa B (NF-kB) and cellular interferon regulatory factors 1 and 
3 (IRF-1 & IRF-3), from regulating the immune system’s response to viral infection. All these lytic gene 
expressions contribute to tumor progression by enhancing the survival or cellular growth of HHV-8 
infected cells (Table 3).  
Table 3. HHV-8 Latent Genes and their Functions 
HHV-8 Gene HHV-8 
Protein 
Cellular 
Homology 
Functions  
ORF73 LANA-1 None Blocks apoptosis, stimulates cellular transformation, 
downregulates p53 and targets Rb (tumor suppressors) 
ORF72  v-Cyc D Cyc D2 Stimulates cell cycle progression 
ORF K13 v-FLIP FLIP Inhibits apoptosis, promotes tumor progression 
ORF K12 Kaposin A None Stimulates cellular transformation 
ORF K11.5 v-IRF-2 IRFs Inhibits NF-kB and cellular IRFs-1 and -3 mediated 
transactivation, causes apoptosis of T-cell receptor, 
stimulates Jurkat cells and double-stranded RNA 
protein kinase 
ORF 10.5 LANA-2 None Inhibits p53-mediated transactivation and apoptosis in 
only B cells 
ORF K15 LAMP None Interacts with growth control proteins 
Abbreviations: v = viral, Cyc = cyclin, IRFs = interferon regulatory factors, LANA = latency-associated 
nuclear antigen, HHV-8 = human herpes virus 8, ORF = open reading frame, Rb = retinoblastoma protein, NF-kB 
= nuclear factor kappa B, FLIP = FLICE-inhibitory protein, RNA = Ribonucleic acid  
References40, 43 45 
 
Of the latent proteins, LANA-1 is probably the most important latent protein because it is highly 
expressed in all HHV-8 associated malignancies and diseases39, 46. Because of this expression, this protein 
has been considered as a reliable marker and many serological assays have used this protein in examining 
latent HHV-8 infections. LANA-1 is also important to the maintenance of the viral episomal DNA, 
therefore, maintaining latent viral persistence in infected cells39, 40, 46. This maintenance of latency is 
achieved through LANA-1’s ability to repress the replication and transcription activator (Rta), a protein 
(ORF50) that is necessary for the initiation of lytic replication47. In addition, this protein can also repress 
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or activate transcription by interacting with the tumor suppressor genes p53 and retinoblastoma protein 
(Rb)40, 48, 49. The tumor protein p53 is a phosphoprotein that prevents the formation of tumors by 1) 
inducing cell cycle arrest so that DNA repair can occur and 2) promoting apoptosis in order to stop the 
proliferation of defective cell. Rb is a protein that prevents damaged cells from progressing through the 
cell cycle. By repressing p53 and Rb, aberrant cellular proliferation continues which this continuation 
may lead to cancer. 
When HHV-8 is activated from latency to lytic replication, the majority of the viral genes are 
expressed during this active stage. The major HHV-8 lytic proteins associated with viral pathogenesis are: 
ORF K2 (viral interleukin-6), ORF74 (viral G-protein-coupled receptor), ORF K6 (macrophage 
inflammatory protein 1), ORF K4 (macrophage inflammatory protein 2), ORF K4.1 (macrophage 
inflammatory protein 3), ORF K9 (viral interferon regulatory factors 1), ORF K10.5-10.6 (viral interferon 
regulatory factors 3), ORF K1 (transforming & immunomodulatory proteins), ORF16 (viral BCL-2), ORF 
K7 (viral inhibitor of apoptosis proteins), ORF K3 (modulator of immune recognition 1), ORF K5 
(modulator of immune recognition 2), and ORF K14 (viral OX2). These lytic genes play an important role 
in pathogenesis of lymphoproliferative diseases and malignancies through their cellular proliferative 
inductions, pro-inflammatory abilities, angiogenic activities, and anti-apoptosis mechanisms. For 
example, viral interleukin 6 (v-IL-6) cytokine induces cellular proliferation. Viral macrophage 
inflammatory proteins 1-3 (v-MIP 1, v-MIP 2, v-MIP 3) and viral OX2 (v-OX2) engage in inflammatory 
activities. Viral G-protein-coupled receptor (v-GPCR), v-IL-6, and v-MIPs contribute to angiogenesis, a 
process that induces blood vessel growth that may contribute to tumor expansion. Viral interferon 
regulatory factor 1 (v-IRF-1), v-IL-6, viral BCL-2 (v-BCL-2), and viral inhibitor of apoptosis (v-IAP) 
proteins prevent apoptosis, therefore, support cellular proliferation. Viral interferon regulatory factor 3 (v-
IRF-3), transforming & immunomodulatory proteins, and modulator of immune recognition proteins 1 
and 2 (MIP-1, MIP-2) have activities that promote HHV-8 lytic replication cycle. Collectively, these lytic 
protein’s functions aid in the progression of HHV-8 associated malignancies and diseases (Table 4). 
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Table 4. HHV-8 Lytic Genes and their Functions 
HHV-8 
Gene 
HHV-8 Protein Cellular 
Homology 
Functions  
ORF K2 v-IL-6 IL-6 Induces cellular proliferation, prevents apoptosis, 
contributes to tumor angiogenesis 
ORF74 v-GPCR IL-8r (or 
CXCL8r) 
Induces cellular transformation, secretes 
angiogenic vascular endothelial growth factors 
(VEGF) 
ORF K6 v-MIP (or v-CCL-
1) 
MIP-I alpha Has pro-inflammatory roles and possibly has 
angiogenic activities, engages chemokine receptor 
CCR-8 
ORF K4 v-MIPII (or v-
CCL-2) 
Has pro-inflammatory roles and possibly has 
angiogenic activities, engages chemokine receptor 
CCR-8 
ORF K4.1 v-MIPIII (or v-
CCL-3) 
Has pro-inflammatory roles and possibly has 
angiogenic activities, engages chemokine receptor 
CCR-4 
ORF K9 v-IRF-1 IRFs Inhibits apoptosis 
ORF K10.5-
10.6 
v-IRF-3 Blocks IFN signaling from cellular IRF-3 and IRF-
7 that have anti-viral, anti-proliferative & 
immunomodulatory properties  
ORF K1 Transforming & 
immunomodulatory 
protein 
ITAM Important for viral replication, modulates 
reactivation 
ORF16 v-BCL-2 BCL-2 Inhibits apoptosis 
ORF K7 v-IAP Survivin- 
delta EX3 
(IAP) 
Inhibits apoptosis 
ORF K3 MIR-1 None Increase endocytosis of MHC class I from surface 
of infected cells (not recognized by cytolytic arm 
of immune system) 
ORF K5 MIR-2 
ORF K14 v-OX2 OX2 (CD200) Activates inflammatory cytokines (IL-1B, TNF-
alpha, IL-6) from myeloid-lineage cells 
Abbreviations: v = viral, r = receptor, IRFs = interferon regulatory factors, HHV-8 = human herpes virus 
8, ORF = open reading frame, IL = interleukin, MIP = macrophage inflammatory protein, CCL = CC chemokine, 
IAP = inhibitor of apoptosis, GPCR = G-protein-coupled receptor, MIR = modulator of immune recognition, CXCL 
= CXC chemokine, MHC = major histocompatibility complex, TNF = tumor necrosis factor, IFN = interferon, 
ITAM = immunoreceptor tyrosine activation motif 
References8, 19, 40 45, 50 
 
Out of all the HHV-8’s ORFs, the lytic ORF K1 gene is the most highly divergent gene in HHV-
8’s genome and has been used to identify 8 known HHV-8 subtypes (A-E, M, N, P, Z) and more than 24 
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clades40, 51, 52. This hypervariable gene is a result of several mutations that have occurred over thousands 
of years, possibly due to some evolutionary pressures53, 54. Epidemiological studies have shown that 
certain K1 sequences are unique to particular ethnic groups and geographical regions8, 51, 53, 55-58. However, 
studies have not shown whether these K1 differences increase or decrease one’s risk for cancer 
development. The K1 gene, which encodes the transmembrane protein that is homologous to the 
immunoreceptor tyrosine activation motif (ITAM), is critical for HHV-8 replication; and, this gene may 
play an important role in viral gene expression that modulates HHV-8 reactivation40, 59, 60.  
For HIV-1 infected individuals, a HIV-1 gene has been implicated to increase the incidence and 
the aggressiveness of KS. HIV-1 infected individuals have the most aggressive form of KS. This 
aggressiveness is caused by the HIV-Tat protein, a transcription activator that is released by HIV-1 
infected T cells43, 61-63. This protein can induce the adhesion growth, migration, and invasion KS spindle 
cells and augment angiogenesis, therefore, affecting the development of KS43. Tat can also induce the 
following cytokines and adhesion molecules: TNF-alpha and –beta, IL-6, ELAM-1, vascular adhesion 
molecule-1 (V-CAM-1), intercellular adhesion molecule-1 (I-CAM-), and monocyte chemotatic protein-1 
(MCP-1), v-GPCR, v-BCL-2, v-IRF-143, 64. These cytokines and molecules aid in KS progression. Matrix 
metalloproteinases 2 and 9 (MMP-2, MMP-9) may also play a necessary role in KS development in HIV-
1 infected individuals through its mediation of vascular and KS cell invasion and angiogenesis43.  
2.3.3 HHV-8 Reactivation/Lytic Replication 
HHV-8 reactivation is the re-entry to lytic replication from latency. Studies have suggested that 
viral reactivation occurs due to immunosuppression or forms of stress; however, physiological conditions 
that trigger reactivation are still undefined44, 65. In addition, clinical studies have shown that ongoing lytic 
replication is required for tumorigenesis66, 67. Therefore, lytic replication is a necessary process in the 
development of HHV-8 associated diseases and malignancies. The switch from latency to lytic replication 
is an important step in the lifecycle of HHV-8 and the development of HHV-8 associated cancers. 
 16 
For HHV-8, ORF 50, a gene that encodes the replication and transcription activator (Rta) protein, 
is necessary and sufficient to make the switch from latency to lytic replication68-72. The protein Rta 
activates immediate-early and early genes such as ORF K8 (Zta or K-bZIP), its own gene ORF50, ORF 
57 (post-transcriptional regulator of gene expression), genes involved in viral DNA replication, and 
structural genes39, 73, 74. By interacting with the following viral promoters, Rta also initiates a cascade of 
lytic gene expressions that may play a central role in tumorigenesis: ORF K12 (kaposin), v-IL-6, v-MIP-
1, v-IRF-1, v-GPCR, and ORF K140, 75-80. These protein functions are described in Table 4.  
Because of these highly expressed viral genes during lytic replication, the HHV-8 is susceptible 
to immune surveillance in immunocompetent individuals; this noticeable expression can disrupt cancer 
progression. For example, in immunocompetent individuals, IRF-7, a cytokine that activates anti-viral 
innate immune response, can down-regulate Rta, therefore, preventing lytic replication but maintaining 
latency74. Therefore, a person’s immune system may be an important determinant in whether HHV-8 
reactivation occurs. 
Viral reactivation is an important part of HHV-8’s lifecycle. The switch from latency to lytic 
replication is essential in the release of viral progeny and the development of HHV-8 associated diseases 
and malignancies.  
2.4 HHV-8 ASSOCIATED MALIGNANCIES 
HHV-8 is known to cause Kaposi’s sarcoma (KS) and has been associated with multicentric 
Castleman’s disease (MCD) and primary effusion lymphoma (PEL), rare lymphoproliferative diseases1, 81-
83. These cancers (KS and PEL) and lymphoproliferative disorder (MCD) have been observed in 
immunocompromised individuals; however, HHV-8’s carcinogenic effects in immunocompetent 
populations are unknown. HHV-8 is a newly discovered virus and little is known about the biology, 
infection, and its carcinogenic effects in susceptible populations. 
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2.4.1 Kaposi’s Sarcoma (KS) 
Kaposi’s sarcoma, the predominant HHV-8 associated malignancy, is a slow, growing vascular 
tumor characterized by multi-focal lesions of the skin. KS is classified as one of the following four types: 
1) classic KS, 2) endemic KS, 3) iatrogenic KS, or 4) acquired immunodeficiency disease syndrome 
(AIDS) associated KS. Classic KS is predominately seen in elderly men of Mediterranean, eastern 
European, or Jewish descent19, 64. This type is known to affect the lower extremities and rarely affects 
visceral organs43, 84. Classic KS was the first type to be identified in 1872 by the dermatologist Moritz 
Kaposi30. Endemic KS is an aggressive type observed in human immunodeficiency virus (HIV) negative 
children and young adults from Africa32, 43, 64, 85, 86. This endemic form involves visceral and/or lymphatic 
organs32, 85, 86.  Iatrogenic KS is a mild type that is seen in post-transplant patients who are on 
immunosuppressive therapy, in particular of Italian, Saudi Arabian, and Ashkenaki or Shepardnazi Jewish 
descent39, 43, 64, 87-89; KS is usually resolved when treatment is reduced or terminated39, 40, 90. AIDS-
associated KS is the most aggressive form found in HIV-infected persons, usually homosexual men. This 
aggressive form affects the skin and visceral organs, causing a systemic manifestation19, 43. Progression of 
KS lesions and visceral dissemination can lead to organ dysfunction or failure, therefore, resulting in 
death40.  
To treat classic and endemic KS, simple excision or radiation is used for single or multiple 
lesions, respectively39.  For recurrent disease, a combination of radiation, surgery, and chemotherapy are 
used as the forms of treatment in classic and endemic KS individuals39. As for iatrogenic KS, 
modification, reduction, or termination of immunosuppressive therapy is used for the regression of KS 
lesions39, 64.  For AIDS-associated KS, highly active antiretroviral therapy (HAART) has been successful 
in reducing KS39, 91. This reduction may be may be attributed to an “immune reconstitution” in HIV-
infected patients91. 
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2.4.2 Primary effusion lymphoma (PEL) 
Pleural effusion lymphoma, also called body cavity-based lymphoma (BCBL), is a fatal non-
Hodgkin’s lymphoma that has a pleural, peritoneal, or pericardial effusion presentation, often in the 
absence of a tumor mass19, 32, 39. However, a solid tumor mass can develop in the lymph nodes, lungs, or 
gastrointestinal tract39, 87. The lymphoma cells are usually monoclonal and of B-cell origin32. Interleukin 
10 (IL-10) and v-IL-6 may contribute to the growth of these lymphoma cells32. PEL is mainly seen in 
AIDS patients. Compared to KS spindle cells, PEL lymphoma cells have a higher copy of HHV-8 DNA, 
50-150 per cell19, 39, 87. 
2.4.3 Multicentric Castleman’s disease (MCD) 
Multicentric Castleman’s disease is a rare lymphoproliferative disorder regulated by an over-
expression of the inflammatory cytokine interleukin 6 (IL-6)19, 92. This disorder is histologically 
characterized by expanded germinal centers that include B cell and vascular proliferations32. There are 
two types of MCD: 1) plasma cell variant, and 2) hyaline vascular variant. Plasma cell variant type is 
found in AIDS patients and is associated with HHV-8 infections32. Clinical presentations of both types are 
fever, anemia, and hypergammaglobulinemia possibly due the elevated levels of IL-664. MCD is the often 
the precursor of non-Hodgkin’s lymphoma8, 93.  
2.4.4 Other Possible Associated Diseases 
Studies have suggested that HHV-8 plays a role in the following diseases: multiple myeloma94, 95, 
angiosarcoma96-100, pemphigus vulgaris and pemphigus foliacesus101, 102, sarcoidosis103, angio-
immunoblastic lymphoma104, pulmonary hypertension105, angiolymphoid hyperplasia with eosinophilia106, 
skin carcinomas in immunocompromised individuals107, primary central nervous system lymphoma108, 
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post-transplantation lymphoproliferative disorders109, 110, pulmonary inflammatory myofibroblastic 
tumor111 and prostate cancer9. Studies have demonstrated negative findings of HHV-8’s relationships with 
these diseases and lymphoma64, 83, 112-122. However, HHV-8’s relationship with most of these diseases and 
cancers still remain inconclusive; therefore, more studies are needed to evaluate these relationships.  
2.5 LABORATORY DETECTION OF HHV-8 
Several laboratory methods have been developed to examine the distribution of HHV-8 infection 
in different risk groups and geographical areas. These methods include 1) the polymerase chain reaction 
(PCR) assay which is used to detect HHV-8 DNA in various bodily fluids and tissues and 2) serological 
assays which are used examine antibodies against HHV-8 antigens in human serum. In comparison to the 
PCR, HHV-8 serological assays are more sensitive for detecting current and past HHV-8 infections. 
However, there is no gold standard assay in examining HHV-8 infections. 
2.5.1 Polymerase chain reaction (PCR) 
HHV-8 PCR has been useful in showing the causal relationship between HHV-8 DNA and HHV-
8 associated malignancies (KS, PEL, and MCD)1, 81-83, 123. This method has also been used in determining 
possible modes of transmission through the detection of HHV-8 DNA in bodily fluids such as saliva, 
semen, and peripheral blood124-131. In addition, the PCR method has allowed the prediction of KS 
development in asymptomatic HIV-positive individuals123. Therefore, the PCR has been a useful tool in 
understanding the biology of HHV-8 even though it is considered a less sensitive method in determining 
HHV-8 infection, possibly due to the quality of the samples, in comparison to serological assays. 
To perform the PCR, studies have used the following primers in looking for the presence of 
HHV-8 DNA in bodily fluids and tissues: ORFs 8, 25, 26, 64, 65, 72, 75, and K1 as well as the 
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glycoprotein B123, 132. ORFs 26 and 72 have shown to be the most sensitive and therefore are commonly 
used as primers in detecting HHV-8 DNA123. The functions of proteins coded by genes detected by these 
common HHV-8 PCR primers are displayed in Table 5. 
2.5.2 Serological Assays 
There are several serological assays that have been developed to examine different HHV-8 lytic 
and latent antigens in order to determine HHV-8 sero-status: immunofluorescence assay (IFA), Western 
Blot, and enzyme-linked immunosorbent assay (ELISA). IFA, which includes mouse monoclonal 
antibody-enhanced immunofluorescence assay, is the oldest HHV-8 assay (available in 1996) and it 
detects latent (LANA) and lytic HHV-8 antigens55. The advantages of the IFA are the high sensitivity for 
HHV-8 lytic antigens (> 97%) and the inexpensive cost; however, this method is time-consuming, not 
easy to use in large studies, requires extensive quality control, and is subjective in interpretation of sero-
status results8, 132, 133. A modified monoclonal antibody-enhanced immunofluorescence assay for 
antibodies against lytic antigens will be used in this research study13.  
As for the ELISA, HHV-8’s whole viral lysates, synthetic peptides, or recombinant peptide 
carrier protein conjugates has been used to determine HHV-8 seroprevalence in populations132, 133. The 
most common HHV-8 genes used for the ELISA are ORFs 65, a small capsid antigen, and K8.1A, a 
glycoprotein associated with the virion envelope. ELISAs produce more objective results than IFAs; 
however, they still require quality controls in their assay and they are less sensitive (83%-87%) than 
IFAs132. As for the Western blot, it can detect latent antigen LANA and the glycoprotein K8.1. However, 
the Western blot is difficult to conduct and it is less sensitive (80%) than IFAs and ELISAs132; therefore, 
it is rarely used in studies to examine HHV-8 seroprevalence in populations.  
Studies have used the following HHV-8 antigens to examine HHV-8 seroprevalence in study 
populations: ORFs 6, 8, 9, 25, 26, 39, 59, 65, 68, 73, K8.1A, and K8.1B123. The most immunogenic HHV-
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8 antigens are ORFs 73 (LANA-1), 65, and K8.1; these antigens are commonly used in serological 
assays123. The functions of these commonly used antigens are displayed in Table 5.  
Table 5. Most Common HHV-8 Assays 
HHV-8 Gene HHV-8 Protein Assay Used 
ORF 26 34 k-Da minor capsid 
protein 
PCR, IFA, ELISA 
ORF 65 Small, basic, highly 
antigenic viral capsid 
protein 
IFA, ELISA 
ORF 72 v-Cyc D, latent 
protein 
PCR 
ORF 73 LANA-1, latent 
protein 
WB, IFA, ELISA 
ORF K8.1 Late-lytic gene that 
encodes for 2 HHV-8 
specific glycoproteins 
(K8.1A and K8.1B)  
WB, IFA, ELISA 
Abbreviations: ORF = open reading frame, WB = Western blot, IFA =  
immunofluorescence assay, ELISA = enzyme-linked immunosorbent assay, 
PCR = polymerase chain reaction, LANA = latency-associated nuclear antigen, 
Cyc = cyclin 
 
The sensitivity and specificity of an assay are important in determining HHV-8 infection in 
populations; however, a gold standard assay has not been identified. The sensitivity and specificity of 
HHV-8 assays have been determined by comparing each assay’s results to known HHV-8 seropositive 
and seronegative control samples. For example, the sensitivity and specificity of lytic versus latent 
antigen assays differ. The lytic antigen assays has been shown to be more sensitive (> 95%) than the 
latent antigen LANA assay8. The lower sensitivity of the latent antigen assay may be due to antibodies 
against lytic antigens preceding antibodies against latent antigens123. As for the comparison of the 
different types of serologic assays, Spira et al. have found that mouse monoclonal antibody-enhanced 
immunofluorescence assay (mIFA) for antibodies against lytic antigens is the most sensitive (97%), 
followed by combined peptide enzyme-linked immunosorbent assay (ORF 65 and ORF K8.1 peptide) 
(93%), ORF K8.1 peptide ELISA (87%), ORF 65 peptide ELISA, mIFA latent (83%), Advanced 
 22 
Biotechnologies ELISA kit  prepared from sucrose gradient-purified HHV-8 whole virions (80%), and the 
least sensitive ORF 65 immunoblot (or Western blot) (80%)132. Pellet also found that mIFA (conducted at 
the University of Pittsburgh) had the highest sensitivity (89.9%) based on a conditional independence 
model by latent class analysis compared to 5 other serological assays that examined HHV-8 sero-status in 
a U.S. blood donor population14; this assay will be used in this research study. However, the specificity of 
the mIFA was low compared to the other assays (97.5%); the ELISA based on induced BC3 cells and two 
BC3 mIFAs against latent LANA antigens and lytic antigens, respectively, had the highest specificity 
(100%)14.  
2.6 THE EPIDEMIOLOGY OF HHV-8 INFECTION 
2.6.1 HHV-8 Seroprevalence by Country 
The seroprevalence of HHV-8 infection varies geographically and is considered endemic in 
African and Mediterranean countries where Kaposi’s sarcoma (KS) is relatively common. The prevalence 
of HHV-8 infection has corresponded with the prevalence of KS: Africa having the highest 
seroprevalence and incidence of KS, followed by Mediterranean counties with intermediate 
seroprevalence and KS incidence, and North America and Northern Europe having the lowest 
seroprevalence with little to no KS. In addition, the predominant types of KS (classic, endemic, AIDS-
associated, or iatrogenic) differ geographically; for example, Sub-Saharan Africa has mostly endemic and 
AIDS-associated KS cases, and the Mediterranean has mostly classic KS cases. Because HHV-8 is a 
newly discovered carcinogenic virus, many studies have been developed to evaluate HHV-8 infections in 
different populations and the following geographical regions: Africa, the Mediterranean, South America, 
the Caribbean, Asia, Europe, and the Oceania. However, assays used to examine HHV-8 infections in 
populations have varied. Therefore, the comparison of HHV-8 seroprevalence among different 
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geographical regions may not be an accurate evaluation due to differences in sensitivity and specificity of 
the assays unless the same assay is used to evaluate HHV-8 infection in different populations. 
Nevertheless, the examination of HHV-8 infections, geographically and in different ethnicities, is 
important in understanding the biology of HHV-8 as well as determining which populations or 
environments are more susceptible in acquiring HHV-8 infection and its associated diseases and 
malignancies. 
2.6.1.1 Sub-Saharan Africa 
Sub-Saharan Africa, a region not considered a part of North Africa, has the highest HHV-8 
seroprevalence and KS incidence in the world. This region has 42 mainland countries and 6 islands that 
are divided into the following geographical parts: Central, East, South, and West Africa134. 
Epidemiological studies have shown different distributions of HHV-8 infection in the general population 
among Central, East, South, and West Africa, seropositivity rates ranging from 5.76% to 87%. Also, the 
incidence of KS has been different in Central, East, South, and West Africa: 30, 23, 13.2, and 4.6 per 
100,000 person-years among men and 8.6, 9.5, 5.7, and 1.4 per 100,000 person-years among women, 
respectively10. Because HHV-8 infection is highly endemic in Sub-Saharan Africa, high incidences of 
endemic and AIDS-associated KS have been observed in this region. 
The seroprevalence of HHV-8 in Sub-Saharan Africa has ranged from 9.42% to 87% for 
antibodies against HHV-8 lytic antigens and 5.76% to 25% for antibodies against HHV-8 latent antigens 
in healthy populations (Figure 1). For example, in East Africa, two studies have found a similar 
seroprevalence for antibodies against HHV-8 lytic antigens in Uganda: 34% was found in 485 mothers 
who took their child to a sickle cell clinic and a 38.7% was found in 62 healthy donors4, 135. In South 
Africa, a HHV-8 seroprevalence of  35% and 14% for antibodies against HHV-8 lytic and latent antigens, 
respectively, was found among 2546 mothers, aged 15 to > 40 years, who attend a vaccination clinic with 
their child in the cities of KwaZulu and Natal136. In Zambia, South Africa, seropositivity rates for 
antibodies against HHV-8 lytic antigens ranging from 37.5% in 40 healthy blood donors to 47.3% in 275 
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pregnant women who attended an antenatal clinic at the University Hospital in Lusaka were found4, 137. 
However, in Botswana, a higher HHV-8 seropositivity rate of 87% for antibodies against lytic antigens 
was detected in the semi-nomadic San people, aged 18-55; and a lower rate of 76% was found in the 
Bantus people, aged 16-642. Intermediate HHV-8 seropositivity rates in East Africa and intermediate to 
high seropositivity rates in South Africa reflect the incidence of KS observed in these areas2. 
As for West Africa, high HHV-8 seropositivity rates but surprisingly low incidences of KS have 
been reported in their healthy populations. For example, in Garoua, North Cameroon, 51% and 25% 
seroprevalence for antibodies against HHV-8 lytic and latent antigens, respectively, was found in 292 
individuals, aged 5 to 40, who attended a general medical outpatient ward138. In South Cameroon, an 
overall seroprevalence of 59.9% for antibodies against HHV-8 lytic antigens were observed in 92 families 
from an isolated village in the Ntem region3. However, in Ghana and Burkina Faso, a lower 
seroprevalence against lytic HHV-8 antigens, 41.9% and 9.42%, respectively, was found in comparison to 
Cameroon. The reasons for the intermediate rates of HHV-8 infection but low KS in West Africa are 
unknown.  
For Central Africa, a higher HHV-8 seropositivity rate has been reported for this area in 
comparison to West and East Africa. In the Democratic Republic of Congo, a seroprevalence of 82% for 
antibodies against HHV-8 lytic antigens was detected in individuals, aged 6-78, without KS. This high 
seropositivity rate in Central Africa parallels the high incidence of KS (30 per 100,000 person-years 
among men) reported for this area, the highest KS incidence in the world. 
In conclusion, the differences in HHV-8 seropositivity rates among and within the Sub-Saharan 
nations may reflect different environmental factors that contribute to the susceptibility of HHV-8 
infections as well as the development of KS in their populations (Figure 1).  
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Note: East Africa’s HHV-8 seroprevalence of 34% and 39.7% represent Kampala, Uganda and Uganda 
(city not identified) populations, respectively. South Africa’s HHV-8 seroprevalence of 35%, 37.5%, 47.3%, 76%, 
and 87% represent KwaZulu/Natal, Zambia (city not identified), and Lusaka, Zambia populations, Botswana Bantu, 
and Botswana San, respectively. West Africa’s HHV-8 seroprevalence of 9.42%, 41.9%, 51%, and 59.9% represent 
Burkina Faso, Ghana, North Cameroon, and South Cameroon populations, respectively. Central Africa’s HHV-8 
seroprevalence of 82% represents the Congo 
Figure 1. Seroprevalence for Antibodies against HHV-8 Lytic Antigens in Sub-Saharan Africa 
General Population 
 
HHV-8 infection is prevalent among infants and children in the Sub-Sahara region (Figure 2). For 
example, in Tanzania, East Africa, a seroprevalence of 56.5% was observed for antibodies against HHV-8 
lytic antigens in 798 children/adolescents, aged 1-17, who participated in a HIV survey; only 2 persons 
were HIV positive139. In Kampala, Uganda, East Africa, HHV-8 seroprevalence of 21% for antibodies 
against lytic and latent antigens was found in 600 children/adolescents, aged 1-16, who attended a sickle 
cell clinic135. Also, in Uganda, seroprevalence of 42.5% and 33% for antibodies against HHV-8 lytic and 
latent antigens, respectively, was found in 212 children/young adults, aged 0-24, who attended an 
outpatient department140.  
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In South Africa, a lower HHV-8 seroprevalence was detected in children. For example, in 
KwaZulu and Natal, South Africa, 2501 children, < 1 to > 6 years of age, who attended a vaccination 
clinic, had an overall seroprevalence of 12% and 7% for antibodies against HHV-8 lytic and latent 
antigens, respectively136. Of these children, seroprevalence of 10% and 7% for antibodies against HHV-8 
lytic and latent antigens, respectively, was observed in 2297 HIV negative individuals; however, higher 
seroprevalence of 31% and 8% for antibodies against HHV-8 lytic and latent antigens, respectively, was 
observed in 153 HIV positive individuals136.  
As for West Africa, HHV-8 seroprevalence of 32.7% for antibodies against lytic antigens in 162 
children, aged 1-9, and a seroprevalence of 59.2% in 147 children/adolescents, aged 10-19, were observed 
in individuals who participated in a survey in the isolated village of Ntem, South Cameroon3. In North 
Cameroon, 39.8% and 25.5% HHV-8 seroprevalence for antibodies against lytic and latent antigens, 
respectively, was observed in 292 children, aged 5-10, who attend a general medical outpatient ward; and, 
51.5% and 23.7% HHV-8 seroprevalence for antibodies against lytic and latent antigens, respectively, 
was observed in adolescents/young adults, aged 15-20, who also attend an outpatient ward138. As for 
Nigeria, a seroprevalence of 14% for antibodies against lytic and latent antigens was observed in 184 
infants, aged 6-38 months, who participated in a randomized community survey141. 
In conclusion, epidemiological studies have shown that HHV-8 infections are prevalent among 
pre-pubertal children, adolescents, and young adults. For pre-pubertal children, this prevalence may be 
due to saliva exchange, the probable mode of HHV-8 transmission in this population.  
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Figure 2. HHV-8 Seroprevalence among Children/Adolescents from Sub-Saharan Africa 
 
Majority of studies conducted in Sub-Saharan Africa have demonstrated that the seroprevalence 
of HHV-8 increases with age. In Tanzania, East Africa, seroprevalence of 42.2% to 67.7% for antibodies 
against HHV-8 lytic antigens was observed in individuals aged 0-4 to aged 10-17, respectively. In 
KwaZulu/Natal, South Africa, seroprevalence of 7.8% to 23.4% for antibodies against HHV-8 lytic 
antigens and seroprevalence of 5.3% to 9% for antibodies against HHV-8 latent antigens were observed in 
children ages < 1 year to ages > 4 years, respectively136. In North Cameroon, West Africa, seroprevalence 
for antibodies against HHV-8 lytic antigens increased from 39.8% in children, aged 5-10 years, to 61.8% 
in adults, aged 30-40 years138. In South Cameroon, HHV-8 seroprevalence for antibodies against lytic 
antigens increased from 32.7% in children, aged 1-9, to 78.9% in adults, aged > 50; however, HHV-8 
seroprevalence in this population peaked in individuals, aged 20-29, (88.9%)3. As for gender, there were 
no differences in HHV-8 seroprevalence observed in the Sub-Saharan Africa populations3, 135, 138-140. 
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2.6.1.2 Mediterranean Countries 
The Mediterranean countries have moderate levels of HHV-8 infection as well as KS 
incidence/prevalence in their populations in comparison to Sub-Saharan Africa. The Mediterranean area 
is made of 21 states along the coastline of the Mediterranean Sea which includes Southern Europe, 
Northern Africa, and Western Asia134. The incidence of KS and the seroprevalence of HHV-8 vary by 
geographical region as well as by ethnicity. For example, studies have shown that Southern Italy has a 
higher KS incidence and HHV-8 seroprevalence than Northern Italy142-144. In addition, studies have shown 
Italians having a higher KS incidence and HHV-8 seroprevalence than Jewish people from Israel144, 145. 
The seroprevalence of HHV-8 in the Mediterranean area reflects mostly the incidence of “classic KS”, a 
form that affects mostly elderly men. Even though the incidence of KS is higher among men, studies have 
shown no gender differences in HHV-8 seroprevalence in the population5-7, 142-144, 146.  
The seroprevalence of HHV-8 in the Mediterranean region has ranged from 4.1% to 31% in the 
general population (Figure 3). In Croatia, HHV-8 seroprevalence of 4.1% was found among blood donors 
in whom low incidence/prevalence of KS has been reported in this country147. In Malta, a seroprevalence 
of 7% for antibodies against HHV-8 lytic antigens and 8.5% for antibodies against lytic and latent 
antigens were detected in elderly men, aged 71-100, and hospitalized men, aged > 65, respectively, in 
Malta; the incidence of KS has been reported to be 2.2 per 100,000 person-years among men and 1.8 per 
100,000 person-years among women2, 143. As for Israel, a seroprevalence of 9.9% were detected in 
families who were relatives of hepatitis B positive blood donors; the incidence of KS has been reported to 
be 1.96 per 100,000 in men and 0.7 per 100,000 in women145.  
In Italy, HHV-8 seroprevalence has shown to increase from Northern Italy to Central Italy and 
from Central Italy to Southern Italy. For example, in Northern Italy, a seroprevalence of 11.9% and 
14.6% for antibodies against HHV-8 lytic and latent antigens, respectively, was observed in 343 healthy 
individuals, aged > 55, from the Province of Mantua; the incidence of KS in this area has ranged from 1.7 
to 5 per 100,000 person-years in men and 0.2 to 2.8 per 100,000 person-years in women142. As for Central 
Italy, a seroprevalence of 15.7% for antibodies against HHV-8 lytic antigens was detected in a random 
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sample of 248 low KS risk patients, aged >18, attending a dermatology clinic in Rome; the incidence of 
KS has been reported to be 0.5-1.5 per 100,000 person-years6. However, in Southern Italy, the 
seroprevalence of HHV-8 appears to be highest in the Mediterranean regions, ranging from 8.5% to 31%, 
with a KS incidence ranging from 6.2-8.8 per 100,000 person-years among men and 2.1-2.5 per 100,000 
person years among women143. 
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Figure 3. HHV-8 Seroprevalence in the Mediterranean General Population 
 
In Southern Italy, the seroprevalence of HHV-8 in the general population has differed greatly 
among the cities. For example, in Western Sicily, a seroprevalence of 11.5% for antibodies against HHV-
8 lytic and latent antigens were observed in 970 individuals from the general population, aged 1 to 70. 
However, a higher HHV-8 seroprevalence of 20.3% for antibodies against lytic and latent antigens was 
detected in elderly outpatients in Sicily143. In Pomigliano d’Arco, Campania, South Italy, a seroprevalence 
of 14.8% for antibodies against HHV-8 latent antigens was detected in 351 heterosexual individuals that 
had no KS or HIV. Cattani et al. showed a seroprevalence of 18.3% for antibodies against HHV-8 lytic 
antigens among 517 healthy individuals from South and Central Italy who attended a Rome outpatient 
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lab7. Cattani et al. also found a 25% HHV-8 seroprevalence for antibodies against lytic antigens in 150 
healthy individuals from Sardinia who attended an outpatient lab7. Vitale et al. also detected a similar 
HHV-8 seroprevalence of 25% for antibodies against lytic and latent antigens as Cattani et al. study 
population; however, Vitale et al. study participants were elderly outpatients, aged > 65, from Sardinia143. 
In Northern and Southern Sardinia, a higher seroprevalence, 31% for antibodies against HHV-8 lytic 
antigens, was found in 297 KS and HIV negative individuals that were hospitalized at a dermatological 
clinic144. These variations in HHV-8 seroprevalence for antibodies against lytic antigens were also seen in 
studies conducted in Albania: 13.8% in healthy lab outpatients and 20% in individuals participating in a 
HIV screening program or infection control program. The wide range of HHV-8 seropositivity rates may 
correspond with the incidence of KS observed in the population. 
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Figure 4. HHV-8 Seroprevalence in the Mediterranean Older Populations, aged > = 50 years 
 
HHV-8 infections have also been seen in children in the Mediterranean area (Figure 5). In Israel, 
children, aged 2-14, were found to have a HHV-8 seroprevalence of 8.6% for antibodies against lytic 
antigens145. As for Italy, HHV-8 seroprevalence in children and adolescents were less than 11%. For 
example, in Northern (Emilia-Romagna), Southeastern (Apulia), and Southern Italy (Sicily), Whitby et al. 
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found a seroprevalence of 4.1%, 3.9%, and 5.8% for antibodies against HHV-8 lytic antigens, 
respectively, in 567 hospitalized, children, aged < 1 to 15, without HIV or KS148. Perna et al. detected a 
seroprevalence of 6.3% for antibodies against HHV-8 lytic and latent antigens in children, aged 1-15, 
from Sicily, South Italy, a seroprevalence similar to Whitby et al. study population5. However, in 
individuals, aged 16-20, from Sicily, Perna et al. found a slightly higher seroprevalence of 8% for 
antibodies against HHV-8 lytic and latent antigens in comparison to children, aged 1-155. Healthy 
children, aged 0-14, from Rome (Central Italy), Albania, and Sardinia (South Italy), collectively, had 
seroprevalence of 9.7% for antibodies against HHV-8 lytic antigens; but, children < 1 year of age had a 
higher HHV-8 seroprevalence of 10.3%7. As for the Western Balkan countries, Chironna et al. found a 
higher HHV-8 seroprevalence of 28% and 18% against 2 antigens in refugees, aged 1-25, from Albania 
and Kosovo, respectively149. However, healthy children from Alexandra, Egypt, aged < 1-25, had the 
highest HHV-8 seroprevalence, 44.7% and 8.5% for antibodies against lytic and latent antigens, than 
children from other Mediterranean areas150. In these children/adolescent populations, the differences of 
HHV-8 seropositivity rates may reflect the cultural behaviors that contribute to HHV-8 transmission, for 
example, saliva exchange. The increase in HHV-8 seroprevalence from adolescence to young adulthood 
may be due to a combination of saliva exchange and sexual behavior.  
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Figure 5. HHV-8 Seroprevalence among Children, aged 1-15 years, from the Mediterranean 
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Studies that examined HHV-8 infections in the Mediterranean region have shown that HHV-8 
infections increase with age in Southern Italy, Israel, and Egypt. In Southern Italy, Serraino et al. have 
shown a significant increase in HHV-8 seroprevalence for antibodies against lytic antigens in individuals 
residing in Northern Sardinia, from 23.2% in 50-64 year olds to 30.7% in > 65 year old people (p-
value=0.03); however, in Southern Sardinia, this increase was not observed in these age groups, 30% in 
both groups144. In Western Sicily, seroprevalence of 5.4%, 8%, and 22.3% against lytic and latent HHV-8 
antigens were observed in 1-5, 16-20, and 51-70 age groups, respectively5. Also, an increase in HHV-8 
seroprevalence for antibodies against latent antigens was found in Pomigliano d’ Arco, Campania, from 
14.5% in 35-55 year olds to 17.5% in > 75 year olds; however, this increase was not significant (p-
value=0.4)146. As for Northern and Central Italy, increase in HHV-8 seropositivity was not consistent with 
increasing age6, 142.  
In Israel, Davidovici et al. has shown that HHV-8 seropositivity rate for antibodies against latent 
antigens significantly increase from 8.6% in 2-14 year olds to 18% in > 55 years olds (p-value=.011)145. 
As for Alexandria, Egypt, a dramatic increase in HHV-8 seropositivity rate was observed in < 1 to > 12 
year olds, from 16.6% to 58%, respectively, for antibodies against lytic antigens and 7.1% to 10%, 
respectively, for antibodies against latent antigens150. Increasing HHV-8 seropositivity rate with 
increasing age may suggest cumulative exposure, sexual and/or asexual (for example, saliva exchange for 
asexual).  
2.6.1.3 South America 
For the continent of South America, the distribution of HHV-8 infections has been the widest 
compared to other countries, from a seroprevalence of 0.3% to 56.8% (Figure 6). This wide distribution is 
partially due to the incidence of KS in the population, in particular, the Amazon basin where endemic KS 
is found8. In addition, this distribution may be a reflection of the economic status of their country. For 
example, a low seroprevalence of 0.3% and 1.1% for antibodies against HHV-8 lytic and latent antigens, 
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respectively, were found among women working in a mentally handicap institution in Sao Paulo, 
Brazil151. Among blood donors in Sao, Paulo, Brazil, a slightly higher HHV-8 seropositivity rate of 2.8% 
for antibodies against HHV-8 lytic antigens was found152. Argentina’s and Santiago de Chile’s blood 
donors had about the same low seropositivity rates for antibodies against HHV-8 lytic antigens, 4% and 
3%, respectively152. However, among low-income families from Northern Brazil, a seroprevalence of 
16.3% for antibodies against HHV-8 lytic and latent antigens was detected153. As for French Guiana, a 
seropositivity rate of 13.2% for antibodies against lytic and latent antigens was found among individuals 
of African origin who participated in a Human T-cell Leukemia Virus 1(HTLV-1) study154; but, a higher 
seroprevalence of 23% for antibodies against lytic and latent antigens was found among Amerindians in 
this same country155. A significantly higher seropositivity rate of 56.25% for antibodies against HHV-8 
lytic antigens was found among blood donors from Lima, Peru; this high rate most likely parallels the 
recent classic KS report of 2.54 cases per 10,000 people156. A similarly high HHV-8 seroprevalence of 
56.8% for antibodies against lytic and latent antigens were detected among Amerindians from Para and 
Amapa, Brazil; however, the prevalence of KS in this population is unknown157. Therefore, KS and 
possibly economic status may explain the low to high incidence of HHV-8 infections in South American 
countries.  
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Figure 6. HHV-8 Seroprevalence in South American Populations 
 
Low to high HHV-8 seropositivity rates were also identified among children residing in South 
America. In Sao Paulo, Brazil, HIV negative and positive children, < 2 of age, who were born to HIV-1 
mothers had a seropositivity rate of 0% and 10.3%, respectively, for antibodies against lytic antigens151.  
However, in Rio de Janeiro, Brazil, a seropositivity rate of 7.59% and 30.7% for antibodies against lytic 
and latent antigens was found in healthy children and children with HIV, aged 0-12, respectively158. In 
Northern Brazil, 12% and 17.4% HHV-8 seropositivity rates were found among children, aged < 10, and 
adolescent, aged 11-20, from low-income families153. But, higher seropositivity rates for antibodies 
against lytic and latent antigens were found among Amerindian children: 44.4% in < 2 year olds, 35% in 
2-9 year olds, and 51.4% in 10-19 years157. The seroprevalence of HHV-8 among healthy children of a 
particular region is comparable to the seroprevalence found among healthy adults. 
In French Guiana, HHV-8 seroprevalence of 2.1% for antibodies against lytic and latent antigens 
was detected among children of African origin 2-4 years of age and it increased to 16.1% in adolescents, 
aged 15-19154. However, in Kazanji et al. study, a higher seropositivity rate for antibodies against lytic 
antigens was found among Amerindian children, 18.4% in < 6 years to 23.3% in 16-20 year olds155. 
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Differences in seroprevalence rates between these two French Guiana populations may be related to 
cultural or possibly genetic differences that increase one’s susceptibility of acquiring this virus. 
As for age, studies conducted in French Guiana showed HHV-8 seropositivity rates increased 
with age, from 5-18% in pre-pubertal children to > 34% in individuals > 50 years of age154, 155. In 
Northern Brazil, the seropositivity rate found in low income families increased from 12% in < 10 year 
olds to 33.3% in individuals, aged > 50153. In Para and Amapa, Brazil, a significant increase in HHV-8 
seropositivity rate was found among Amerindians, from 44.4% in < 2 year olds to 82.3% in > 50 years (p-
value < 0.001)157. However, in Lima, Peru, HHV-8 seropositivity rates, 65% to 50%, were consistent 
among the 18 to > 45 year old blood donors156. In counties that had low HHV-8 seroprevalence, their 
rates did not increase with age152, 158. As for gender differences, there were no significant differences in 
HHV-8 seropositivity rates found in South American populations except for in children who attended a 
university hospital in Rio de Janeiro, Brazil (p-value = 0.0002)158.  
2.6.1.4 Caribbean Islands 
The Caribbean islands, which are composed of 28 territories located in the Caribbean Sea, have 
been reported to have moderate levels of HHV-8 infections. However, the prevalence of KS is unknown 
for most of this area; the International Agency for Research on Cancer has reported little to no KS in this 
region10. However, Jamaica has been reported to have low incidence of KS159, 160. In Tobago, no KS cases 
have been reported since the establishment of the cancer registry11. 
Few studies that have been conducted in Caribbean populations have reported seropositivity rates 
ranging from 1.3% to 29.0% (Figure 7). For example, in Havana City, Cuba, HHV-8 seroprevalence of 
16.9% for antibodies against HHV-8 lytic antigens was found among 379 individuals who participated in 
a hospital-based case-control study161. Among individuals who had blood collected from Haiti (n = 52) 
and the Dominican Republic (n = 40), a seroprevalence of 29% and 13%, respectively, for antibodies 
against lytic and latent antigens was found162. As for Jamaica, seroprevalence of 3.6% for antibodies 
against HHV-8 lytic antigens was found in 250 healthy blood donors from Jamaica4. A similar HHV-8 
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seropositivity, 2.7%, was found among 1010 donors in the Jamaica Transfusion Study163. However, a 
lower HHV-8 seropositivity of 0.68% for antibodies against HHV-8 lytic and latent antigens was found in 
146 women at a gynecology clinic in Jamaica159. The differences in HHV-8 seropositivity between the 
genders in Jamaica may be due to differences in lifestyle behaviors that increase one’s risk for acquiring 
HHV-8 infection. 
In Trinidad, a low seropositivity rate of 1.3% for antibodies against lytic antigens was reported in 
160 healthy blood donors from Trinidad4. However, Hoffman et al. found a significantly higher HHV-8 
seropositivity rate of 20.1% for antibodies against lytic antigens among 174 Trinidadian men without 
prostate cancer who participated in a case-control study9. The reason for the differences in HHV-8 
seropositivity rates in Trinidad may due to 1) the IFA being more sensitive than the whole virus ELISA, a 
seroprevalence of 20.1% opposed to 1.3%, respectively; and, 2) the study populations may be different. A 
similar HHV-8 seropositivity rate, 22.9%, was found among 140 Tobagonian men without prostate 
cancer, Trinidad’s neighbor island9. The moderate levels of HHV-8 infection but no KS may reflect the 
health status of the population, environmental factors that affect the development of KS, or an under-
report of KS in HHV-8 positive individuals.  
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Figure 7. HHV-8 Seroprevalence in Caribbean Populations 
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As for HHV-8 infections rates among children residing in the Caribbean, no study has been 
conducted in the population.  
2.6.1.5 North America 
In North America, HHV-8 seropositivity rates and the incidence/prevalence of KS have been 
estimated to be low. Majority of these HHV-8 infections and KS cases have been estimated to come from 
HIV-infected individuals164. The incidence of KS has been 3 and 0.7 cases per million men and women, 
respectively8, 165. But, in non-HIV individuals, studies have found HHV-8 seropositivity rates ranging 
from 2.5% to 23% in U.S. populations (Figure 8). For example, Pellet et al. found an overall HHV-8 
seroprevalence of 3.0-3.5% in blood donors from 6 U.S. major cities14. Engels et al. found a HHV-8 
seroprevalence of 2.5% for antibodies against either latent or lytic among individuals sampled from the 
National Health and Nutrition Examination Survey III in the U.S. 166. Hoffman et al. found a 
seroprevalence of 5.1% for antibodies against lytic antigens among U.S. blood donors9. As Hoffman et al, 
Ablashi et al. found a similar seropositivity rate for antibodies against lytic antigens, 5.2%, among healthy 
individuals from the U.S.4. Engels et al. found 5.9%, 2.7%, and 6.7% HHV-8 seropositivity rates for 
antibodies against lytic antigens and 5.4%, 6.1%, and 4.4% for antibodies against latent antigens among 
New York residents of the Jewish, Protestant, and Catholic faiths, respectively167. But, in Baltimore, 
Maryland, a seroprevalence of 11.3% for antibodies against lytic antigens was found among pre-cardiac 
surgery patients168. An even higher seroprevalence for antibodies against lytic antigens, 23%, and latent 
antigens, 5%, was found in blood donors from Houston, Texas169. These differences of HHV-8 
seropositivity rates observed among different study populations may be due to 1) environmental and/or 
cultural differences, 2) genetic susceptibility in acquiring this virus, or 3) different assays used to examine 
HHV-8 infection in the study population.  
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Figure 8. HHV-8 Seroprevalence in U.S. Populations 
 
Similar HHV-8 seropositivity rates found in adults were also observed in U.S. children. Matro et 
al. found a seropositivity rate for antibodies against lytic and latent antigens of 4% among 552 children, 
aged 6 months to 17 years, who attended a hospital in Atlanta and North Georgia area141. But, Baillargeon 
et al. detected a higher seroprevalence of 26% for antibodies against lytic and latent antigens from 123 
healthy children, aged 1-13, from South Texas170. These differences in seropositivity rates may be 
attributed to ethnicity and/or socioeconomic differences. Majority of the children from South Texas were 
84.5% Hispanic, usually of low socioeconomic status. The hospitals around the Atlanta and North 
Georgia area are surrounded by affluent neighborhoods. Therefore, the children attending the Atlanta 
hospitals may be of a different demographic than the South Texas children; these different environments 
may affect their susceptible to acquiring HHV-8.  
As for examining age with HHV-8 seropositivity rates, only two studies examined this 
association in North American populations. From the Atlanta area, HHV-8 seropositivity rates were 4.2%, 
6%, 1.2%, and 2% among children, 6-11 months, 5-6, 11-12, and 15-17 years of age, respectively; these 
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rates did not significantly increase with age141. In South Texas, seropositivity rates were 18.4%, 30.6%, 
and 26.1% among children ages 0-5, 6-11, and > 12, respectively; these rates appear to increase with 
age170. The pattern of rate differences between these two populations may suggest differences in 
cumulative exposure to HHV-8. As for gender differences with HHV-8 seropositivity, this association 
was not documented in these North American study populations.  
2.6.1.6 Northern Europe 
In Northern Europe, HHV-8 seropositivity rates and the incidence/prevalence of KS have been 
estimated to be low, similarly to North America. For example, seropositivity rates have been estimated to 
be < 5% in the population; and, annual rates of KS has been estimated to be 0.14 cases per million8. 
Because of “reported low” seropositivity rates and incidence of KS in the population, few studies have 
been conducted in examining HHV-8 infections among healthy individuals. Tedeschi et al. conducted a 
population-based sero-survey among 520 individuals, aged 30-60 years, from Sweden in which 
seropositivity rates of 14.4% and 1.7% for antibodies against lytic and latent antigens, respectively, were 
found171. Seropositivity rates in this study population did not increase with age. In addition, there were no 
significant gender differences in HHV-8 seropositivity171. Tedeschi et al. have demonstrated that 
moderate rates of HHV-8 infection are present in Northern Europe’s general population, rates that are 
similar to parts of the Mediterranean and the Caribbean171. 
2.6.1.7 Asia 
The distribution of HHV-8 infections in Asia, which includes Eastern and Southeastern Asia, has 
varied greatly, from 0.2% in Eastern Asia to 53.7% in Southeastern Asia (Figure 9). In Eastern Asia, a 
seroprevalence of 0.2% for antibodies against HHV-8 latent antigens were found among blood donors 
from Japan172. But in Taiwan, a seroprevalence of 19.2% for antibodies against lytic and latent antigens 
were found among healthy blood donors, aged 31-40 years173.  
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As for Southeastern Asia, a wider distribution of HHV-8 seropositivity rates was observed. In 
Thailand, a seropositivity rate of 4% for antibodies against lytic antigens was found among healthy adult 
blood donors. In Malaysia, a similar rate as Thailand, 4.4% for antibodies against lytic antigens, was 
found among healthy blood donors, aged 9-85years4. But, in Cambodia, a seroprevalence of 53.7% for 
antibodies against lytic antigens was detected among individuals, aged 4-69 years, who participated in a 
Schistosoma mekongi cross-sectional study174. Differences in seropositivity rates among these Asian 
countries may be attributed to cultural and/or environmental differences that increase one’s risk for 
acquiring this virus. However, little to no cases of KS has been reported in this region10. 
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Figure 9. HHV-8 Seroprevalence in Asian Populations 
 
As for HHV-8 infections among children from Asia, low to high seropositivity rates have also 
been observed. In Eastern Asia, a seropositivity rate of 3.5% for antibodies against lytic antigens was 
found in South Korean children, aged 1-15 years175; and, seropositivity rates of 3-4% and 12.1% for 
antibodies against lytic and latent antigens were detected among Taiwanese children/adolescents, < 10 
and 11-20 years of age, respectively173. As for Southeastern Asia, seropositivity rates of 68.8% and 50% 
for antibodies against lytic antigens were found among Cambodian children/adolescents < 13 and 13-17 
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years of age, respectively174. The seropositivity rates found in Eastern and Southeastern children reflect 
the rates found in adults from the same geographical area.  
As for HHV-8 seropositivity with age, Sarmati et al. found a significant decrease with 
seropositivity and increasing age among Cambodian children/adolescents: 68.8%, 50%, and 24.4% in < 
13, 13-17, and >17 year olds, respectively (p-value < 0.001)174. However, Haung et al. found inconsistent 
patterns of HHV-8 seropositivity rates with age in Taiwan; seropositivity rates increase from 3% in < 5 
year olds to 19.2% in 31-40 year olds, but decrease to 13.5% in > 70 year olds173. The reasons for the 
inconsistent and decreasing pattern of HHV-8 seropositivity rates with increasing age in Asia are not 
known. As for gender differences, Sarmati et al. found no difference in seropositivity rates among 
Cambodian women and men174; other studies conducted in Asia did not examined this association. 
2.6.1.8 Oceania 
As for the Oceania area, only one study has been conducted that examined HHV-8 seropositivity 
rates in the general population. In this study, a seroprevalence of 0.3% for antibodies against lytic and 
latent antigens were detected in Vanuatu, Southwest Pacific; an area that is consisted of 4 islands: 
Aneityum Island, Etafe Island, Pantecost Island, and Santos Island176. The low seroprevalence of 0.3% in 
the Southwest Pacific was attributed to one HHV-8 seropositive individual from the Santos Island. This 
low HHV-8 seropositivity rate observed in this country also reflects the low to no incidence of KS 
reported in this geographical region. 
2.6.2 Seroprevalence in High-Risk Populations 
Studies have shown that certain groups are at high risk for acquiring HHV-8 infection as well as 
developing KS in comparison to the general population. These high risk groups are the following: 
individuals infected with HIV/AIDS or other sexually transmitted diseases, homosexual males, injection 
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drug users, and organ transplant recipients. Studies that examined these groups in different geographical 
areas are listed below.  
2.6.2.1 HIV/AIDS Infected Persons 
The rates of HHV-8 infection have been high among individuals infected with HIV/AIDS in 
comparison to healthy persons from non-KS endemic area (Figure 10). For example, in Japan, 
seroprevalence of 10.5% for antibodies against latent antigens was detected among HIV positive men 
opposed to 0.2% among healthy blood donors172. In Northern Thailand, a seroprevalence of 28.1% for 
antibodies against HHV-8 lytic antigens was observed in HIV positive couples versus 18.3% in HIV 
negative couples177. In Sao Paulo, Brazil, a seroprevalence of 8% and 1.2% for antibodies against lytic 
and latent antigens, respectively, were found in HIV positive mothers opposed to 0.3% and 1.1% for 
antibodies against lytic and latent antigens, respectively, in healthy women151. In the U.S., a 
seroprevalence of 18.2% against HHV-8 lytic antigen was found in HIV positive women with high-risk 
sexual behavior in comparison to a seroprevalence of 11.6% detected among their negative 
counterparts126; and, a seroprevalence of 23% for antibodies against HHV-8 lytic and latent antigens 
among HIV positive homosexual men versus 10.7% in HIV negative homosexual men were found178.  
In KS endemic areas, differences in HHV-8 seropositivity rates between HIV infected and non-
infected persons are inconsistent (Figure 10). In Ghana, West Africa, a seroprevalence of 45.5% for 
antibodies against HHV-8 lytic and latent antigens was observed in HIV positive individuals opposed to 
32.3% in HIV negative individuals, aged 10-70 years179. But, in Uganda among sexually active 
adolescent, aged 15-19 years, HIV negative individuals had a seropositivity rate of 40% for antibodies 
against HHV-8 lytic and latent antigens opposed to 28.9% in HIV positive individuals180. Also, in 
Zambia, Olsen et al. found no association between HIV and HHV-8 from participants, aged 14-84 years, 
who participated in a hospital-based HIV seroprevalence study181. A possible explanation for HHV-8 
seropositivity differences between HIV and non-HIV persons in KS endemic areas is that HHV-8 is 
 43 
transmitted sexually and asexually in these populations unlike non-KS endemic area where sexual 
transmission is predominant in acquiring HHV-8. 
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Figure 10. HHV-8 Seropositivity Rates between HIV Infected and Non-HIV Persons in Different 
Geographical Areas 
 
HIV/AIDS has also increased the incidence/prevalence of KS throughout the world. In countries 
like the U.S, KS was rarely seen in the population until the onset of the 1980s AIDS epidemic among 
homosexual men. During this epidemic, AIDS-KS was estimated to ~ 40% among homosexual men in 
San Francisco40, 182. A retrospective study showed that HHV-8 infection, seroprevalence of 24.6%, was 
present among homosexual men in San Francisco in 1978, a time before the AIDS epidemic183. Therefore, 
HHV-8 may have been present in high-risk sexual behavior population well before the AIDS epidemic in 
the U.S.  
As for countries where KS (classical and endemic) was prevalent before the AIDS epidemic, the 
incidence/prevalence of KS has also increased as a result of this epidemic, AIDS-KS. With the 
development of highly active anti-retroviral therapy (HAART) and safe sex educational programs, the 
incidence of KS has decreased among HIV-infected patients in the United States90. This decrease in KS 
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may be attributed to an “immune reconstitution” in HIV-infected patients91. However, for countries in 
Sub-Saharan Africa, HAART is not available due to the high financial costs of these medications; 
therefore, KS remains a public health problem in these HHV-8 endemic countries. 
2.6.2.2 Other Sexually Transmitted Diseases Infected Persons 
Since HIV infection is highly associated with HHV-8, other sexually transmitted diseases (STDs) 
have been examined to see if they are associated with this virus. The most studied STDs and HHV-8 
relationship, excluding HIV, are hepatitis B virus (HBV), hepatitis C virus (HCV), and herpes simplex 2 
virus (HSV-2). With HBV, Janier et al. and Sarmari et al. found that men who attend an STD clinic in 
France and men who were prison inmates in Italy, respectively, were > 2 times more likely to be HHV-8 
seropositive than their HBV negative counterparts184, 185. For HCV, Cannon et al. found that HIV positive 
and negative women with high risk behaviors from U.S. were 1.7 times more likely to be HHV-8 
seropositive than HCV negative persons126; but, Schinaia et al. found a higher risk, odd ratio of 8.9, in 
individuals who participated in a HIV screening and infection control program in Albania186. As for HSV-
2, prison inmates from Italy, individuals who were attending an outpatient ward in Northern Cameroon, 
and men who attended a STD clinic in France were 1.7, 2, and 7.1 times more likely, respectively, to be 
HHV-8 seropositive than their HSV-2 negative counterparts126, 184, 185. However, several studies have 
found no significant association with these STDs and HHV-8126, 174, 184, 185, 187. 
STDs such as herpes simplex 1 (HSV-1), gonorrhea, syphilis, and Chlamydia have also been 
studied with HHV-8 infection. Some studies have found significant positive associations with gonorrhea 
and HHV-8 as well as syphilis and HHV-8. Casper et al. and Lavreys et al. found that gonorrhea-infected 
women who practiced high-risk sexual behaviors in the U.S. and gonorrhea-infected female prostitutes in 
Kenya, respectively, were > 2 times more likely to be HHV-8 seropositive than women who did not have 
gonorrhea178, 188. Cannon et al. found that HIV positive and negative women with high risk behaviors from 
U.S. who had syphilis were 2 times more likely to HHV-8 seropositive than women who did not have 
syphilis126. As for HSV-1 and Chlamydia, there were no significant association found with these STDs 
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and HHV-8126, 178. Also, insignificant associations between HHV-8 and these two STDS, gonorrhea and 
syphilis, were found126, 180. 
In conclusion, inconsistent study results have been reported for HBV, HCV, HSV-2, gonorrhea, 
and syphilis in examining HHV-8 seropositivity risk; none of these STDs have been associated with KS 
development or other HHV-8 associated diseases and malignancies. The relationship between these STDs 
and HHV-8 infections still remain inconclusive.  
2.6.2.3 Homosexual Men 
In developed countries, like the U.S., homosexual men are at higher risk for acquiring HHV-8 
infection as well as developing KS than the general population. For example, homosexual men who 
attended a STD clinic in France were 3.7 times more likely to HHV-8 seropositive than heterosexual 
men184. This higher risk applies for not only HIV-infected homosexual men, but also, to HIV negative 
homosexual men in comparison to the general population8, 189, 190. However, HIV-infected homosexual 
men are more likely to develop KS and to be HHV-8 seropositive than HIV negative homosexual men8, 
178. For example, among homosexual adolescents, HIV positive males had a twice as high HHV-8 
seropositivity rate, 23%, than males who did not have HIV, 10.7%178. Studies have examined HHV-8 
seropositivity rate in homosexual men, in particular HIV-infected men, and compared their rates to other 
groups such as bi-sexual and heterosexual men, with or without HIV infection (Figure 11). These studies 
have shown that homosexual men have higher HHV-8 seropositivity rates than bi-sexual men, 
heterosexual men, and the general population178, 184, 187, 191. 
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Figure 11. A Comparison of HHV-8 Seropositivity Rates among Homosexual, Bisexual, and 
Heterosexual Men and Healthy Donors from Different Geographical Areas 
2.6.2.4 Injection Drug Users 
Studies have shown that the duration of injection drug use increases one’s risk for acquiring 
HHV-8 infection. In a study that examined HHV-8 seropositivity rates in injection drug users from San 
Francisco Bay area, women, heterosexual men, and men who have sex with men (MSM) who have 
injected drugs for > 40 years were 5.8, 3, and 3.9 more likely, respectively, to be seropositive than 
individuals who injected drug for < 10 years192. A study conducted in women at high risk for acquiring 
HIV from Detroit, Baltimore, New York, and Providence, Rhode Island also found an increased risk for 
HHV-8 infection by duration of injection drug use; women who used injection drugs daily during the 
study were 3.2 more likely to be seropositive than women who were not injection drug users126. For these 
two U.S. study populations, the association of injection drug use and HHV-8 seropositivity still existed 
after adjusting for HIV status126, 192. However, in a study conducted in the Netherlands, injection drug use 
was not significantly associated with HHV-8 seropositivity or the frequency of injection drug use193. The 
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reason for no association in the Netherlands study population is probably due to the low seropositivity 
rate of 2.7% found among 1179 injection drug users, unlike the San Francisco study (seropositivity rate of 
10% in women, 10% heterosexual men, 23% MSM) and the U.S. multi-center study (seropositivity rate of 
16.1% in women). 
2.6.2.5 Organ Transplant Recipients 
Because organ transplant recipients usually become immunocompromised due 
immunosuppressive therapy, HHV-8 infection has become a public health concern due to possible 
development of KS, the iatrogenic form that is common in solid-organ transplant recipients. Organ 
transplant recipients who are from areas that are associated with endemic and classic KS are usually at 
higher risk for KS development than recipients not from those KS areas. Several studies have examined 
seropositivity rates in post-organ transplants recipients, in particular renal transplant patients, from 
different geographical areas (Table 6). 
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Table 6. HHV-8 Seroprevalence in Post-Organ Transplant Recipients 
Author Country Number of 
Recipients 
Type of 
Transplant 
HHV-8 Sero-
status for 
antibodies 
against lytic 
antigens 
HHV-8 Sero-
status for 
antibodies 
against latent 
antigens 
Delorme et al.194 Quebec, 
Canada 
150 Renal 0% 
Panayiotakopoulos 
et al. 195 
Athens, 
Greece 
48 Renal 4.2%  
Garcia-Astudillo 
et al. 196 
Spain Kidney 
(Renal) = 788; 
Liver = 231 
Kidney, Liver Kidney = 0.6% 
Liver = 3.4% 
Stein et al. 197 Johannesburg, 
South Africa 
430 Renal  7.3% 
Alzahran et al. 198 Saudi Arabia 150 Renal  18% 
Jenkins et al. 13 U.S. Liver = 46, 
Kidney 
(Renal) =19,  
Heart = 13,  
Multi-organ = 
12, Lung = 10 
Liver, Kidney, 
Heart, Multi-
organ, Lung 
Overall: 20% 
Liver = 21.7% 
Kidney 
=15.8% 
Heart = 23% 
Multi-organ = 
16.7% 
Lung = 20% 
 
 
Some studies have shown that the solid-organ transplant recipients had a higher seropositivity 
rate than the healthy study participants: 18% versus 1.7% in Saudi Arabia and 20% versus 9.9% in the 
U.S., respectively13, 198. These study results suggest that organ transplant recipients are at higher risk for 
acquiring HHV-8 infection. In addition, solid-organ transplant recipients may be at higher risk for HHV-8 
reactivation. Jenkins et al. have shown that 10% solid-transplant organ recipients seroconvert from pre-
transplantation to post-transplantation; none of their donors were HHV-8 seropositive. The 
seroconversion that occurred in Jenkins et al. study may have been a reactivation based on high antibody 
titers after transplantation; therefore, undetectable antibodies titers at pre-transplantation were reactivate 
to detectable antibody titers after transplantation due to immunosuppressive conditions.  
Studies have indicated that organ transplant recipients are at high risk for developing KS in areas 
where endemic and classic KS are common. For example, Garcia-Astudillo et al. was able to observe KS 
development in 0.5% of the kidney transplant recipients and 2.16% of the liver transplant recipients from 
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Spain within 33.7 and 10.4 months, respectively, after post-organ transplantation196. As for the U.S. where 
endemic and classic KS is rare, KS usually occurs in 0.5% of transplant recipients13. 
2.6.3 Prevalence of HHV-8 Subtypes (Clades) 
HHV-8 has a varied genome with many subtypes (A-E and N) as well as the M and P alleles that 
are based on the open reading frame (ORF) K1 gene, a transmembrane protein51, 52. Each of these 
subtypes shows predominance in different geographical areas and ethnic backgrounds52, 199. Studies have 
reported that subtypes A and C are found in Europe, Middle East, America, and Asia53, 55, 58; subtype B is 
found in Africa8, 51, 55; subtype D is found in the Pacific Islands200; subtype D and E are found in native 
South American Indian population55; and, subtype N is found in South Africa56, 57. As for the Caribbean 
islands, subtypes A, B, and C have been found in Cuba201; but for the other islands, HHV-8 subtypes have 
not been reported, yet. The subtype differences found in these different geographical regions support the 
idea that HHV-8 has been in the population for a long time, possibly over 35,000 years56, 199, 202. The link 
between these subtypes and the development of HHV-8 associated diseases and malignancies are not 
known51, 53, 58, 203-205.  
2.6.4 Transmission 
HHV-8 can be transmitted sexually or non-sexually. Identifying the presence of HHV-8 DNA has 
been useful in studying routes of HHV-8 infection. HHV-8 DNA has been identified in peripheral blood 
mononuclear cells, urine, semen, prostate, and saliva as well as the rectal, vaginal, and cervical sites91, 124, 
125, 127, 128, 136, 150, 191, 206-211. Studies have shown that saliva has the highest viral load followed by peripheral 
blood mononuclear cells in comparison to other sites. These data suggest that saliva and peripheral blood 
mononuclear cells are primary sites involved in viral shedding (i.e. viral replication)127, 207, 211. Because of 
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the prevalence of viral shedding at these sites, saliva and blood are considered the main routes of HHV-8 
infection in the population124-130, 207, 211. 
2.6.4.1 Sexual Transmission 
Several studies have shown HHV-8 infection is associated with sexual behaviors such as number 
of sex partners, sex with an HIV partner, and the number of sex partners with KS56, 130, 182, 212, 213. In non-
endemic KS areas, sexual transmission appears to be the predominant mode of HHV-8 infection. For 
example, in the U.S., individuals who have been infected with a sexually transmitted disease or identified 
as “men having sex with men” (MSM) have higher HHV-8 seropositivity rates, 11%-23%, in comparison 
to U.S. healthy blood donors, 3% - 5.3%4, 9, 14, 126, 178. The exact methods of acquiring HHV-8 among these 
“high-risk sexual behavior” individuals have been examined. Recent data suggests that HHV-8 
transmission may occur through the exchange of infectious semen, in particular, among HIV-1 infected 
individuals12, 214. 
For geographic regions where KS is endemic, high-risk sexual behaviors and sexually transmitted 
diseases such as HIV/AIDS correspond with an increase in the prevalence of HHV-8 infection and KS in 
that population. For example, in Ghana, a seropositivity rate of 45.5% was reported among HIV positive 
individuals as opposed to 32.3% in non-infected persons179. However, in Uganda among sexually active 
adolescents, a higher HHV-8 seropositivity rate of 40% was observed in HIV negative individuals as 
opposed to 28.9% in HIV-infected persons180. The findings from the study conducted in Uganda suggest 
that sexual transmission may not be the only mode of acquiring HHV-8 infection. Therefore, both sexual 
and non-sexual transmissions are probable modes of acquiring HHV-8 infection in KS endemic areas. 
2.6.4.2 Non-sexual Transmission 
Studies have suggested that HHV-8 can be transmitted non-sexually. In KS endemic areas, HHV-
8 seropositivity rates have ranged from 9.7% in 0-14 year old children from Italy to 39.8% in 5-10 year 
old children from Sub-Saharan Africa7, 138, 157. These rates, especially among pre-pubertal children, 
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suggest non-sexual modes of HHV-8 transmission. Saliva exchange, for example, premastication of foods 
or mother’s saliva to clean wounds, is most likely the probable non-sexual route of transmission among 
pre-pubertal children. For infants, vertical transmission due to HHV-8 shedding into cervicovaginal 
secretions may be one route of HHV-8 infection12, 215; however, studies suggest that this transmission 
route might be rare, due to the low HHV-8 viral load detected in cervicovaginal secretions12, 215. Saliva is 
thought to have the highest HHV-8 viral load compared to any other body site or fluid127, 207, 211. 
Therefore, saliva may be the predominant route of acquiring HHV-8 infection. Because of the high HHV-
8 seropositivity rates observed among children, non-sexual transmission has been identified as the 
predominant mode of HHV-8 infection in KS endemic areas8, 55. 
Studies have also reported that organ transplantation and parenteral transmission are routes of 
non-sexual HHV-8 transmission. For example, with organ transplantation, HHV-8 infection as well as KS 
have been shown to be transmitted from donors to organ recipients54, 216. For parenteral transmission, 
some studies suggest that HHV-8 can be transmitted through blood transfusion and injection drug use192, 
217, 218. These non-sexual routes of transmission may be a major concern for endemic KS areas. 
2.6.4.3 Familial Transmission (non-sexual) 
HHV-8 infection has also been shown to be transmitted among 1st degree family members 
(mother, father, and siblings). Studies have found highly significant familial correlation in HHV-8 
seropositivity rates between mother and child in French Guiana, South Cameroon, rural Tanzania, South 
Africa, and Central and Southern Israel study populations3, 136, 139, 145, 154. Significant associations in HHV-
8 seropositivity rates have also been found between siblings in French Guiana, South Cameroon, and rural 
Tanzania3, 139, 154. Studies conducted in Israel and rural Tanzania found significant associations in HHV-8 
seropositivity rates between father and child and between spouses139, 145; however, these relationships 
were insignificant in French Guiana and South Cameroon3, 154. The associations between parents and child 
and between siblings suggest that saliva or interpersonal contacts (exchange of bodily fluids of broken 
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skin) may be routes of HHV-8 transmission154. As for populations that found an association of HHV-8 
infection between spouses, sexual transmission may be the probable mode of transmitting this virus.  
Studies have also found familial associations with KS and HHV-8 seropositivity rates among 1st 
degree family members. For example, He et al. found that not all mothers infected with KS had children 
infected with KS; but, all children infected with KS had mothers infected with KS137. Guttman-Yassky et 
al. reported that classic KS patients’ 1st degree family members were > 6–fold more likely to be HHV-8 
seropositive than the hospital controls219. In conclusion, these two studies have demonstrated that HHV-8 
infected or KS individuals can affect the HHV-8 sero-status of their 1st degree relatives; however, this 
route of this transmission is not known. 
2.6.5 Genetic Susceptibility 
Based on familial clustering studies, two studies have suggested that some individuals are 
genetically susceptible to HHV-8 infection and KS development. In the French Guiana HHV-8 infection 
familial clustering study, Plancoulaine et al. found that individuals who were homozygous for the human 
genome D allele, DD, were predisposed to HHV-8 infection220. From this study, Plancoulaine et al. has 
concluded that a possible recessive gene controls the susceptibility or resistance to HHV-8 infection, 
particularly in childhood, in endemic populations220 . In the Israel KS familial clustering study, Guttman-
Yassky et al. found that four immunocompetent siblings from a large consanguineous family that were 
clinically diagnosed with classical KS had GC genotype at the -174 interleukin 6 (IL-6) locus, a cytokine 
that may a role in KS pathogenesis; and, three of the four siblings had the DRB1*11 HLA allele, a 
possible risk factor for KS development221-223. In addition, seven out of eight family members without 
classical KS were HHV-8 seropositive; all of the family members except for the father had the GC 
genotype; and, most of the family members had the DRB1*11 HLA allele223. From this study, Guttman-
Yassky et al. has concluded that HHV-8 infected individuals with the IL-6 GC genotype and/or DRB1*11 
HLA allele may be at higher risk for KS development223. 
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2.6.6 Possible Environmental Risk Factors 
Some studies have examined environmental factors that may contribute to acquiring HHV-8 
infection and/or KS development in high risk HHV-8/KS populations135, 224-226 (Table 7). However, these 
environmental factors’ influence on HHV-8 infection and KS development are controversial. 
Table 7. Possible Environmental Co-factors for HHV-8 Infection and KS Development 
Co-factors Possible Influences 
Bloodsucking Insects Increase HHV-8 infection and KS development  
Volcanic areas Increase KS development 
Increase Iron Exposure Increases KS development 
Amyl nitrite 
capsules/inhaled nitrites 
Increase KS development 
Cigarette smoke Decreases KS development 
Use surface water 
(associated with poor 
hygiene) 
Increases HHV-8 infection 
Aqueous and organic 
extracts of natural products 
(i.e., plants, marine 
invertebrates, and fungi) 
Cause reactivation of HHV-8 
 
2.7 PROSTATE CANCER 
Prostate cancer is a global health issue with 679,023 new cases worldwide in 200210. However, 
little is known about the etiology or prevention of this disease. In the United States, prostate cancer is one 
of the most common cancers and the 2nd leading cause of cancer death in men227. It has been estimated 
that 218,890 men will be diagnosed and 27,050 men will die from this malignancy in the year of 2007227. 
Based on these statistics, prostate cancer is a public health problem in the U.S. However, for African-
American men, having the highest incidence and mortality rate than any other ethnic group, prostate 
cancer is a public health burden227.  
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This prostate cancer burden is not only observed in the U.S., but also, in other countries, in 
particular, among men of African descent. For the African-Caribbean male population of Tobago, 11% 
prostate cancer prevalence rate at initial screening was estimated from the population-based longitudinal 
Tobago Prostate Screening Survey17. The reason for this high rate is not known. A case-control study 
conducted among African-Caribbean men from Tobago suggests that HHV-8 infection may possibly be a 
risk factor for prostate cancer9. Further epidemiological studies are needed to examine the relationship 
between HHV-8 infection and prostate cancer development. 
2.7.1 Biology of Prostate Cancer 
The prostate gland is a male organ that is located in front of the rectum and under the urinary 
bladder. The gland is composed of two parts: an epithelium and a connective tissue stroma that is 
comprised of smooth muscle. The prostate’s function is to produce a small amount of seminal fluid in the 
male’s semen; the remaining seminal fluid is produced by the seminal vesicles.  
The development of the prostate gland is regulated by peptide cytokines and sex steroids like 
estrogen and androgens228. Androgens, the most important part in prostate development, are male 
hormones that are present during fetal development into adulthood. Androgens (i.e, testosterone) along 
with growth factors (i.e, transforming growth factor and epidermal growth factors) and stromal cells 
signaling play an important role in maintaining a healthy prostate through the counterbalance of apoptosis 
and cellular proliferation229, 230. Disruption of this balance in prostate epithelial cells can lead to the 
development of prostate cancer. 
2.7.1.1 Pathogenesis 
The pathogenesis of prostate cancer is complex and not well-defined. This process usually starts 
when the DNA of normal prostate epithelial cells are altered or mutated, therefore causing uncontrollable 
cellular growth due to improper or the lack of cellular repair. This uncontrollable growth can develop into 
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a preneoplastic lesion, followed by a primary tumor, and finally a growth that can metastasize, causing 
invasion and destruction of other body tissues and organs (i.e, bone). This cellular process, from normal 
prostate epithelial cells to malignant tumor, can occur in several known pathways such the inactivation of 
tumor suppressor genes, the activation of oncogenes, the lack of apoptosis, or angiogenesis as well as 
pathways that are not yet known230. These known pathways are described below.  
2.7.1.2 Oncogenes/Tumor Suppressor Genes 
Oncogenes are created through the genetic alteration of pro-oncogenes, normal regulatory genes. 
This alternation can occur through mutation of the coding region or translocation of two genes231.  
Oncogenes are thought to be positive regulators of the cell cycle. Oncogenes that may contribute to the 
development of prostate cancer include ras oncogene, c-myc, EIF3S3, ERBB2, PSCA, and the AR 
(androgen receptor) gene.  
Tumor suppressor genes play significant role in the prostate epithelial cellular growth. These 
genes are negative regulators of the cell cycle; therefore, their function is to inhibit abnormal cellular 
proliferation in the prostate. This inhibitory function can be lost when a tumor suppressor gene is 
inactivated, possibly due to allelic deletions, mutations, or loss of expression, allowing for the progression 
of prostate cancer due to uncontrolled growth of the prostate epithelial cells. Tumor suppressor genes that 
may play a role in the development of prostate cancer are RB1 (retinoblastoma gene), TP53, DCC 
(deleted in colon carcinoma gene), BRCA1, p16 MST1/CDKN2, p21 WAF1/C1P1 232. The most studied tumor 
suppressor genes are RB1 and TP53. The loss of pRB function requires the inactivation of both gene 
copies of a diploid cell, the “two-hit” theory. As for TP53, the inactivation of one allele is required for its 
function to be lost which leads to prostate cancer. 
2.7.1.3 Apoptosis 
Apoptosis is defined as programmed cell death and plays an important role in controlling the 
growth of prostate epithelial cells. This process contributes to the maintenance of a homeostatic 
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environment in the prostate by creating a balance with cellular proliferation. If apoptosis is suppressed, 
tumor progression can occur if DNA damaged or mutated prostate epithelial cells continue to proliferate 
uncontrollably. The proteins that play a role in the apoptotic process are listed in Table 8230, 233-235. 
Table 8. Regulators of Apoptosis 
Types Examples 
Oncogenes/ Tumor Suppressor 
genes 
p53, bcl-2/bax, myc 
Growth factor & Growth factor 
receptors 
NGF/NGFR, TNF-alpha/FAS, TGF-
beta/TGFR 
Intracellular Signal 
Transducers 
Protein kinase C and Ca2+ 
Extracellular matrix regulators 
& Signal transducers 
Fibronectin and transmembrane 
integrin receptors 
Endonucleases Ca2+- and Mg2+- dependent DNase 
and cytoplasmic proteases typified 
ICE 
 
The bcl-2 family is considered the most important mediators of apoptosis because they can 
suppress and induce this process236. The TP53 gene functions as a tumor suppressor by regulating 
apoptosis, cell cycle checkpoints, DNA replication and repair which ultimately maintains genomic 
stability236. If the p53 gene is altered, aberrant epithelial cells are created, resulting in the progression of 
prostate cancer. 
2.7.1.4 Angiogenesis 
Angiogenesis, the formation of new blood vessels, is a process involved in embryonic 
development, wound healing, and reproduction237. In addition, angiogenesis aids in the development of 
tumors and metastases by expanding its vascular set-up through degradation of basement membrane by 
protease, proliferation and migration of endothelial cells, cell adhesions, and formation/expansion and 
survival of blood vessels238, 239. Studies have shown that angiogenesis positively correlated with Gleason 
score (measurement of tumor differentiation), tumor stage, metastases formation, and survival; however, 
this association was not found with serum prostate specific antigen (PSA) levels240-246.  
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Before angiogenesis can occur, normal endothelial cells must switch to the angiogenic 
phenotype244. Angiogenic stimulators such as acidic fibroblast growth factor (aFGF), basic fibroblast 
growth factor (bFGF), cyclooxgenase-2 (COX-2), and vascular endothelial growth factor (VEGF) make 
this switch possible in response to some stress such as inflammation or hypoxia238, 244, 247. The most 
studied angiogenic stimulator is VEGF, a cytokine important in vasculargenesis and angiogenesis.  
The angiogenic process can also be prevented by the following inhibitors: thrombospondin-1 
(TSP-1) upregulated by p53, interferon alpha and beta, angiostatin and endostatin237, 244. Because of their 
abilities to arrest tumor growth, these inhibitors have been targeted for antiangiogenic therapy for prostate 
cancer. 
2.7.2 Prostate Cancer Screening/Treatment 
Prostate Cancer screening is consisted of two examinations: serum prostate-specific antigen 
(PSA) determination and digital rectal examination (DRE). The American Cancer Society and the 
American Urological Association recommend these two tests annually in men starting at the age of 50 
with > 10 life-expectancy years, and the age of 45 in men who have a family history of prostate cancer or 
of African descent.  
PSA is a serine protease that is secreted by prostate epithelial cells. Serum PSA concentrations 
increase when prostate’s glandular structure is disrupted by inflammation, hyperplasia, or neoplasia248. 
For prostate neoplasia, serum PSA determination has been considered as the best marker in determining 
prostate cancer progression, with a sensitivity reported to be 71%-81%249-251. Individuals who have a 
serum PSA concentration of > 4 ng/ml have been considered to be at high risk of developing prostate 
cancer; > 4 ng/ml is the recommended cutoff in referring men for a prostate biopsy, a procedure used to 
detect prostate cancer. However, this > 4 ng/ml cutoff has been questioned, especially in individuals at 
high risk for prostate cancer, for example, African-American men. A study conducted in men with 
“normal” serum PSA concentrations had detected prostate cancer in 15.2% of these men252. Because of 
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these missed prostate cancer diagnosis, some researchers have suggested lowering the serum PSA 
concentration cut-point in high-risk populations. Also, to distinguish between benign and malignant 
tumors, alternative methods such as PSA Velocity, Free PSA Measurement, and PSA Density have been 
suggested to use instead of total serum PSA concentration in determining prostate cancer risk. These 
recommended changes for the current serum PSA determination’s standard are still an on-going debate. 
DRE is a procedure in which prostate abnormalities such nodules, induration, or irregular areas 
are evaluated. If any of these abnormalities are noted, prostate biopsy is usually recommended in order to 
determine prostate cancer status. DRE and serum PSA determination are recommended to be used 
together as screening tools for prostate cancer; this combination gives a higher detection rate for localized 
prostate cancer, 78%,  opposed DRE and serum PSA alone, 56% and 75%, respectively251. 
Prostate biopsy, a procedure used to detected prostate cancer, is recommended to be performed on 
individuals who have a serum PSA concentration of > 4 ng/ml and/or an abnormal DRE. Transrectal 
Ultrasound-Guided Biopsy (TRUS) with random systematic parasagittal sextant biopsies has been used as 
the standard protocol in performing prostate biopsies. This needle-biopsy procedure takes six samples of 
the peripheral zone of the prostate, the area where most cancers have been thought to form253, 254. These 
samples will be used to determine the presence or absence of prostate cancer as well as the grade of the 
tumor (well, moderately, poorly differentiated). However, this standard sextant biopsies technique has 
been reported to have a false negative rate of 15% to 31%255, 256. Studies have found by increasing the 
biopsy core, the detection rate increase by 30% to 35%257, 258. Therefore, increasing biopsy sampling (i.e., 
10-core biopsy) will improve the sensitivity of this procedure. 
As for symptoms related to prostate cancer, men are usually asymptomatic in the early stages; 
however, symptoms such as frequent urination, hematuria, or impotence may be experienced at an 
aggressive stage. As for treatment, it is determined on whether the prostate cancer is localized or distant 
metastasis. If the prostate cancer is localized, the following treatment options are available: radial 
retropubic prostatectomy (RRP), external beam radiotherapy (XRT), hormone therapy, brachytherapy, or 
watchful waiting. Radial retropubic prostatectomy which is an excision of the prostate, seminal vesicles, 
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and adjacent tissue has been the preferred surgical procedure due to its low mortality, acceptable 
morbidity, and high disease-free survival rates259. As for advanced prostate cancer cases, monotherapy 
with antiandrogens, androgen receptor antagonists, have been used; however for androgen-independent 
prostate cancer cases, there is no cure.   
2.7.3 Rates of Prostate Cancer 
Prostate cancer is the 2nd most common cancer diagnosed in men in U.S.; the 2nd most common 
cancer diagnosed in men in the European Union; and, the 4th most common cancer diagnosed in men 
worldwide260. According to the International Agency for Research on Cancer, North America had the 
highest rates of prostate cancer; and, Eastern Asia had the lowest rates of prostate cancer in 2002 while, 
the mortality rates were highest in the Caribbean region and, lowest in Eastern Asia10 (Figure 12). 
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2.7.4 Risk Factors 
The etiology of prostate cancer remains unknown; however, studies have identified risk factors 
that contribute to the development of this disease. Race, older age, family history, diet, and the 
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Figure 12. Global Incidence and Mortality Rates (Age Standardized) 
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presentation of high-grade prostatic intraepithelial neoplasia (HGPIN) in the prostate are known risk 
factors for prostate cancer development. Other factors like benign prostatic hyperplasia (BPH), obesity, 
smoking, and viral infections have been examined as possible risk factors in prostate cancer development; 
however, their contribution to this disease development is still unclear.   
2.7.4.1 Race 
African-American men have the highest incidence of prostate cancer; and, Asian and American 
Indian men have the lowest incidence of prostate cancer than any other racial or ethnic group. For 
example, African-American men were found to have > 65-fold greater risk in comparison to mainland 
Chinese men and 2-fold greater risk in comparison to White Americans227, 261. Also, African-American 
men have a higher prostate cancer mortality rate than White Americans. These higher incidence and 
mortality rates may be related to the higher serum PSA levels, higher androgen levels, more advanced 
prostate cancer, worse Gleason score (the grade of prostate cancer), and higher recurrence rates of 
prostate cancer found among African-American men than their white counterparts9, 262-268. African-
American men have not only displayed these high rates of prostate cancer, but also, men of African 
descent from other countries such as Tobago, Jamaica, England, and South America260, 269-271. The high 
prostate cancer rates observed among black men, in particular, African-American men, suggest that 
genetic as well as environmental factors play a role in the etiology of prostate cancer.    
Studies have suggested that genetic differences in the androgen receptor, the gene encoding type 
2 steroid 5-alpha reductase (SRD5A2), and possibly vitamin D binding protein gene may increase 
African-American men’s risk for prostate cancer. For the androgen receptor, African-American men have 
been found to have shorter repeats of CAG and GGC gene lengths found on exon-1 of the Xq11-12 
chromosome in comparison to White and Asian men272-274. These repeats control the transcriptional 
activation of the androgen receptor, therefore, increasing androgen activity which increases prostate 
cancer risk272, 273. As for the SRD5A2 gene, it converts testosterone (an androgen) to dihydrotestosterone 
(DHT), a “more potent” hormone in the prostate epithelial cell which affect cellular proliferation, cellular 
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differentiation, and the lack of cellular apoptosis272, 275, 276. In Reichardt et al. study, African-American 
men were found to have specific polymorphic alleles (TA repeat alleles) of the SRD5A2 gene opposed to 
White and Asian men; these alleles may elevate enzyme activity that increase dihydrotestosterone levels, 
therefore, increasing prostate cancer risk in African-American men277. For the vitamin D binding protein 
gene, high levels of vitamin D has been postulated to decrease prostate cancer risk261, 278. Polymorphic 
variations of the vitamin D binding protein gene between Black and White Americans were found278; 
however, its association with prostate cancer remains unknown.  
Environmental factors such as diet may also play a role in African-American men’s higher risk 
for prostate cancer. Studies suggest that African-American men large consumption of dietary fats, low 
zinc levels, low selenium, and low consumption of lycopene-containing foods which increase their risk 
for developing prostate cancer229, 261, 279-281. For example, dietary fats increase androgen which is 
responsible for the development and growth of the prostate263, 282.  Zinc which is an essential mineral is 
considered an antioxidant that participates in cellular growth and replication283 as well as mitochondrial 
apoptogenesis which lower prostate cancer risk284. Selenium is a trace element that may inhibit cellular 
proliferation, induce apoptosis, and modulate androgen regulated gene285. Lycopene, a carotenoid, may 
inhibit cellular growth286. Consumption differences of these dietary items have been found between 
African-American men in comparison to White and Asian men261.  
2.7.4.2 Age 
The incidence of prostate cancer increases with age. Men who are 75 years of age have > 100-
fold higher risk for prostate cancer than men who are 45 years of age287. In the U.S. from 2000-2004, 
incidence rates of 8.4%, 27.3%, and 36.7% were found in men between the ages of 45-54 years, 55-64 
years, and 65-74 years, respectively227. The mortality rates of prostate cancer also increase with age. In 
the U.S. from 2000-2004, a mortality rate of 6.6%, 20.8%, and 41.8% were found in men between the 
ages of 55-64 years, 65-74 years, and 75-84 years, respectively227. Therefore, age is an important risk 
factor for prostate cancer. 
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2.7.4.3 Family History 
Studies have indicated that men with 1st degree relatives (father, brother, or son) with prostate 
cancer are at higher risk than men with no family history of prostate cancer. Whittlemore et al. reported 
that men with a family history of prostate cancer were at a 2 to 3-fold higher risk for prostate cancer 
development287, 288. The Massachusetts Male Aging Study reported a 3.78 higher risk in men with a 
prostate cancer family history than men without a prostate cancer family history260, 289. Steinberg et al. 
reported that men with a 1st degree, 2nd degree, and both 1st and 2nd degree relatives had a 2-fold, 1.7-fold, 
and 8.8-fold higher risks of developing prostate cancer, respectively290, 291. In addition, men with 
hereditary prostate cancer are presented with this disease at an earlier age than other prostate cancer 
cases292. As a result of this earlier presentation, the American Cancer Society has recommended an earlier 
screening age (begin at or before the age of 45) for men with a strong family history of prostate cancer. 
Studies have identified prostate cancer susceptibility genes that are associated with hereditary prostate 
cancer in men292; these genes are listed in Table 9.  
Table 9. Possible Prostate Cancer Susceptibility Genes 
Gene Chromosome 
position 
Associations 
Hereditary Prostate 
Cancer I (HPC1) 
gene 
1q24-25 - Found in 6% of hereditary 
prostate cancer cases 
Prostate (PCAP) 
gene 
1q42.2-43 - Found among men in Southern 
and Western Europe 
Human Prostate 
Cancer (HPCX) 
gene 
Xq27-28 - Associated with late-onset 
prostate cancer 
- Found in 16% of hereditary 
prostate cancer cases 
- Not found in African-Americans 
HPC2/ELAC2 17p12 - Linked to a Utah family 
HPC20 20q13 - Associated with late-onset 
prostate cancer 
Note: References292-299   
 
Studies have also suggested these genes may have been acquired through x-linked or autosomal-
recessive inheritance292, 300.  
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2.7.4.4 Prostatic Changes 
 
HGPIN is considered a pre-malignant lesion for prostate carcinogenesis301. HGPIN precedes the 
onset of prostate cancer within 10 years302; and, it increases with age which this increase also correlates 
with prostate cancer development302-304. In addition, HGPIN is multi-focal like prostatic carcinoma and 
they are both found in the same peripheral zone305. HGPIN has a phenotype and genotype that is between 
normal prostate epithelium and prostate carcinoma306. African-American men, aged 50-60 years, have 
been found to have a higher frequency of HGPIN in comparison to their White counterparts306-310;  and, 
mainland Japanese men have been found to have a lower frequency than American men306, 311, 312. These 
higher and lower rates of HGPIN parallels the high and low incidences of prostate cancer found in 
African-American and Asian men, respectively. 
2.7.4.5 Diet 
Studies have suggested that diet may increase prostate cancer risk in men. Foods like dietary fats, 
red meat, dairy products, and soy products as well as selenium, vitamin E (alpha-tocopherol), vitamin D, 
and lycopene have been indicated to have an affect on prostate cancer development229, 279, 285. Possible 
effects of these agents are listed in Table 10. 
Table 10. The Association between Higher Intake of Food Items and Prostate Cancer Risk 
Food Items Function(s) Increased or Decreased 
Prostate Cancer Risk 
Dietary fats Increase androgen levels  Increased risk 
Selenium Inhibits cellular proliferation, induces 
apoptosis, and modules androgen genes  
Decreased risk 
Vitamin E  
(alpha-tocopherol) 
Has anti-androgenic activity Decreased risk 
Vitamin D Inhibits proliferation on prostate cancer 
cells 
Decreased risk 
Lycopene Inhibits cellular growth Decreased risk 
Soy Inhibits cellular proliferation and has anti-
angiogenesis and antioxidant properties 
Decreased risk 
Note: References229, 279, 285-287   
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Large-scale clinical trials such as the Nutritional Prevention of Cancer Trial, the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Trial, the Beta-Carotene and Retinol Efficacy Trial, and 
most recently SELECT have been conducted to examine whether certain dietary factors like selenium and 
alpha-tocopherol can be used as chemopreventive agents in reducing prostate cancer risk285.  
2.7.4.6 Other Possible Risk Factors 
The relationship between prostate cancer risk and other possible risk factors such as benign 
prostatic hyperplasia (BPH, an overgrowth of the prostate), obesity, physical activity, and viruses have 
not been well-defined; studies have reported conflicting results. Therefore, more research is needed to 
study the effects of BPH, obesity, or viruses on the development of prostate cancer. 
2.8 HHV-8, PROSTATE CANCER, AND INFLAMMATION 
Chronic inflammation may play a role in the pathogenesis of prostate cancer. Chronic 
inflammation is a persistent inflammatory response that is triggered by an infectious agent, environmental 
factor, (i.e., diet, physical or chemical injury, or hormonal exposure), or a combination of both313, 314. 
Chronic inflammation triggered by an infectious agent has caused the development of the following 
known cancers: Hepatitis B & C (liver cancer), Helicobacter pylori (stomach cancer), Schistosomes (bile 
duct/bladder cancer), human papillomaviruses (cervical carcinoma), human polyomaviruses 
(mesotheliomas, brain tumors), Epstein-Barr virus (B-cell lymphoproliferative diseases and 
nasopharyngeal carcinoma), Human T-cell Leukemia Virus-1 (T-cell leukemias), and HHV-8 (KS, 
primary effusion lymphoma)315, 316. As for the development of prostate cancer, evidence has shown that 
inflammation may be associated with prostate cancer. For example, studies have found anti-inflammatory 
agents such as aspirin or non-sterodial anti-inflammatory drugs (NSAIDS) reducing prostate cancer risk 
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~15-20314, 317-320. These anti-inflammatory studies support the presence of inflammation in the prostate; 
therefore, the relationship between chronic inflammation and prostate cancer should be examined.  
2.8.1 Infectious agents and Prostate Cancer 
Studies have suggested that infectious agents (certain bacteria and viruses) may contribute to the 
development of prostate cancer314, 321. For example, sexually transmitted diseases (STDs) such as 
Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomomas vaginalis, and Treponema pallidum 
(syphilis) and non-sexually transmitted diseases such as Propionibacterium acnes and Escherichia coli 
are known to infect the prostate and cause acute or chronic bacterial prostatitis, inflammation of the 
prostate314, 322-327. In addition, studies have identified DNA from viruses like human papillomavirus 
(HPV), human herpes simplex virus (HSV-2), cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and 
HHV-8 in the prostate which may also contribute to chronic inflammation15, 209, 314, 328-332. Chronic 
inflammation has been hypothesis as another pathway to prostate carcinogenesis through the recruitment 
of macrophages, lymphocytes, and mast cells which elicit inflammatory cytokines that can 1) cause 
cellular and genomic damage and 2) increase tissue repair, cellular replication, and angiogenesis in the 
prostate314, 321, 331, 333-337.  
Epidemiological studies have found a significant positive association between prostate cancer and 
the following STDs: HPV type 18, syphilis, gonorrhea, and HHV-89, 331, 338, 339 (see Table 11). Based on a 
longitudinal study of men who attended a std clinic, serum PSA levels, a marker of prostate cancer 
progression, have been found to be increased in men who were diagnosed with a std, > 40% increase, than 
their negative counterparts340. However, the influence of STDs on serum PSA levels remains unclear due 
to conflicting study results on the relationship between chronic prostatitis caused by these infections and 
prostate cancer339, 341, 342. As for the relationship between inflammatory cells and prostate cancer, there 
have been no epidemiological studies conducted yet that have examined this relationship. In conclusion, 
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the association between these infectious agents and prostate cancer development still remains 
inconclusive.   
Table 11. Significant Positive Associations between Infectious Agents and Prostate Cancer 
Infectious Agents Odds Ratio (OR)/Relative Risk(RR) 
(95% Confidence Interval) 
History of any STDs339 RR= 1.44 (1.24-1.66)  
HPV type 18338 RR= 2.59 (1.17-5.75)  
History of syphilis339 RR= 2.30 (1.34-3.94)  
History of gonorrhea339 RR= 1.36 (1.15-1.61)  
HHV-89 OR= 2.24 (1.29-3.90)  
 
2.8.2 HHV-8 and Prostate Cancer 
HHV-8 may be a contributor in the inflammatory process in the prostate. Previous studies have 
shown the presence of HHV-8 DNA in prostatic tissue as well as in semen15, 209, 332. HHV-8 is known to 
express viral proteins in infected cells during latency (i.e, LANA-1) and lytic replication (i.e, v-IL-6). 
LANA-1 is known to block apoptosis, stimulate cellular transformation, downregulate p53, and target Rb 
(tumor suppressor); and, viral Il-6 (v-IL-6) is known to induce cellular proliferation, prevent apoptosis, 
and contribute to tumor angiogenesis. A recent study has shown the expression of HHV-8 proteins 
(LANA-1, vIL-6, and K8.1) in normal prostates; and, there was evidence of local inflammation 
(macrophage/monocyte marker and B-cell marker) in the prostate16. This data supports the presence of 
HHV-8 in the prostate and its possible role in the inflammatory process. The presence of these viral 
expressions may contribute to the development of prostate cancer by injuring prostate epithelial cells, 
which result in proliferative inflammatory atrophy (PIA) which leads to the prostate carcinogenesis314.  
Viral IL-6 (v-IL-6) may play an important role in the development of prostate cancer. This 
cytokine is a homology of human IL-6 (hIL-6) and it is expressed during HHV-8’s early-lytic replication 
stage8, 39, 40 343. Studies have reported that viral IL-6 shares between 24% to 62% similar amino acid 
sequence to hIL-68, 39. These IL-6s also have similar functions which are to “bestow upon the infected cell 
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resistance to immune mediated apoptotic stimuli, thus ensuring the survival and propagation of the viral 
pathogen” 344. However, vIL-6 stimulates multiple cellular pathways to induce cellular proliferation40; 
and, it can bind directly to glycoprotein 30 (gp30) to initiate signaling through several pathways (i.e. Jak-
STAT) unlike hIL-6 that also needs IL-6R alpha, a co-receptor8, 40. Because of the IL-6’s similar 
properties and functions, HHV-8’s vIL-6 may be a major contributor to the development of prostate 
cancer in some individuals. 
2.8.3 HHV-8 and Prostate Cancer Studies 
The relationship between HHV-8 infection and prostate cancer has been examined in many study 
populations. Hoffman et al. found significant association between HHV-8 seropositivity and prostate 
cancer in Tobago (Tobago cases versus Tobago controls and Tobago cases versus Trinidad controls) and 
in Pittsburgh, Pennsylvania (Pittsburgh cases versus US blood donors)9. However, inverse associations 
were found between HHV-8 seropositivity and prostate cancer in U.S. populations345, 346 (Table 12). A 
nested case-control study conducted among men in the U.S. Health Professional Follow-up Study found a 
significant inverse association between prostate cancer and HHV-8 seropositivity (O.R. = 0.70, 95% C.I., 
0.52 – 0.95), with seropositivity of 13.5% and 18% for the cases and controls, respectively347. Studies that 
found a found positive but non-significant association were conducted in populations in Pittsburgh, 
Pennsylvania and the Bologna region in Italy9, 345. The reason for differences in association between 
HHV-8 and prostate cancer among Tobago, Pittsburgh, Italy, other U.S. populations, and Finland may be 
related to lifestyle or genetic differences in the populations.  
Most of these studies used the same serological assay, mIFA, which detects antibodies against 
HHV-8 lytic antigens9, 13, 345, 347. 
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Table 12. HHV-8 Seropositivity and Prostate Cancer Studies 
 Prostate Cancer 
Cases (n/N) 
(% HHV-8 +) 
Controls (n/N) 
(% HHV-8 +) 
Odds Ratio (95% 
Confidence Interval)  
Tobago cases vs Tobago 
controls (Hoffman 2004) 
55/138 (39.9%) 32/140 (22.9%) 2.24 (1.29-3.90) 
Tobago cases vs Trinidad 
controls (Hoffman 2004) 
55/138 (39.9%) 35/174 (20.1%) 2.63 (1.56-4.50) 
Pittsburgh cases vs US blood 
donors (Hoffman 2004) 
20/100 (20%) 9/177 (5.1%) 4.67 (1.91-11.65) 
Pittsburgh cases vs Pittsburgh 
cancer controls (Hoffman 2004) 
20/100 (20%) 13/99 (13%) 1.65 (0.77-3.54) 
Finland cases vs Finland  
controls (Korodi 2005) 
3/163 (1.8%) 7/288 (2.4%) 0.74 (0.19-2.88) 
Italy cases vs Italy BPH controls 
(Jenkins 2007) 
4/10 (40%) 13/34 (38.2%) 1.08 (0.27-4.33) 
Washington, DC cases (Black) 
vs Washington, DC BPH 
controls (Black) (Jenkins 2007) 
7/41 (17.1%) 19/98 (19.0%) 0.88 (0.35-2.24) 
U.S. White cases vs U.S. White 
controls (Jenkins 2007) 
19/104 (18.7%) 20/80 (24.4%) 0.71 (0.36-1.43) 
U.S. Black cases vs. U.S. Black 
controls (Jenkins 2007) 
17/95 (17.5%) 21/75 (27.5%) 0.56 (0.28-1.14) 
Note: In bold, numerator not given 
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3.0  PUBLIC HEALTH SIGNIFICANCE 
Prostate cancer is a global health issue with 679,023 new cases detected in 2002 worldwide10. 
African-American men are known to have the highest incidence and mortality rate than any other ethnic 
group, incidence rate 60% higher and mortality rate 2-fold higher than Whites in the U.S. 227. High rates 
of prostate cancer have also been observed in the African-Caribbean population of Tobago, an 11% 
prevalence rate at initial screening17. Prostate cancer is a public health problem, particularly in men of 
African descent; therefore, possible etiologies of this cancer need to be examined in high-risk populations.   
HHV-8 infection varies geographically, ranging from 3% in the U.S. to 87% in Botswana where 
KS is endemic.  However, little is known about this newly, discovered virus’ biology, pathogenesis, and 
carcinogenic effects.  Hoffman et al. demonstrated that men with prostate cancer have a significantly 
higher HHV-8 seropositivity rate than men without prostate cancer, 39.9% and 22.9%, respectively (p-
value = .003)9. Studies have shown that HHV-8 DNA and its viral proteins are present in prostatic 
tissue15, 16. However, HHV-8’s influence on prostate cancer development remains unknown.  
To understand the relationship between prostate cancer and HHV-8, we propose to examine 
HHV-8 seropositivity among Tobago women, identify possible modes of sexual transmission of HHV-8, 
study the natural history of HHV-8 seropositivity, and investigate the relationship between HHV-8 and 
prostate cancer risk. This study “The Evaluation of HHV-8 Infection in Tobago” will be an important 
resource in understanding HHV-8 and possible relationships between HHV-8 infection and prostate 
cancer. We hope that this study will provide knowledge that assists in the development of appropriate 
interventions to prevent HHV-8 infection and possibly prostate cancer in at risk populations.  
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4.1 ABSTRACT 
Human herpesvirus 8 (HHV-8) infection is present in 22.9% of Tobago men. However, 
seroprevalence and modes of transmission of HHV-8 among Tobago women are not known. HHV-8 
seropositivity rates in Tobago women were examined and compared rates to Tobago men of similar ages. 
To assess possible modes of transmission, sexual behavior among Tobago women was examined to 
determine its association with HHV-8 seropositivity.   
A cross-sectional study was conducted in 213 Tobago women, ages 18-65 years, who participated 
in the Tobago Cervical and Oral Cancer Screening Study. HHV-8 seropositivity was determined by a 
monoclonal immunofluorescence assay. Age-specific rates were compared to those previously observed 
in men. Logistic regression analyses were performed to determine the association between HHV-8 
seropositivity and sexual behavior among the women.   
HHV-8 seroprevalence among Tobago women was 14.1% (95% C.I., 10 - 19%), with no 
significant differences with men of similar age (p-value = .741).  Age < 17 years at first sexual 
intercourse was found to have a minimal significant association with HHV-8 seropositivity (O.R. = 2.51, 
95% C.I. = 1.09-5.78) in women. 
HHV-8 age-specific rates were similar between genders. Sexual activity may not be a major 
contributor to HHV-8 infection among Tobago women. 
 
 
 
 73 
4.2 INTRODUCTION 
Human herpesvirus 8 (HHV-8), a member of the Family Herpesviridae and subfamily 
Gammaherpesvirinae, is the causal agent of Kaposi’s sarcoma (KS) and primary effusion lymphoma and 
has been associated with multicentric Castleman’s disease1, 81-83. HHV-8 seroprevalence varies 
geographically and is considered endemic in Mediterranean countries where seropositivity rates are as 
high as 31% in Southern Italy144, and in Sub-Saharan Africa, where seropositivity reaches 87% in 
Botswana Africa2. KS is relatively common in these areas: incidence is as high as 8.8 and 30 per 100,000 
population per year in Italy and Sub-Saharan Africa, respectively2, 10, 143, 144. In the United States and parts 
of Northern Europe where KS is not prevalent, low to moderate HHV-8 seropositivity rates (3% to 23%) 
have been reported4, 8, 9, 14, 169. 
HHV-8 infection is known to be a sexually transmitted disease (STD); however, the presence of 
HHV-8 infection among pre-pubertal children suggests that HHV-8 can also be transmitted non-sexually. 
Studies have suggested non-sexual transmission (i.e., saliva exchange) as the primary mode of HHV-8 
transmission in hyper-endemic KS areas like Sub-Saharan Africa8, 12, 55. However, in non-KS endemic 
areas like the U.S. and Northern Europe, sexual transmission is believed to be the predominant mode of 
HHV-8 transmission among high-risk populations such as men having sex with men12, 166, 348, 349 .  
In the Caribbean islands,  six studies4, 9, 159, 161-163 have examined HHV-8 infection; however, only 
two studies161, 163 examined possible modes of HHV-8 transmission. To have a better understanding of 
HHV-8 infection in the Caribbean island of Tobago, we used rates from a previously conducted cross-
sectional study among 215 healthy Tobago women, 18-65 years of age. In this population, we examined 
HHV-8 seropositivity rates, and investigated possible modes of transmission by analyzing  available 
information on sexual behavior. 
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4.3 METHODS 
4.3.1 Study Population 
The Tobago Cervical and Oral Cancer Screening Study is a cross-sectional study conducted 
among healthy women to examine the prevalence of oral and cervical human papillomavirus (HPV) 
infections in Tobago350. Between July and August 2004, study participants were recruited by posters, 
flyers, television, radio public announcements, presentations in churches, seminars with health care 
workers at the Tobago hospital, and word of mouth. Women who had a terminal illness, did not sign an 
informed consent, or were not the ages 18-65 years were excluded from participation in the study. Two-
hundred sixteen women were approached, and 215 of them agreed to participate in the screening. Blood, 
cervical, and oral epithelial cells were collected at the study visit.  Of the 215 women, blood samples were 
available for all except 2 study participants; as a result, 213 women were included in the present study. 
Demographic and health information, family medical history, and sexual lifestyle behaviors were 
collected through the Tobago Cervical and Head and Neck Cancer Health Assessment which included the 
standardized questionnaire by the University of Pittsburgh Head and Neck Cancer Program as well as 
elements from the Centers for Disease Control and Prevention’s Sexual Lifestyle Questionnaire350. The 
sexual lifestyle part of the assessment was self-administered in a private room, and then enclosed in a 
sealed envelope by the participant. At the end of the study, all of the participants’ assessments were 
mailed to the University of Pittsburgh for data entry and data analysis. 
HHV-8 seropositivity rates of Tobago men, ages 40-65 years, were used as a comparison. These 
men represented the control group in a case-control study on the association between HHV-8 
seropositivity and prostate cancer conducted in Tobago between 1997 and 20009. Control male 
participants were drawn from a population-based prostate cancer screening study17, and had normal 
digital rectal examination (DRE) and serum prostate-specific antigen (PSA) values < 4.0 ng/mL17. An 
additional 97 men, ages 40-65 years, from the Tobago prostate cancer screening study (n = 3201) were 
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added to the existing controls (n = 62), giving a total of 159 men between the ages 40-65 years; their 
seropositivity rates were compared to those observed in a subset of the Tobago women (n = 122) 
belonging to the same age range (40-65 years)9. 
Demographic information for men was collected from the Tobago Prostate Cancer Screening 
Survey questionnaire. Sexual lifestyle behaviors were not collected during this survey. All blood samples 
were tested for antibodies against HHV-8 lytic antigens at the University of Pittsburgh. 
All study participants signed an informed consent that was approved by the University of 
Pittsburgh Biomedical Institutional Review Board (IRB) and the IRB of the Division of Health and Social 
Services, Tobago House of Assembly.  
4.3.2 Laboratory Methods 
A modified HHV-8 monoclonal antibody-enhanced immunofluorescence assay (mIFA) that 
assessed lytic antigens using the BCBL-1 cell line, as described elsewhere13, was used to test blood 
specimens (plasma from Tobago women & serum from Tobago men) for HHV-8 seropositivity at the 
University of Pittsburgh. A HHV-8 seropositive result was reported for specimens that gave fluorescence 
at the dilution cut-off value of 1:100. For each mIFA run, known HHV-8 positive and negative sera were 
included. All blood specimens were tested in duplicates per lab run on 2 different days. A 10% random 
sample of blood specimens were tested twice in a blinded fashion per assay run. Agreement between 
duplicates was substantial 351 (Kappa intra-batch = 0.78, 95% confidence interval [C.I.], 0.38 –1.00, based on 
n = 33 sample pairs; Kappa inter-batch = 0.61, 95% C.I.,  0.46 - 0.77, based on n = 202 sample pairs with 
non-missing mIFA test results from the first two laboratory runs). HHV-8 antibody titers were also 
determined by mIFA on serially diluted serum samples (1:100 to 1:51,200). All blood specimens that 
were analyzed by mIFA were assessed microscopically by the same reader. 
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4.3.3 Data Analysis 
The overall frequency and age-specific frequency distribution were used to measure the 
seroprevalence of HHV-8 infection among the Tobago women. Pearson’s chi-square test was used to 
examine whether there were any differences in HHV-8 seropositivity rates among these age groups (18-
29, 30-39, 40-49, 50-59, 60-65 years).  HHV-8 antibody titer of women who tested HHV-8 seropositive 
was examined by age groups. Fisher’s exact test was used to determine whether there was a difference in 
antibody titer (low, < 800 versus high, > 800) between younger (ages 18-39 years) and older (ages 40-65 
years) women. 
The Mantel-Haenszel chi-square test was used to determine if there was a difference in the 
overall seroprevalence of HHV-8 infection between Tobago women and men of comparable age, after the 
Breslow-Day test for homogeneity was conducted. The Pearson’s chi-square test or Fisher’s exact test (if 
appropriate) was used to examine whether there were any differences in age-specific HHV-8 
seropositivity rates for each age group (40-49, 50-59, 60-65 years) between genders.  
Logistic regression analyses were performed to assess the independent contribution of each study 
variable (age, marital status, history of cancer, oral and cervical HPV detection, and sexual lifestyle 
behavior variables) to HHV-8 sero-status, and to analyze the interaction of age and the study variables on 
HHV-8 sero-status.  
Nine sexual behaviors plus results from HPV oral and cervical screening listed in Table 13 were 
scored (0 or1) based on a prior hypothesis of their likelihood of having a positive association with HHV-8 
seropositivity. A score of 0 was given to the reference group (no risky behavior and/or no presence of 
HPV DNA); a score of 1 was given to the exposed group that had the risky behavior and/or presence of 
HPV DNA (Table 13). The studied variable “Number of partners in the past 12 months” was collapsed to 
none or one partner (score = 0) in comparison to two or more partners (score = 1). Women who did not 
answer all 9 sexual behavior questions and had no HPV oral or cervical results were excluded from this 
analysis. To alleviate converging problems in the logistic regression model, sexual behavior scores were 
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divided in the following categories: category 1 (scores 1-4), category 2 (score 5), category 3 (score 6), 
category 4 (score 7), and category 5 (scores 8-11). 
All data analyses were conducted with SPSS version 12.0; an alpha level of 0.05, two-sided, was 
set for all the analyses. 
4.4 RESULTS 
4.4.1 Study Population Characteristics 
A total of 213 Tobago women, ages 18-65 years, was included in the study. The median age was 
41.0 years (25-75% percentile, 35-48 years). Of these women, 83.1% identified themselves as African-
Caribbean, 7% as mixed race, and 1.9% as East-Indian; 8% of the women did not report their race. The 
majority of women reported that they were married at the time of interview (51.6%). 
The HHV-8 sero-status of 159 Tobago men, ages 40-65 years, were compared to that of the 
subset of Tobago women of comparable age (n = 122). The median age of the male study population was 
59.0 years (25-75% percentile, 53-63 years).  The median age of the female subset study population was 
47.0 years (25-75% percentile, 45-53 years). The majority of the female subset and of the men reported 
that they were married at the time of the interview (62.3% and 71.7%, respectively).  
4.4.2 HHV-8 Seroprevalence 
An overall seroprevalence of 14.1% (95% C.I., 10 - 19%) for antibodies against HHV-8 lytic 
antigens was found among Tobago women. HHV-8 seroprevalence point estimates varied across age 
groups, with the lowest prevalence observed in the age group 30-39 years, and the highest prevalence 
observed in the age group 60-65 years (Figure 13). However, there were no significant differences in 
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HHV-8 age-specific seropositivity rates among the age groups (18-29, 30-39, 40-49, 50-59, 60-65 years) 
(p-value = .835).  
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Figure 13. HHV-8 Seropositivity Rates According to Age in Tobago Women and Men 
 
4.4.3 HHV-8 Antibody Titers Distribution 
There were 30 HHV-8 seropositive women; their IgG antibody titer against HHV-8 lytic antigens 
ranged from 1:100 to 1:6400 (Figure 14). The median antibody titer was 400 (25-75% percentile, 200-
800) among the seropositive women. Overall, women, ages 40-65 years, were more likely to have an 
antibody titer of > 800 (8.2%, n = 10/122) than women, ages 18-39 years (0%, n = 0/90) (p-value = .006). 
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Figure 14. The Frequency of HHV-8 Antibody Titers in HHV-8 Seropositive Tobago Women by Age 
Groups (N = 30) 
4.4.4 Comparison of HHV-8 Seropositivity Rates between Tobago Women and Men 
Across age groups 40-65 years, HHV-8 seropositivity rates were 14.8% (95% C.I., 9.0 - 22.3%) 
in women and 20.8% (95% C.I., 14.7 - 27.9%) in men. Adjusting for age, the test of homogeneity (p-
value = .946) and differences in HHV-8 seropositivity between men and women were not statistically 
significant (p-value = .741) (Figure 13). However, in each age group, Tobago women had a lower HHV-8 
seropositivity rate than their male counterparts (Figure 13). 
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4.4.5 Risk Factors for HHV-8 Infection 
HHV-8 seropositivity was analyzed in relation to sexual lifestyle behavior in women (Table 13). 
HHV-8 seropositivity was not statistically associated with any sexual behavior variables, except for “age 
at first sexual intercourse”. Tobago women who reported to have their first sexual intercourse at < 17 
years of age were 2.51-fold more likely (95% C.I., 1.09-5.78)  to be HHV-8 seropositive than women 
who reported to have their first sexual intercourse at > 18 years of age.  In addition, marital status, history 
of cancer, and HPV DNA detected in oral and cervical cavity were not associated with HHV-8 sero-
status. 
No significant interactions were observed between age and any studied variable. 
Out of the 9 sexual behavior variables plus 2 HPV screening variables listed in Table 13, the 
combined sexual behavior scores (including HPV screening results) ranged from 1 to 9 with a mean score 
of 6.3 (95% C.I., 6-6.5) among 115 women. In the logistic regression model, the number of women in the 
combined sexual behavior score categories were the following: 15 in category 1 (scores 1-4), 15 in 
category 2 (score 5), 30 in category 3 (score 6), 35 in category 4 (score 7), and 20 in category 5 (scores 8-
11).There was no statistically significant association between HHV-8 seropositivity and the combined 
sexual behavior scores after adjusting for age (p-value = .282). There was no statistically significant 
association with HHV-8 seropositivity when the combined sexual behavior scores were divided into two 
categories: low score of < 6 (6.7% seropositive, n = 2/30) and high score of > = 6 (17.6% seropositive, n 
= 15/85) (p-value = .231).  
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Table 13. Potential Risk Factors for HHV-8 Infection in Tobago Women 
Variables 
(Reference/ Exposed 
Groups) 
Number in  
Reference/Exposed 
Groups 
Odds ratio* 
 
 
95% Confidence 
Interval 
Marital Status 
(married/widow  vs. 
single/other)  
118/92 .74 .31-1.76 
History of Cancer (no/yes) 198/8 2.17  .40 – 11.94 
Age at 1st sexual 
intercourse (age  > 
106/87 
18 vs. 
age < 17) 
2.51  1.09 – 5.78 
Number of lifetime 
partners (one partner vs. 2 
or more partners) 
29/164 .81  .28 – 2.33 
Ever diagnosed with a 
STD (no vs. yes) 
175/21 1.84  .61 – 5.50 
Sexual intercourse in the 
past 12 months (no vs. yes) 
25/170 1.65  .42 – 6.42 
Number of partners in the 
past 12 months (none vs. 
one partner; none vs. two 
or more partners) 
17/153 .76  .19 – 3.13 
17/43 .79  .17 – 3.76 
Condom used during 
vaginal sex 
(sometimes/frequently vs. 
no) 
104/82 .86  .37 – 2.00 
Ever had oral sex  (no vs. 
yes) 
59/128 .63  .26 – 1.55 
Condom used during oral 
sex (sometimes/always vs. 
no) 
16/111 1.18  .25 – 5.73 
Partner performed oral sex 
(no vs. 
occasionally/frequently) 
33/153 .61  .22 – 1.69 
HPV detected in oral 
cavity (no vs. yes) 
197/15 1.58  .42 – 5.97 
HPV detected in cervix (no 
vs. yes) 
137/75 .92 .4 – 2.11 
Note. - * = age-adjusted, HPV= Human papillomavirus, STD= sexually transmitted disease, vs. = versus 
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4.5 DISCUSSION 
This study indicates that HHV-8 infection is present among Tobago women at a frequency similar 
to that previously reported in men3, 9, 144, 166. The seropositivity rate observed among these women is 
comparable to rates found among women in the Mediterranean area6, 7, 142. As for KS,  this incidence has 
been reported to range from 0.2 to 2.8 per 100,000 population per year among women in the 
Mediterranean region142, 143, 145. In Tobago, no cases of KS have been reported for women and men during 
the period of 1994-199710, 11. The lack of KS in Tobago despite the moderate rates of HHV-8 infection 
may be due to the immune status of the population, genetic make-up that prevents disease 
development/progression to clinical stage, possible environmental factors (for example, diet), under-
reporting of KS to health officials, or a small population size. 
A gradual increase in HHV-8 seropositivity was observed among Tobago women, from ages 30-
39 years to ages 60-65 years. Women ages 18-29 years had a higher HHV-8 seropositivity in comparison 
to women ages 30-49 years; this higher seropositivity among younger women may be due to a cohort 
effect. Women > 40 years of age had a higher prevalence of antibody titer > 1:800 than women ages < 39 
years. The reason for the higher antibody titers among older women may be due to cumulative exposure 
to HHV-8. As for the male controls in Hoffman et al. study, the overall median antibody titer among these 
seropositive men (n = 15/159), ages 40-65 years, was lower (median = 400) in comparison to women (n = 
18/122) of similar ages (median = 800)9. The reason for the lower median antibody titers among men in 
comparison to women is not known. 
As for gender and HHV-8 seropositivity with age, the overall HHV-8 seropositivity rate as well 
as the rates across age groups (40-49, 50-59, 60-65 years) were higher in Tobago men in comparison to 
Tobago women; however, these seropositivity rates did not significantly differ. This lack of significant 
gender difference in seropositivity rates is consistent with studies conducted in Sub-Saharan Africa3, 
Italy144, and the United States166, 169.   
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Few studies have examined HHV-8 infection in Caribbean populations. Studies conducted in 
Dominican Republic162, Cuba161, and Haiti162 found moderate HHV-8 seropositivity rates for antibodies 
against HHV-8 lytic antigens, 13%, 16.9%, and 29%, respectively. These seropositivity rates are similar 
to rates found in Tobago. Also, no gender difference in HHV-8 seropositivity rate found in the Cuba 
study161 is consistent to the present study’s finding; the study conducted in Dominican Republic and Haiti 
did not report gender seropositivity rates162.  
In the present study, HHV-8 seropositivity rates were higher than rates reported in other 
Caribbean populations. For example, in Jamaica, three studies reported low HHV-8 seropositivity rates of 
0.68% among women attending gynecology clinics, 2.7% among blood donors (ages 18 to 63 years), and 
3.6% among blood donors (ages 18 to 64 years); in these studies, a whole virus enzyme-linked 
immunoassay and/or immunofluorescence assay testing for antibodies against lytic and latent HHV-8 
antigens were used 4, 159, 163. In Trinidad, HHV-8 seropositivity rate of 1.3% among female and male blood 
donors (ages 18 to 64 years) was found by using a whole virus enzyme-linked immunoassay 4. The low 
HHV-8 seropositivity rates found in Trinidad and Jamaica populations in comparison to the present study 
population may be due to differences in study populations or in the sensitivity of the serological assay 
used to examine HHV-8 infection. The serological assay, mIFA, used in the present study has been 
reported to have a sensitivity of 89.9% and specificity of 97.5% 14. Based on studies that used serological 
assays to examine patterns of change in HHV-8 antibody responses, antibody titers have shown to 
decrease over time in some individuals352, 353. Therefore, HHV-8 serological assays may not be sensitive 
enough to detect all HHV-8 exposed individuals. The decline in antibody titers suggests that HHV-8 
infection may be underestimated in cross-sectional studies.  
In this study, a significant association between HHV-8 sero-status and age at first sexual 
intercourse was found among women. A study conducted among female prostitutes and age-matched 
controls in Oviedo and Barcelona, Spain found a similar association between HHV-8 seropositive status 
and age at first sexual intercourse354; but, this association was not confirmed by studies conducted among 
U.S. women 126, 355.  A study conducted in Cuba which included women and men did not find an 
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association between HHV-8 seropositivity and age at first sexual intercourse161. The minimal association 
between HHV-8 seropositivity and age at first sexual intercourse reported in the present study suggests 
that sexual activity may not be the predominate mode of HHV-8 transmission in Tobago. 
Sexual transmission may not be the only mode of HHV-8 transmission in Tobago. In this study, 
several variables that assess sexual lifestyle behaviors were not associated with HHV-8 sero-status among 
the women. In addition, the detection of HPV DNA in oral or cervical cavity was not associated with 
HHV-8 seropositivity. The lack of associations between seropositivity and several sexual behavior 
variables is consistent with previous studies that examined similar sexual lifestyle behaviors and HHV-8 
sero-status among women166, 355.  
Non-sexual transmission of HHV-8 may play a role in Tobago. Evidence of HHV-8 infection 
among pre-pubertal children in other populations suggests non-sexual routes of HHV-8 transmission, and 
point at saliva as the probable route of transmission7, 12, 138, 157. Saliva is known to have the highest viral 
load and viral shedding in comparison to other sites such as peripheral blood mononuclear cells, urine, 
semen, and prostate127, 207, 211, 356. Due to the age of the present study population, > 18 years of age, 
evidence of non-sexual transmission through oral transmission was not observed. However, to evaluate 
whether oral transmission through sexual behaviors was associated with HHV-8 sero-status, women who 
participated in oral sexual activities and/or had the presence of HPV DNA in their oral cavity were 
examined and found to have higher risk for HHV-8 infection than their counterparts. Tobago women were 
less likely to be seropositive if they ever had oral sex or if they had partners who performed oral sex on 
them; in contrast, they were more likely to be seropositive if they did not use condoms during oral sex or 
if HPV was detected in their oral cavity.  However, none of these associations were statistically 
significant. 
There are some limitations in the present study. One limitation is that for Tobago men, sexual 
lifestyle behavior data were not available. A recent study has shown sexual lifestyle behaviors such as 
duration of sexual activity in years, the number of lifetime sex partners, and co-infection with other STDs 
to be associated with HHV-8 seropositive status among heterosexual men166. Another limitation is the 
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limited power to examine the association between HHV-8 sero-status and sexual lifestyle behaviors 
among women. Sexual lifestyle behavior variables were missing in some of the women’s responses; 
however, this missing data was less than 14% for most variables.  
The present study is the first to examine the relationship between several sexual lifestyles 
behaviors and HHV-8 infection in the Caribbean. A good estimation of HHV-8 seroprevalence among 
women, ages 18 to 65 years, based on a 95% confidence interval width of < 10% was calculated. This 
study had enough study participants to detect a doubling of HHV-8 seropositivity (from 15% to 30%) 
with 80% power to test at alpha level of 0.05, two-sided.  
In conclusion, the present study provides evidence that HHV-8 infection is present in Tobago.  
However, sexual activity may not be a major contributor in acquiring HHV-8 infection. Non-sexual 
transmission of HHV-8 may also occur in Tobago; however, evidence of this transmission remains not 
known. Understanding possible modes of HHV-8 transmission will help design programs aimed at 
interrupting this viral infection in populations. Further studies, especially longitudinal studies, are needed 
to examine HHV-8 infection, transmission, and its relationship with possible associated malignancies in 
Tobago. 
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5.0  PAPER 2: THE NATURAL HISTORY OF HUMAN HERPESVIRUS 8 
SEROPOSITIVITY IN A COHORT OF TOBAGO MEN OF AFRICAN DESCENT, 1997-
2007 
 
(Will submit to a peer-reviewed journal) 
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5.1 ABSTRACT 
Human herpesvirus 8 (HHV-8) is the causal agent of Kaposi’s sarcoma (KS) and primary 
effusion lymphoma (PEL). In populations at high risk for KS, in particular, HIV/AIDS patients and organ 
transplant recipients, the natural history of HHV-8 infection has been examined. However, for healthy 
populations, the natural history of HHV-8 infection is not known. To study the natural history of HHV-8 
infection among a presumably healthy adult population, HHV-8 seroconversion and seroreversion rates as 
well as persistent seropositivity were examined among African-Caribbean men in Tobago.  
A random sample of 501 Tobago men at risk for incident prostate cancer, ages 40-81 years, was 
selected from the Tobago Prostate Cancer Screening Survey. The inclusion criteria were men who had a 
serum specimen at baseline visit and at wave 2 and/or wave 3 visits. Men diagnosed with prostate cancer 
at the baseline visit were excluded. Demographic information was collected, and serum prostate specific 
antigen (PSA) levels and digital rectal examination (DRE) were recorded.  Serum specimens available for 
each study visit were tested for HHV-8 seropositivity by monoclonal antibody-enhanced 
immunofluorescence assay (mIFA) at each study visit. HHV-8 seropositivity was examined at baseline 
visit, wave 2, and wave 3 visits. Pearson’s chi-square, Fisher’s exact, or Mann-Whitney tests were used to 
compare HHV-8 seropositivity with baseline characteristics. Logistic regression was used to see whether 
there was a difference in baseline HHV-8 seropositivity among men who had blood collected at all study 
visits in comparison to men who had blood collected at only two study visits. HHV-8 seroconversion 
(seronegative at baseline visit to seropositive at subsequent visit) and seroreversion (seropositive at 
baseline visit to seronegative at subsequent visit) rates and their 95% confidence intervals were calculated 
using a Poisson distribution. To evaluate persistent seropositivity, the Kaplan-Meier approach was used to 
examine the seroreversion event-free survival to estimate persistent seropositivity.  
Of the 501 men identified as at risk for incident prostate, 407 (81.2%) study participants were 
included in the analysis. The frequency of HHV-8 seropositivity was 16.5% (95% C.I., 13.0% - 20.4%), 
18.5% (95% C.I., 14.1% - 23.6%), and 16.6% (95% C.I., 12.8% - 21.0%) at baseline visit, wave 2 visit, 
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and wave 3 visit, respectively. The HHV-8 seroconversion rate was 0.50 per 100 person-years (95% C.I., 
0.22-0.99); and, the HHV-8 seroreversion rate was 2.52 per 100 person-years (95% C.I., 1.09-4.96). 
Among HHV-8 seropositive men at baseline visit, the rate of persistent seropositivity was 0.856 (standard 
error = 0.05) at 5.5 years after baseline visit.  
 We found a low HHV-8 seroconversion rate and a moderate seropositivity rate at each study visit 
among Tobago men, aged 40-81 years. These data suggest that HHV-8 infection is present in Tobago, 
however; this viral infection is probably acquired at a younger age, < 40 years. We also found a moderate 
seroreversion rate among Tobago men; this pattern of change suggests that a more sensitive serological 
assay is needed. Further studies are needed to understand HHV-8 infection and possible risk factors for 
acquiring HHV-8 infection in Tobago.  
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5.2 INTRODUCTION 
Human herpesvirus 8 (HHV-8), a gammaherpesvirus, causes life-long infection that can result in 
disease (i.e, Kaposi’s sarcoma [KS], primary effusion lymphoma [PEL], or multicentric Castleman’s 
disease [MCD])1, 81-83 which is usually seen in immunocompromised individuals. KS, the most common 
HHV-8 associated malignancy, is prevalent in Sub-Saharan Africa and Mediterranean populations where 
high and moderate HHV-8 seropositivity rates have been reported, respectively. To understand the natural 
history of HHV-8 infection, patterns of antibody responses against HHV-8 latent and/or lytic antigens 
have been examined in populations at high-risk for HHV-8 associated diseases such as populations 
infected or at risk for HIV/AIDS213, 352, 357-360, organ transplant recipients13, 353, 361-367, blood transfusion 
patients168, and chronically ill individuals353, in which the frequency of HHV-8 seroconversion (0.7-52%) 
and seroreversion (0.4-82%) has been observed. However, in healthy populations, these patterns of 
change in HHV-8 sero-status over time, as well as the determinants of such change, have not been 
studied.  
In the Caribbean island of Tobago, HHV-8 seropositivity rates of 39.9% and 22.9% among 
African-Caribbean men with and without prostate cancer, respectively, were detected9. To examine 
patterns of change and persistent antibody responses against HHV-8 lytic antigens, we conducted a 
prospective cohort study among prostate cancer-free Tobago men, aged 40-81 years, who participated in 
the longitudinal, population-based Tobago Prostate Cancer Screening Survey. By examining HHV-8 
seroconversion and seroreversion rates and persistent seropositivity levels in a presumably healthy 
population, we hope to have a better understanding of the natural history of HHV-8 infection in the 
Tobago population. 
 90 
5.3 METHODS 
5.3.1 Study Design and Study Population 
A cohort study was conducted to examine HHV-8 seroconversion, seroreversion, and persistent 
seropositivity rates among a presumably healthy cohort of men from the Caribbean island of Tobago. The 
study population included men of African descent who participated in the longitudinal, population-based 
Tobago Prostate Cancer Screening Survey in Tobago17. This ongoing longitudinal study, initiated in 1997, 
consists of men who participated at a baseline visit (October 1997 to August 2003), followed by wave 2 
visit (February 1999 to August 2003), and/or wave 3 visit (May 2004 to March 2007). The study 
inclusion criteria were men ages 40-81 years, who participated at baseline visit, who had blood collected 
at baseline visit and at wave 2 and/or wave 3 visits, who were not diagnosed with prostate cancer by 
prostate biopsy at the baseline visit, and signed an informed consent approved by the Institutional Review 
Boards of the Tobago Division of Health and Social Services and the University of Pittsburgh. 
At each study visit, demographic information and medical history were ascertained, serum 
specimen was collected, and DRE was performed by a Tobago physician.  Study participant’s 
demographic information and medical history questionnaires were mailed to the University of Pittsburgh. 
Serum specimens were stored in a -20oC freezer at the Tobago Health Studies office in Scarborough, 
Tobago and later shipped and stored in a -80oC freezer at the University of Pittsburgh. The study 
participants’ serum specimens were used for serum PSA and HHV-8 testing. 
In this cohort, the Tobago Prostate Cancer Screening Survey database contained information on 
3,380 study participants (Figure 15). Out of these unique study identifications, 2,688 men were 
considered prostate cancer-free (no diagnosis of prostate cancer) at baseline visit based on serum prostate 
specific (PSA) level of < 4 ng/mL, normal or minimally abnormal digital rectal examination (DRE) result, 
and/or no confirmed prostate cancer biopsy diagnosis at baseline screening. Among the men at risk for 
incident prostate cancer, 2,002 men were identified in the Tobago Prostate Cancer Screening biological 
 91 
database as having serum collected at baseline visit and at a wave 2 visit and/or wave 3 visit. Of these 
2,002 men, a simple random sample of 501 men was selected to investigate the natural history of HHV-8 
infection among Tobago men of African descent. 
 
3,100 who had blood collected at Visit 1
2,688 at risk of incident prostate cancer
3,380 men in Visit 1 Survey
Missing blood (n=280)
Prevalent Prostate 
Cancer (n=346)Missing Age (n=7)
Age < 40 (n=23)
Age > 81 (n=36)
2,002 had Visit 2 and/or Visit 3 blood collected
Final Cohort: Random sample of 501 out of 2,002 men, 
40-81 year-old, prostate cancer-free  
Figure 15. Flowchart of Eligibility Criteria of Tobago Men at Risk for Incident Prostate Cancer 
 
5.3.2 Laboratory Methods 
Serum specimens were tested for antibodies against HHV-8 lytic antigens with a modified HHV-
8 monoclonal antibody-enhanced immunofluorescence assay (mIFA) , as described elsewhere13, using the 
BCBL-1 cells that contain a doxcycline-inducible RTA gene368. The cutoff value for a HHV-8 
seropositive result was specific fluorescence at dilution of 1:100. For each mIFA run, known HHV-8 
positive and negative sera were included; and, for each participant, the serum specimens for each of his 
study visits were tested on the same IFA slide. Each serum specimen was tested in duplicate on separate 
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days in which the slide order was different on these 2 testing days. If there were disagreements in HHV-8 
test results on the 2 different lab days, a 3rd lab day run was performed to determine the HHV-8 sero-
status of the specimen. All serum specimens that were analyzed by mIFA were assessed microscopically 
in a blinded fashion by the same reader. Laboratory analysis used only frozen serum specimens thawed 
once and never re-frozen.  
5.3.3 Data Analysis 
Baseline characteristics listed in Tables 14 and 15 were recorded and compared in the following 
groups using Pearson’s chi-square, Fisher’s exact, or Mann-Whitney tests: 1) men included the sampling 
scheme in comparison to men excluded from the sampling scheme, and 2) study participants with a 
baseline HHV-8 test result in comparison to study participants with no baseline HHV-8 test result.  The 
frequency of HHV-8 seropositivity at baseline, wave 2, and wave 3 visits was examined, and stratified by 
the date of laboratory analysis (< = April 6, 2008 and > April 6, 2008). The lab stratification was 
performed in order to examine possible effects from performance drift manifesting on April 6 as a change 
in split sample test-retest reproducibility. Age-specific seropositivity was also examined across age 
groups (40-49, 50-59, 60-69, 70-81 years). The Pearson’s chi-square, Fisher’s exact, or Mann-Whitney 
tests were also used to examine whether there were any significant associations between baseline HHV-8 
seropositivity and baseline characteristics. Logistic regression was used to see whether there was a 
difference in baseline HHV-8 seropositivity among men who had blood collected at every study visit 
(baseline, wave 2, and wave 3 visits) in comparison to men who had blood collected at only two study 
visits (baseline and wave 2 visits, baseline and wave 3 visits). 
HHV-8 seroconversion was defined as a HHV-8 seronegative specimen at baseline visit that 
became HHV-8 seropositive at wave 2 or wave 3visit. HHV-8 seroreversion was defined as a HHV-8 
seropositive specimen at baseline visit that became HHV-8 seronegative at wave 2 or wave 3visit.  The 
HHV-8 seroconversion and seroreversion rates were calculated as the incidence rate per 100 person-years. 
 93 
The 95% confidence interval of HHV-8 seroconversion and seroreversion rates were estimated using the 
Poisson distribution. The overall HHV-8 seroconversion and seroreversion rate was examined and 
stratified by the date of laboratory analysis. Pearson’s chi-square, Fisher’s exact, or Mann-Whitney tests 
were used to examine whether there were any differences in baseline characteristics between the HHV-8 
seroconverters and persistent HHV-8 seronegative men and between HHV-8 seroreverters and persistent 
HHV-8 seropositive men.  
For the non-HHV-8 seroconverters and non-HHV-8 seroreverters, the follow-up time in this 
cohort was considered as the interval time between the first date of serum specimen collected to the last 
date of serum specimen collected, wave 2 or wave 3 visit. For HHV-8 seroconverters, the follow-up time 
was the time elapsed from the first serum specimen’s collection date to the midpoint in time between the 
last seronegative specimen’s collection date and the first seropositive specimen’s collection date. For 
HHV-8 seroreverters, the follow-up time was the time elapsed from the first serum specimen’s collection 
date to the midpoint in time between the last seropositive specimen’s collection date and the first 
seronegative specimen’s collection date.  
The frequency of persistent HHV-8 seropositivity, defined as HHV-8 seropositive at baseline 
visit to wave 2 and/or wave 3, was examined among the Tobago men.  The Kaplan-Meier approach was 
used to examine the seroreversion event-free survival to estimate persistent seropositivity at different time 
points.  
All data analyses were conducted at alpha level 0.05 in SPSS 15.0 for Windows. 
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5.4 RESULTS 
5.4.1 Baseline Characteristics 
There were significant differences in baseline characteristics between Tobago men included in the 
sampling scheme (n = 2002) in comparison to men excluded from the sampling scheme (n = 686). Men 
who were not part of the sampling scheme were significantly older in age, had a higher serum PSA, had a 
higher frequency of abnormal DRE, had a lower frequency of married/ever married, and a higher 
frequency of ever smoke cigarettes > 6 months (p-values < 0.03) (Table 14). 
Table 14. Comparison of Baseline Characteristics of Tobago Men Excluded and Included in the 
Sampling Scheme 
 Excluded from the 
Sampling Scheme 
(N=686) 
Included in the Sampling 
Scheme (N=2002) 
P-value 
Median Age (in years) 54 years 52 years .005 
Median Serum PSA 
(ng/mL) 
1.1 ng.mL 
(n=675) 
1.1 ng/mL 
(n=1978) 
.015 
Abnormal DRE 20.4% 
(n=108/529) 
15.9% 
(n=284/1786) 
.016 
Married/Ever Married 79.8% 
(n=541/678) 
83.4% 
(n=1660/1990) 
.032 
< 11 years of education 72.9% 
(n=496/680) 
74.0% 
(n=1471/1989) 
.604 
Ever had Gonorrhea 21.9% 
(n=146/667) 
20.6% 
(n=403/1954) 
.488 
Ever had Syphilis 3.7% 
(n=24/643) 
4.5% 
(n=86/1897) 
.389 
Ever smoke cigarettes 
> 6 months 
49.9% 
(n=340/682) 
39.8% 
(n=792/1989) 
.000 
Diagnosed with 
Prostatitis  
1.4% 
(n=9/651) 
1.5% 
(n=28/1893) 
.859 
Diagnosed with Benign 
Prostatic Hyperplasia 
(BPH) 
6.6% 
(n=44/670) 
7.4% 
(n=145/1951) 
.455 
Note: PSA = prostate specific antigen, DRE = digital rectal examination, N and n = the number of study 
participants 
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Of the 501 prostate cancer-free African-Caribbean men in Tobago, a baseline HHV-8 sero-status 
result was not missing on 415 men (82.8% of the study population); eight of these men had a pending 
HHV-8 test result wave 2 visit or wave 3 visit. When baseline study characteristics were compared 
between men with non-missing and missing baseline HHV-8 test results, there was a significant 
difference in median age, gonorrhea diagnosis, and benign prostatic hyperplasia (BPH) (p-values < 0.03); 
however, no significant difference was found with serum PSA level, marital status, level of education, 
DRE, syphilis diagnosis, ever smoke cigarettes > 6 months, and prostatitis (p-values > 0.1) (Table 15). As 
for the duration of follow-up time in the study cohort, a median follow-up time of 5.14 years (range: 0.42 
to 9.18 years) and 5.30 years (range: 1.10 to 7.67 years) was observed among the study participants with a 
non-missing and missing baseline test results, respectively; however, these follow-up times were not 
significantly different (p-value = 0.602) (Table 15). Therefore, the final analysis included 407 study 
participants with non-missing HHV-8 test results at baseline and at every subsequent wave attended. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
Table 15. Comparison of Baseline Characteristics of Tobago Men who had a Tested or Not Tested 
Serum Specimen at Baseline Visit 
 Tested Serum Sample 
(N=415) 
Not Tested Serum 
Sample (N=86) 
P-value 
Median Years of 
Follow-up (range) 
5.14 years 
(0.42 to 9.18 years) 
5.30 years 
(1.10 to 7.67 years) 
.602 
Median Age (in years) 52 years 57.5 years .009 
Median Serum PSA 
(ng/mL) 
1.0 ng.mL 1.3 ng/mL .108 
Abnormal DRE 14.9% 
(n=54/363) 
17.9% 
(n=14/78) 
.495 
Married/Ever Married 81.9% 
(n=339/414) 
87.2% 
(n=75/86) 
.234 
< 11 years of education 78.4% 
(n=323/412) 
72.1% 
(n=62/86) 
.204 
Ever had Gonorrhea 18.0% 
(n=72/401) 
30.6% 
(n=26/85) 
.008 
Ever had Syphilis 5.5% 
(n=22/397) 
3.8% 
(n=3/80) 
.783 
Ever smoke cigarettes  
> 6 months 
41.9% 
(n=173/413) 
36.0% 
(n=31/86) 
.316 
Diagnosed with 
Prostatitis  
1.3% 
(n=5/390) 
1.2% 
(n=1/84) 
1.00 
Diagnosed with Benign 
Prostatic Hyperplasia 
(BPH) 
6.2% 
(n=25/406) 
12.9% 
(n=11/85) 
.029 
Note: PSA = prostate specific antigen, DRE = digital rectal examination, N and n = the number of study 
participants 
 
5.4.2 HHV-8 Seropositivity Rates 
Among 407 eligible study participants at risk for incident prostate cancer, HHV-8 seropositivity 
was 16.5% (95% confidence interval [C.I.], 13.0% - 20.4%), 18.4% (95% C.I., 14.1% - 23.6%), and 
16.5% (95% C.I., 12.8% - 21.0%) at baseline visit, wave 2 visit, and wave 3 visit, respectively (Figure 
16). HHV-8 seropositivity at each study visit did not vary significantly according to the date of laboratory 
analysis (p-values > 0.2) (Figure 16). The baseline age-specific HHV-8 seropositivity rates were the 
following: 6.9% (n = 12/175) in men 40-49 years, 16.1% (n = 18/112) in men 50-59 years, 28.0% (n = 
23/82) in men 60-69 years, and 36.8% (n = 14/38) in men 70-81 years (p-value = 0.000). As for baseline 
 97 
characteristics, there were no significant differences between HHV-8 seropositive and seronegative men 
(p-values > 0.2), except for age and serum PSA levels (p-values < 0.01) (Table 16).  
16.5%
18.5%
16.6%
14.3%
16.8% 15.3%
18.8% 20.1% 17.9%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
50.0%
Baseline Visit Wave 2 Visit Wave 3 Visit
Overall
< = April 6 
> April 6
N1=407, N2=210, N3=197 N1=276, N2=137, N3=139 N1=338, N2=170, N3=168
<=April 6 vs 
>April 6:
All p-values 
> 0.2 
 
Note : N1 = the total number of study participants, N2 = the number of study participants who had the 
serum specimens tested before or on April 6, 2008, N3 = the number of study participants who had the 
serum specimens tested before after April 6, 2008 
Figure 16. HHV-8 Seropositivity Rates, Stratified by Laboratory Analysis, among Tobago Men  
(N = 407) 
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Table 16. Comparison of Baseline Characteristics between HHV-8 Seropositive Men (N = 67) and 
HHV-8 Seronegative Men (N = 340) in Tobago 
 HHV-8 Seropositive 
Men (N=67) 
HHV-8 Seronegative 
Men (N=340) 
P-value 
Median Years of 
Follow-up (range) 
5.35 years 
(1.40-8.77 years) 
5.00 years 
(.42-9.18 years) 
.030 
Median Age (in years) 60 years 50 years .000 
Median Serum PSA 
(ng/mL) 
1.35 ng/mL 1.00 ng/mL .006 
Abnormal DRE 19.7% 
 (n=12/61) 
13.9%  
(n=41/296) 
.244 
Married/Ever Married 86.6%  
(n=58/67) 
80.5%  
(n=273/339) 
.245 
< 11 years of education 76.1%  
(n=51/67) 
78.6%  
(n=265/337) 
.649 
Ever had Gonorrhea 19.7%  
(n=13/66) 
17.4%  
(n=57/328) 
.653 
Ever had Syphilis 3.2% 
 (n=2/63) 
5.5% 
 (n=18/326) 
.754 
Ever smoke cigarettes 
> 6 months 
31.3%  
(n=21/67) 
43.5%  
(n=147/338) 
.065 
Diagnosed with 
Prostatitis  
1.6%  
(n=1/63) 
1.3%  
(n=4/320) 
.595 
Diagnosed with Benign 
Prostatic Hyperplasia 
(BPH) 
10.8% 
 (n=7/65) 
5.4%  
(n=18/334) 
.102 
Note:  PSA = prostate specific antigen, DRE = digital rectal examination, N and n = the number of study 
participants 
 
There were 69, 131, and 207 men who had blood collected at baseline and wave 2 visits, baseline 
and wave 3 visits, and baseline, wave 2, and wave 3 visits, respectively. Their mean ages were 56.7 years, 
52.4 years, and 53.6 years, respectively. There was a significant association between baseline HHV-8 
seropositivity and the number of study visits men had blood collected (p-value = 0.05) (Table 17). Men 
who had blood collected at baseline and wave 3 visits had a lower frequency of HHV-8 seropositivity 
(10.7%) than men who had blood collected at all study visits (20.8%) (age & the date laboratory analysis 
adjusted Odds ratio [O.R.] = 0.482, 95% C.I., 0.247 – 0.942). Men who had blood collected at baseline 
and wave 2 visits also had a lower frequency of HHV-8 seropositivity (14.5%) than men who had blood 
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collected at all study visits (age & the date of laboratory analysis adjusted O.R. = 0.507, 95% C.I., 0.229 – 
1.120).  
Table 17. The Association between the Number of Study Visits Blood Collected and Baseline HHV-8 
Seropositivity among Tobago Men 
 Percentage of 
HHV-8 
Seropositivity 
*Unadjusted Odds 
Ratio (95% 
confidence 
interval) 
**Age-adjusted 
Odds Ratio (95% 
confidence 
interval) 
*Age- and Lab-
adjusted Odds 
Ratio (95% 
confidence 
interval) 
Baseline and  
Visit 2 Only 
14.5% 
(n=10/69) 
.646  
(.305 – 1.368) 
.490  
(.222 – 1.079) 
.507  
(.229 – 1.120) 
Baseline and 
 Visit 3 Only 
10.7% 
(n=14/131) 
.456 
 (.239 - .873) 
.469  
(.241 - .915) 
.482  
(.247 - .942) 
All Study Visits 20.8% 
(n=43/207) 
Reference Reference Reference 
Note: * Wald’s p-value = 0.05, ** Wald’s p-value = 0.037, n = the number of study participants, Age is continuous, 
Lab-adjusted is stratified by the date of laboratory analysis (<= April 6, 2008 versus > April 6, 2008)  
 
5.4.3 HHV-8 Seroconversion and Seroreversion 
Of the 340 study participants who were HHV-8 seronegative at baseline visit, there were 8 HHV-
8 seroconversions per 1599.22 person-years (incidence rate: 0.5 per 100 person-years, 95% C.I., 0.22-
0.99).  When examined by the date of laboratory analysis, there was no significant difference in the 
proportion of seroconverters identified on <= April 6, 2008 and > April 6, 2008 (p-value = 1.0) (Figure 
17). When HHV-8 seroconverters and persistent HHV-8 seronegative men were compared, there were no 
significant differences for most of the baseline studied variables (p-values > 0.2), except for marital status 
and median years of follow-up (Table 18). Persistent HHV-8 seronegative men had a higher frequency of 
being married or ever married (81.3%) than the HHV-8 seroconverters (50%) (p-value = 0.049).  
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Note: N1 = the total number of study participants, N2 = the number of study participants who had the 
serum specimens tested before or on April 6, 2008, N3 = the number of study participants who had the 
serum specimens tested before after April 6, 2008 
Figure 17. Overall HHV-8 Seroconversion (N = 340) and Seroreversion (N = 67) Rates, Stratified by 
the Date of Laboratory Analysis among Tobago Men 
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Table 18. Comparison of Baseline Characteristics between HHV-8 Seroconverters (N = 8) and 
Persistent HHV-8 Seronegative Men (N = 332) 
 HHV-8 Seroconverters 
(N=8) 
Persistent HHV-8 
Seronegative Men 
(N=332) 
P-value 
Median Years of 
Follow-up* (range) 
3.15 years 
(.60-5.48 years) 
5.00 years 
(.42-9.18 years) 
.007 
Median Age (in years) 56 years 50 years .299 
Median Serum PSA 
(ng/mL) 
2.0 ng/mL 1.0 ng/mL .317 
Abnormal DRE 0% 
(n=0/7) 
14.2% 
(n=41/289) 
.599 
Married/Ever Married 50% 
(n=4/8) 
81.3% 
(n=269/331) 
.049 
Ever had Gonorrhea 0% 
(n=0/8) 
17.8% 
(n=57/320) 
.359 
Ever had Syphilis 0% 
(n=0/8) 
5.6% 
(n=18/319) 
1.00 
Diagnosed with 
Prostatitis  
12.5% 
(n=1/8) 
1.0% 
(n=3/312) 
.097 
Diagnosed with Benign 
Prostatic Hyperplasia 
(BPH) 
12.5% 
(n=1/8) 
5.2% 
(n=17/326) 
.361 
Note:  PSA = prostate specific antigen, DRE = digital rectal examination, N and n = the number of study 
participants, * = based on the definition of the follow-up time for HHV-8 seroconverters 
 
As for HHV-8 seroreversion, there were 8 HHV-8 seroreversions per 317.43 person-years 
(incidence rate: 2.52 per 100 person-years, 95% C.I., 1.09-4.96).  When examined by the date of 
laboratory analysis, a higher frequency of seroreverters were identified on > April 6, 2008 in comparison 
to <= April 6, 2008; however, this difference was not statistically significant (p-value = 0.281) (Figure 
17). When HHV-8 seroreverters and persistent HHV-8 seropositive men were compared, there were no 
significant differences for most of the baseline studied variables (p-values > 0.2), except for age and 
median years of follow-up (Table 19). Persistent HHV-8 seropositive men had a higher median age (61 
years) than the seroconverters (48 years) (p-value = 0.021). 
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Table 19. Comparison of Baseline Characteristics between HHV-8 Seroreverters (N = 8) and 
Persistent HHV-8 Seropositive Men (N = 59) 
 HHV-8 Seroreverters 
(N=8) 
Persistent HHV-8 
Seropositive Men 
(N=59) 
P-value 
Median Years of 
Follow-up* (range) 
1.79 years 
(.55-5.46 years) 
5.34 years 
(1.40-8.77 years) 
.001 
Median Age (in years) 48 years 61 years .021 
Median Serum PSA 
(ng/mL) 
1.4 ng/mL 1.3 ng/mL .687 
Abnormal DRE 0% 
(n=0/7) 
22.2% 
(n=12/54) 
.327 
Married/Ever Married 100% 
(n=8/8) 
84.7% ( 
n=50/59) 
.585 
Ever had Gonorrhea 12.5% 
(n=1/8) 
20.7% 
(n=12/58) 
1.00 
Ever had Syphilis 0% 
(n=0/7) 
3.6% 
(n=2/56) 
1.00 
Diagnosed with 
Prostatitis  
0% 
(n=0/8) 
1.8% 
(n=1/55) 
1.00 
Diagnosed with Benign 
Prostatic Hyperplasia 
(BPH) 
0% 
(n=0/8) 
12.3% 
(n=7/57) 
.583 
Note:  PSA = prostate specific antigen, DRE = digital rectal examination, N and n = the number of study 
participants, * = based on the definition of the follow-up time for HHV-8 seroconverters 
 
There was one participant who seroconverted from baseline visit to wave 2 visit, then 
seroreverted from wave 2 visit to wave 3 visit. Based on the HHV-8 seroconversion definition, this 
individual was classified as a HHV-8 seroconverter. 
Among seropositive men at baseline visit, the frequency of persistent seropositivity was 88.1% 
(95% C.I., 77.8% - 94.7%). When HHV-8 seroreversion-free survival was examined, the rate of persistent 
seropositivity was 0.856 (standard error = 0.05) at 5.5 years after baseline (Figure 18). 
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Figure 18. HHV-8 Seroreversion-free Survival among Persistent Seropositive Tobago Men at Risk 
for Incident Prostate Cancer (N = 67) 
5.5 DISCUSSION 
In this present study, a HHV-8 seroprevalence of 16.5%, 18.5%, and 16.6% against HHV-8 lytic 
antigens was detected at baseline, wave 2, and wave 3 visits, respectively, among African-Caribbean 
Tobago men at risk for incident prostate cancer. These moderate HHV-8 seropositivity rates in Tobago 
are consistent to rates found in Mediterranean countries5-7, 142, 146 and other Caribbean countries such as 
the Dominican Republic162 and Cuba161. Unlike the Mediterranean where KS is prevalent, no KS cases 
have been reported in Tobago since the establishment of Trinidad/Tobago cancer registry in 199410, 11. 
The reasons for the lack of reported KS cases in Tobago are not yet known. 
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In Tobago, a case-control study conducted among African-Caribbean men in the Tobago Prostate 
Cancer Screening Survey found a higher HHV-8 seropositivity rate of 39.9% and 22.9% in men with and 
without prostate cancer, respectively9, in comparison to seropositivity rates reported in the present study. 
The reason for the higher seropositivity among men without prostate cancer in the case-control study is 
that these men were older (mean age, 67 years) than the men in the present study (mean age, 54 years). 
Studies have shown that HHV-8 seropositivity increases with age3, 5, 138, 145, 146, 153, 157. In the present study, 
baseline HHV-8 seropositivity increased from 6.9% in men 40-49 years to 36.8 % in men 70-81 years. 
Therefore, age may be a factor for the HHV-8 seropositivity difference between the Tobago men in the 
present study and the Tobago men in Hoffman et al. study.  
A low HHV-8 seroconversion incidence rate of 0.5 per 100 person-years was found among 
Tobago men, aged 40-81 years. This seroconversion rate is comparable to incidence rates found among 
drug users (0.7 per 100 person-years) who were participants in the Amsterdam Cohort Study358 and Greek 
hemodialysis patients (0.28 per 100 person-years) who were participants in the Multicenter Hemodialysis 
Cohort on Viral Hepatitis353. In populations at high risk for sexually transmitted diseases (STDs), higher 
HHV-8 seroconversion rates were reported among HIV-negative homosexual men (2.6 - 3.8 per 100 
person-years)358, 359, HIV-infected men (6.2 per 100 person-years)358, and STD clinic attendees (3.2 per 
100 person-years)360. As for other study populations, several  studies have examined the frequency of 
HHV-8 seroconversion among post-organ transplant patients, with frequencies ranging from 2% to 15%13, 
362-366. Possible modes of HHV-8 transmission, sexually and/or non-sexually (i.e., HHV-8 seropositive 
organ donor, contaminated blood product, saliva exchange, etc.), may explain the seroconversion rates 
observed in populations at high risk for STDs (which includes HIV/AIDS infected individuals) as well as 
seroconversion rates found in organ transplant recipients. As for the Tobago population, reasons for 
HHV-8 seroconversion among Tobago men, aged 40-81 years, are less clear than the previously described 
study populations. There was no significant difference in STDs diagnosis such as syphilis and gonorrhea 
between HHV-8 seroconverters and persistent seronegative men; manner of fact, none of the 
seroconverters reported that they were ever diagnosed with these diseases. Therefore, sexual transmission 
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may not be the mode of acquiring HHV-8 infection for HHV-8 seroconverters in this study population. 
Nevertheless, a low seroconversion rate in men aged > 40 years, and a moderate seropositivity rate 
detected at three time points in this 9-year cohort suggest that HHV-8 infection is acquired at younger 
ages, < 39 years, in Tobago. 
As for HHV-8 seroreversion, an incidence rate of 2.52 per 100 person-years was found among the 
Tobago men. This seroreversion rate was lower than the rate reported in hemodialysis patients in Greece, 
16.4 per 100 person-years353. HHV-8 seroreversions were also reported in post-transplant patients (0.4-
55%)168, 361-363 and HIV-infected individuals (5%-82%)352, 357. In Tobago, the frequency of HHV-8 
seroreversion was 11.9%; this frequency was similar to ones observed in studies conducted in post-organ 
transplant and HIV-infected populations. The fact that HHV-8 seroreversions are observed in high-risk 
KS populations suggest the following: low sensitivity of the serologic assay, restoration of participant’s 
immune function, or poor quality of participant’s serum specimen352, 361. For the presumably healthy men 
in the present study, the observation of HHV-8 seroreversion may indicate that they had low HHV-8 
antibody titers at baseline visit which became undetectable by the serological assay at a subsequent study 
visit. Therefore, misclassification of HHV-8 seropositivity may be occurring among persons with low 
antibody titers. The serological assay used in the present study, mIFA, is reported to have a sensitivity of 
89.9% and specificity of 97.5%, respectively 14. However, evidence of HHV-8 seropositive individuals 
testing seronegative at a follow-up visit for a “life-long” infection indicates that a more sensitive assay is 
needed. In addition, all HHV-8 seroreversion occurred within 5.5 years after baseline visit, which this 
action suggests that these men probably had low antibody titers at baseline visit that became undetectable 
within 5.5 years after the baseline visit. The moderate HHV-8 seroreversion rate among seropositive men 
in Tobago reflected the high persistent seropositivity found in this present study (88.1%).  
Even though this Tobago cohort allowed the examination of HHV-8 seropositivity rates at three 
different time points and the patterns of change in HHV-8 sero-status over a 9 year period, there were 
some limitations to this study. First, selection bias may have been introduced in the study. There were 
significant differences in baseline characteristics between Tobago men included and excluded in the 
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sampling scheme. Men excluded in the sampling scheme were individuals who did not have serum 
specimens available for HHV-8 testing for more than one study visit. This unavailability may explain 
why these men were older in age, had a higher frequency of abnormal DRE, had a lower frequency of 
married or ever been married, and a higher frequency of ever smoke cigarettes > 6 months. Also, baseline 
HHV-8 sero-status was missing for 17.2% of the study population (n = 501). Higher median age, 
gonorrhea diagnosis, and benign prostatic hyperplasia (BPH) were found to be statistically different 
between men with missing and non-missing baseline HHV-8 test results. However, there were no 
differences in other baseline characteristics as well as the duration of follow-up time in the cohort.  
Another limitation in the present study was that 49.1% (n = 200/407) of the men did not have 
blood collected at all three study visits. Men who had blood collected at baseline and wave 3 visits only 
and baseline and wave 2 visits only had lower HHV-8 seropositivity than men who had blood collected at 
all study visits. Even after adjusting for age, there was still an inverse association in HHV-8 seropositivity 
among the men who had blood collected at two study visits in comparison to men who had blood 
collected at all study visits. The reason for the higher seropositivity in men who had blood collected at all 
study visits is not known.  
Even though the Tobago men in the present study were assumed to be healthy at baseline visit, 
their immune status was not known. Higher HHV-8 seropositivity rates have been found among 
immunocompromised individuals, for example, HIV/AIDS patients, than healthy individuals126, 151, 172, 177; 
therefore, information on the participant’s immune status may help explain HHV-8 seropositivity rates in 
Tobago.  A fourth limitation in the present study is the variability of serological assay, mIFA, used to test 
serum specimens for HHV-8 seropositivity. The mIFA is a biological assay that may have variability in 
detecting antibodies against HHV-8 lytic antigens. To control for possible variability in the lab assay, 
serum specimens were tested on two separate days, in a blinded fashion, in order to test-retest 
reproducibility. All of the men’s study visit serum specimens were tested on the same mIFA slide. In the 
present study, stratified analysis by laboratory date was used to compare days in which a consistent kappa 
statistic of > 0.85 was observed (before and on April 6, 2008) in comparison to days in which the kappa 
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statistic ranged from 0.54 to 1.00 (after April 6, 2008). Based on the stratified analysis, there was no 
significant difference in HHV-8 seropositivity by date of laboratory analysis. Finally, levels of HHV-8 
antibody titers were not examined on HHV-8 seropositive men. HHV-8 antibody titers would have 
provided information on whether HHV-8 reactivations have occurred among Tobago men and whether 
low antibody titers were the reason for HHV-8 seroreversion. Also, antibody titers may explain the 
participant (noted as a seroconverters) who seroconverted from baseline visit to wave 2 visit, then 
seroreverted from wave 2 visit to wave 3 visit. In this scenario, antibody titers would have provided more 
information on the sensitivity of the assay. 
To our knowledge, this present study was the first to investigate the natural history of HHV-8 
infection in a presumably healthy cohort over a 9 year period.  In this study, a low HHV-8 seroconversion 
rate and a moderate HHV-8 seroreversion rate were found. In addition, a moderate HHV-8 seropositivity 
rate was detected at each study visit. Further studies are needed to examine the natural history of HHV-8 
seropositivity among men who develop prostate cancer and possible risk factors for acquiring HHV-8 
infection in Tobago. 
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6.0  PAPER 3: HUMAN HERPESVIRUS 8 SEROPOSITIVITY IN RELATION TO 
INCIDENT PROSTATE CANCER AMONG MEN OF AFRICAN DESCENT IN 
TOBAGO 
 
(Will submit to a peer-reviewed journal) 
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6.1 ABSTRACT 
Human herpesvirus 8 (HHV-8) is the causal agent of Kaposi’s sarcoma (KS) and primary 
effusion lymphoma and is associated with multicentric Castleman’s disease. In the Caribbean island of 
Tobago, HHV-8 seropositivity has been associated with screen-detected prevalent prostate cancer among 
African-Caribbean men in the Tobago Prostate Cancer Screening Survey (Odds ratio [O.R.] = 2.24; 95% 
confidence interval [C.I.], 1.29-3.90). To further understand the association between prostate cancer and 
HHV-8 infection, a case-control study was conducted to examine whether HHV-8 seropositivity before 
prostate cancer diagnosis was associated with screen-detected incident prostate cancer in African-
Caribbean men in the Tobago Prostate Cancer Screening Survey.  
A case-cohort study was conducted among a random sample of 501 out of 2,002 Tobago men at 
risk for prostate cancer (the sub-cohort controls, including 30 screen-detected incident prostate cancer 
cases) and all 116 screen-detected incident prostate cancer men (the cases) who participated in the 
population-based Tobago Prostate Cancer Screening Survey at a baseline visit and wave 2 visit (2nd 
recruitment time period), and/or wave 3 visit (3rd recruitment time period). The inclusion criteria were 
men, ages 40-81 years, who had a serum specimen at baseline visit and at wave 2 and/or wave 3 visit, and 
were not screened positive for prostate cancer at baseline visit. Demographic information and medical 
history were collected, and serum prostate specific antigen (PSA) levels and digital rectal examination 
(DRE) were recorded.  Serum specimens were tested for HHV-8 seropositivity by monoclonal antibody-
enhanced immunofluorescence assay (mIFA).  
The frequency of HHV-8 seropositivity at each study visit was examined and compared between 
incident prostate cancer cases in the sub-cohort and incident prostate cancer cases not in the sub-cohort 
and between incident prostate cancer cases and prostate cancer-free men in the sub-cohort. Cox 
proportional hazards modeling for the case-cohort design was used to calculate relative risks (Hazard 
ratios [H.R.]) in order to determine whether HHV-8 seropositivity was associated with screen-detected 
incident prostate cancer, after controlling for possible confounders. 
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There were 81.1% (n = 382/471) prostate cancer-free men in the sub-cohort, 83.3% incident 
prostate cancer cases in the sub-cohort (n = 25/30), and 75.6% (n = 65/86) incident prostate cancer cases 
not in the sub-cohort included in the final analysis. At the baseline, wave 2, and wave 3 visits, HHV-8 
seropositivity levels were the following: 16.8%, 19.3%, and 16.9% among prostate cancer-free men, 
respectively; 12.0%, 9.1%, and 11.1% among incident prostate cancer cases in the sub-cohort, 
respectively; and, 20.0%, 23.1%, and 19.6% among incident prostate cancer cases not in the sub-cohort, 
respectively. HHV-8 seropositivity among these two comparison groups did not differ at any study visit 
(p-values > 0.3). There were inverse associations between baseline HHV-8 seropositivity and screen-
detected incident prostate cancer when age and baseline prostate cancer screening results (abnormal DRE 
or serum PSA >= 4 ng/mL versus normal/minor abnormal DRE, serum PSA < 4 ng/mL, or no screening 
results) (H.R. = 0.454, 95% C.I., 0.221 – 0.933) and age only (H.R. = 0.517, 95% C.I., 0.262 – 1.020) 
were considered. 
In this up to 9-year cohort of Tobago men, inverse associations between HHV-8 seropositivity 
and screen-detected incident prostate cancer suggest that HHV-8 seropositivity may not be related to 
prostate cancer incidence. Further studies are needed to examine the difference in the relationship with 
HHV-8 seropositivity between screen-detected incident prostate cancer and screen-detected prevalent 
prostate cancer among Tobago men of African descent.  
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6.2 INTRODUCTION 
Prostate cancer is a global health issue with 679,023 new cases worldwide in 200210. It is the 2nd 
most common cancer diagnosed in men in the United States and the European Union; and, the 4th most 
common cancer diagnosed in men worldwide260. In the U.S., African-American men are known to have 
the highest incidence and mortality rate than their white counterparts. Similarly, high rates of prostate 
cancer have been reported in men of African descent in Tobago, Jamaica, England, and South America260, 
269-271. Race, older age, family history, the presence of high-grade prostatic intraepithelial neoplasia 
(HGPIN), and possibly diet are prostate cancer risk factors. However, other factors like infectious agents 
may play a role in prostate carcinogenesis since little is known about the etiology of prostate cancer. 
Observational studies have found positive associations between infectious agents and prostate 
cancer9, 331, 338, 339. In addition, viral DNA such as human papillomavirus (HPV), human herpes simplex 
virus (HSV-2), cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and human herpesvirus 8 (HHV-8) 
have been identified in prostatic tissue15, 209, 314, 328-332. Studies have hypothesized that the presence of 
infectious agents in the prostate may elicit an inflammatory immune response that leads to prostate 
cancer314, 315, 321. This link between prostate cancer and inflammation has been supported by 
epidemiological studies that have observed lower prostate cancer risk among users of anti-inflammatory 
agents, such as aspirin314, 317-320.  
Among HHV-8 infected individuals, HHV-8 may contribute to the inflammatory process in the 
prostate. HHV-8 has been shown to infect prostatic epithelial cells15. The expression of HHV-8 proteins 
(LANA-1, vIL-6, and K8.1), as well as evidence of local inflammation (macrophage/monocyte marker 
and B-cell marker), have been found in the prostate16. Therefore, the presence of HHV-8 DNA and 
proteins in the prostate may contribute to the development of prostate cancer by injuring prostatic 
epithelial cells, which results in proliferative inflammatory atrophy (PIA)314, 321 that leads to the prostate 
carcinogenesis.  
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In the Caribbean island of Tobago, Hoffman et al. reported an association between HHV-8 and 
prevalent screen-detected prostate cancer among men of African descent (Odds ratio [OR] = 2.24; 95% 
confidence interval [CI], 1.29-3.90)9. In a population where an 11% prostate cancer prevalence rate at 
initial screening was estimated from the population-based longitudinal Tobago Prostate Cancer Screening 
Survey17, examining possible relationships between HHV-8 and prostate cancer may explain the high rate 
of prostate cancer observed in this population. Unlike a previous case-control that examined prevalent 
screen-detected prostate cancer at the baseline visit in the Tobago Prostate Cancer Screening Survey, the 
present study examined the association between HHV-8 seropositivity and screen-detected incident 
prostate cancer at two subsequent visits. Studying possible relationships between HHV-8 seropositivity 
and prostate cancer may shed light on the biological mechanism of HHV-8 as well as a possible risk 
factor for prostate cancer.  
6.3 METHODS 
6.3.1 Study Population 
The Tobago Prostate Cancer Screening Survey is an ongoing population-based longitudinal study 
that is designed to estimate the prevalence and incidence of prostate cancer as well as to study possible 
risk factors for prostate cancer among men >= 40 years of age in Tobago17. This longitudinal study, which 
was initiated in 1997, had three study visits: baseline visit (October 1997 to August 2003), wave 2 visit 
(February 1999 to August 2003), and wave 3 visit (May 2004 to March 2007). At each study visit, 
demographic information, medical history, and possible prostate cancer risk factors were ascertained for 
each study participant by questionnaire. In addition, serum specimens were collected; and, a digital rectal 
examination (DRE) was performed by a Tobago physician. Questionnaires were mailed to the University 
of Pittsburgh, Department of Epidemiology in Pittsburgh, Pennsylvania. Serum specimens were stored in 
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a -20oC freezer at the Tobago Health Studies office in Scarborough, Tobago and later shipped and stored 
in a -80oC freezer at the University of Pittsburgh, Department of Epidemiology. Serum specimens were 
used for serum prostate specific antigen (PSA) testing and detection of HHV-8 antibodies against HHV-8 
lytic antigens. 
To screen for prostate cancer, men who had a serum PSA level of >= 4 ng/mL and/or an 
abnormal DRE were referred to a Tobago physician for prostate biopsy.  According to a standard 
protocol, sextant random prostate biopsies were obtained using a trans-rectal ultrasound and spring-
loaded, disposable, fine bore needles17. The prostate biopsies were stored in formalin and shipped at room 
temperature to the University of Pittsburgh, Department of Epidemiology and were analyzed by 
pathologists at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania. 
At baseline visit, information on a total of 3,380 men was recorded in the survey’s database. Of 
these men, 97% reported to be of African descent. For the present study, the inclusion criteria were men, 
ages 40-81 years, who were prostate cancer-free (no prostate cancer diagnosis by biopsy) at baseline visit, 
had blood collected at baseline visit and at wave 2 and/or wave 3 visits, and signed an informed consent 
approved by the Institutional Review Boards of the Tobago Ministry of Health and Social Services and 
the University of Pittsburgh The controls, known as the sub-cohort (which included men who developed 
prostate cancer at wave 2 or 3 visit), were prostate cancer-free men at the baseline visit. The cases were 
men who had a prostate biopsy-confirmed incident prostate cancer diagnosis at wave 2 visit or wave 3 
visit. . A simple random sample of 501 out of 2,002 men with an available baseline visit serum specimen 
and wave 2 and/or wave 3 visits serum specimens from a total cohort of 2,688 men identified at risk for 
prostate cancer, as described elsewhere (McDonald AC, paper 2), were classified as the sub-cohort (471 
prostate cancer-free men and 30 screen-detected incident prostate cancer cases) from the Tobago Prostate 
Cancer Screening Survey. A total of 116 incident prostate cancer cases was identified in the Tobago 
Prostate Cancer Screening Survey; of these men, 86 were not part of the sub-cohort. Sixty-six and fifty 
men were identified as incident prostate cancer cases at wave 2 visit and wave 3 visit, respectively.  
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6.3.2 Laboratory Methods 
A modified monoclonal enhanced HHV-8 monoclonal antibody-enhanced immunofluorescence 
assay (mIFA) , as described elsewhere13, using the BCBL-1 cells that contain a doxcycline-inducible RTA 
gene368 was used to test serum for antibodies against HHV-8 lytic antigens. A HHV-8 seropositive result 
was indicated by specific fluorescence at a dilution >= 1:100. For each mIFA run, known HHV-8 positive 
and negative sera were included. Also, a serum specimen from each study participant’s study visits was 
tested on the same IFA slide. Each serum specimen was tested in duplicate on separate days.  The mIFA 
slide order of the serum specimens was different on these two testing days. If there were disagreements in 
HHV-8 test results on the two different lab days, a 3rd lab day run was performed to determine the HHV-8 
sero-status of the specimen. Case and control serum specimens were included in each batch. All serum 
specimens that were analyzed by mIFA were assessed microscopically in a blinded fashion by the same 
reader. Laboratory analysis used only frozen serum samples thawed once and never re-frozen. 
6.3.3 Data Analysis 
Pearson’s chi-square, Fisher’s exact, or Mann-Whitney tests were used to examine differences in 
baseline characteristics listed in Table 14 between men included in the sampling scheme in comparison to 
men excluded from the sampling scheme. Also, these tests were used to examine differences in baseline 
characteristics listed in Table 14 and additional studied variables (median years of follow-up, family 
history of prostate cancer, ever diagnosed with cancer, have taken ibuprofen in the past 12 months, have 
taken aspirin in the past 12 months) in the following groups: 1) men with missing and non-missing 
baseline and wave  2 visit and/or wave 3 visit HHV-8 test results in prostate cancer-free men and all 
screen-detected incident prostate cancer cases, 2) screen-detected incident prostate cancer cases in the 
sub-cohort and not in the sub-cohort,  3) and screen-detected incident prostate cancer cases and prostate 
cancer-free men in the sub-cohort.  
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The frequency of HHV-8 seropositivity was examined at each study visit and by the date of 
laboratory analysis (< = April 6, 2008 and > April 6, 2008). This stratification was performed in order to 
examine possible effects from the performance drift manifesting on April 6 as a change in split sample 
test-retest reproducibility. Pearson’s chi-square or Fisher’s exact test was used to determine if there was a 
significant difference in HHV-8 seropositivity between screen-detected incident prostate cancer cases in 
the sub-cohort and screen-detected incident prostate cancer cases not in the sub-cohort and between 
screen-detected incident prostate cancer cases and prostate cancer-free men in the sub-cohort. Age-
specific HHV-8 seropositivity rates were examined at the baseline visit and compared between screen-
detected incident prostate cancer cases in the sub-cohort and screen-detected incident prostate cancer 
cases not in the sub-cohort and between screen-detected incident prostate cancer cases and prostate 
cancer-free men in the sub-cohort.  Logistic regression, adjusted for age (as a continuous variable) and the 
date of laboratory analysis (< = April 6, 2008 and > April 6, 2008), was used to see whether there was a 
difference in baseline HHV-8 seropositivity among prostate cancer-free men and all screen-detected 
incident prostate cancer cases who had blood collected at all study visits (baseline, wave 2, and wave 3 
visits) in comparison to prostate cancer-free men and all screen-detected incident prostate cancer cases 
who had blood collected at only two study visits (baseline and wave 2 visits, baseline and wave 3 visits).   
Markers of prostate cancer (abnormal DRE and serum PSA level >= 4 ng/mL) and HHV-8 
seropositivity were examined and compared between screen-detected incident prostate cancer cases not in 
the sub-cohort and screen-detected incident prostate cancer cases in the sub-cohort and between screen-
detected incident prostate cancer cases and prostate cancer-free men in the sub-cohort at each study visit. 
Fisher’s exact test was used to determine whether there was a difference in HHV-8 seropositivity in these 
two comparison groups. 
Cox proportional hazards modeling for the case-cohort design, the un-weighted method369, was 
used to calculate relative risks (Hazard ratios [H.R.]) in order to examine the following associations: 1) 
the association between baseline HHV-8 seropositivity and screen-detected incident prostate cancer, 
adjusted for age (as a continuous variable) and adjusted for age (as a continuous variable) and baseline 
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screening results (serum PSA >= 4 ng/mL or abnormal DRE results in comparison to normal serum PSA, 
normal DRE results, or no screening results); 2) the association between baseline HHV-8 seropositivity 
and screen-detected incident prostate cancer in baseline screen-negative men, adjusted for age (as a 
continuous variable); and, 3)  the association between baseline HHV-8 seropositivity and screen-detected 
incident prostate cancer diagnosed at wave 2 visit and wave 3 visit, separately, adjusted for age (as a 
continuous variable) and baseline screening results. 
Stratified analyses were conducted using Cox proportional hazards modeling for the case-cohort 
design to examine the following associations between baseline HHV-8 seropositivity and screen-detected 
incident prostate cancer, adjusted for age (as a continuous variable): 1) baseline screening results (serum 
PSA >= 4 ng/mL or abnormal DRE results [positive] in comparison to normal serum PSA and/or DRE 
results or no screening results [negative]); 2) median age (< the median age in comparison to >= the 
median age); 3) the date of laboratory analysis (< = April 6, 2008 in comparison to > April 6, 2008); and, 
4) benign prostatic hyperplasia (BPH) or prostatitis (have BPH or prostatitis in comparison to do not have 
BPH or prostatitis). For each stratified analysis, an interaction term was examined to determine whether 
there was a significant difference between the two regression models. 
The follow-up time for the screen-detected incident prostate cancer cases was from the date of the 
baseline visit blood collection to the visit blood collection date in which the cancer was diagnosed or 
detected. The follow-up time for the prostate cancer-free men was the date of the baseline visit blood 
collection to the time these men were censored, which was either the time of their last study visit or wave 
3 visit. 
Data analyses were conducted at alpha level 0.05 in SPSS 15.0 for Windows and SAS version 
9.1. 
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6.4 RESULTS 
6.4.1 Baseline Characteristics 
Between Tobago men included in the sampling scheme (n = 2002) in comparison to men 
excluded from the sampling scheme (n = 686), there were significant differences in baseline 
characteristics (Table 14). Men who were not part of the sampling scheme were significantly older in age, 
had higher serum PSA levels, had a higher frequency of abnormal DRE, had a lower frequency of 
married/ever married, and a higher frequency of ever smoking cigarettes > 6 months (p-values < 0.03).  
Of the eligible study population, 81.1% (n = 382/471) prostate cancer-free men in the sub-cohort, 
83.3% screen-detected incident prostate cancer cases in the sub-cohort (n = 25/30), and 75.6% (n = 65/86) 
screen-detected incident prostate cancer cases not in the sub-cohort had a baseline HHV-8 test result and 
wave 2 visit and/or wave 3 visit test results for HHV-8 . When baseline characteristics were compared 
between men with a missing and non-missing baseline and wave 2 visit and/or wave 3 visit HHV-8 test 
results, there were no significant differences between these two groups for most of the baseline 
characteristics listed in Table 20. However, among the screen-detected incident prostate cancer cases who 
had a missing baseline and wave 2 visit and/or wave 3 visit HHV-8 test results, they had more years of 
education and a higher frequency of benign prostatic hyperplasia (BPH) in comparison to men who did 
not have missing HHV-8 test results at these visits (p-values < 0.02). Among the prostate cancer-free men 
who had missing HHV-8 test results at baseline and wave visit 2 and/or wave visit 3, they were older in 
age, had a higher frequency of ever having gonorrhea, and a higher frequency of BPH in comparison to 
their counterparts (p-values < 0.03).  
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Table 20. Baseline Characteristics among Tobago Men, aged 40-81 years, with and without HHV-8 
Test Results 
 Not Tested 
Incident 
Cases (N=26) 
Tested 
Incident 
Cases (N=90) 
P-
valuea 
Not Tested 
Controls 
(N=89) 
Tested 
Controls 
(N=382) 
P-
valueb 
Median Years of 
Follow-up 
3.03 years 
(n=26) 
3.58 years 
(n=90) 
.489 5.13 years 
(n=89) 
5.15 years 
(n=382) 
.857 
Median Age (in 
years) 
60 years 
(N=26) 
60 years 
(n=90) 
.830 57 years 
(n=89) 
51 years 
(n=382) 
.002 
Median Serum PSA 
(ng/mL) 
2.25 ng/mL 
(n=26) 
2.85 ng/mL 
(n=88) 
.769 1.2 ng/mL 
(n=84) 
1.0 ng/mL 
(n=380) 
.289 
Abnormal DRE 33.3% 
(n=8/24) 
28.6% 
(n=24/84) 
.652 16.5% 
(n=13/79) 
13.7% 
(n=46/335) 
.533 
Married/Ever 
Married 
96.2% 
(n=25/26) 
84.4% 
(n=76/90) 
.185 11.2% 
(n=10/89) 
19.2% 
(n=73/381) 
.078 
< 11 years of 
education 
61.5% 
(n=16/26) 
83.3% 
(n=75/90) 
.017 74.2% 
(n=66/89) 
77.6% 
(n=294/379) 
.491 
Family history of 
prostate cancer 
7.7%  
(n=2/26) 
4.8%  
(n=4/84) 
.625 4.8% 
(n=4/83) 
7.7% 
(n=27/350) 
.480 
Ever diagnosed 
with cancer 
0%  
(n=0/26) 
0% 
 (n=0/90) 
------ 0% 
(n=0/86) 
0.3% 
(n=1/380) 
1.00 
Ever had 
Gonorrhea 
26.9% 
(n=7/26) 
14.6% 
(n=13/89) 
.145 29.9% 
(n=26/87) 
17.9% 
(n=66/369) 
.012 
Ever had Syphilis 0%  
(n=0/25) 
3.4%  
(n=3/87) 
1.00 6.0% 
(n=5/83) 
5.2% 
(n=19/366) 
.761 
Prostatitis 
diagnosed 
0%  
(n=0/25) 
0% 
 (n=0/87) 
------ 1.2% 
(n=1/86) 
1.4% 
(n=5/359) 
1.00 
Benign prostatic 
hyperplasia (BPH) 
diagnosis 
32.0% 
(n=8/25) 
11.4% 
(n=10/88) 
.013 11.5% 
(n=10/87) 
5.1% 
(n=19/375) 
.026 
Has taken 
Ibuprofen (in the 
past 12 months) 
11.5% 
(n=3/26) 
5.7%  
(n=5/88) 
.380 5.6% 
(n=5/89) 
5.1% 
(n=19/372) 
.846 
Has taken Aspirin 
(in the past 12 
months) 
19.2% 
(n=5/26) 
11.2% 
(n=10/89)` 
.287 7.9% 
(n=7/89) 
11.6% 
(n=44/378) 
.304 
Smoke cigarettes 
 (> 6 months) 
30.8% 
(n=8/26) 
35.6% 
(n=32/90) 
.651 37.1% 
(n=33/89) 
41.6% 
(n=158/380) 
.437 
Note: PSA = prostate specific antigen, DRE = digital rectal examination, N and n = number of study participants, 
 ---- = p-value not determined, a = the p-value of the comparison between the incident cases groups, b = the p-value 
of the comparison between the controls groups 
 
Among Tobago men who had a baseline HHV-8 test result and wave 2 visit and/or wave 3 visit 
HHV-8 test results, most of the baseline characteristics listed in Table 21 did not differ between screen-
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detected incident prostate cancer cases in the sub-cohort and screen-detected incident prostate cancer 
cases not in the sub-cohort. Screen-detected incident prostate cancer cases in the sub-cohort were older in 
age and had a higher frequency of BPH than screen-detected incident prostate cancer cases not in the sub-
cohort (p-values < 0.03). When these characteristics were compared between screen-detected incident 
prostate cancer cases and prostate cancer-free men in the sub-cohort who had baseline and wave 2 visit 
and/or wave 3 visit HHV-8 test results, screen-detected incident prostate cancer cases had shorter years of 
follow-up time, older in age, had higher serum PSA levels, and had a higher frequency of abnormal DRE 
and BPH diagnosis than prostate cancer-free men (p-values < 0.02); however, these observations were 
expected (Table 21). 
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Table 21. Comparison of Baseline Characteristics among Tobago Men, aged 40-81 years, with 
Baseline and Wave 2 and/or Wave 3 HHV-8 Test Results 
 Incident Cases 
not in Sub-
Cohort (N=65) 
Incident Cases 
in the Sub-
Cohort (N=25) 
Controls in the 
Sub-Cohort 
(N=382) 
P-
valuea 
P-
valueb 
Median Years of 
Follow-up 
3.61 years 
(n=65) 
3.57 years 
(n=25) 
5.15 years 
(n=382) 
.358 .000 
Median Age  
(in years) 
60 years  
(n=65) 
64 years  
(n=25) 
51 years 
(n=382) 
.039 .000 
Median Serum 
PSA (ng/mL) 
3.15 ng/mL 
(n=64) 
2.8 ng/mL 
(n=24) 
1.0 ng/mL 
(n=380) 
.694 .000 
Abnormal DRE 27.4%  
(n=17/62) 
31.8%  
(n=7/22) 
13.7% 
(n=46/335) 
.695 .021 
Married/Ever 
Married 
81.5%  
(n=53/65) 
92.0% 
(n=23/25) 
80.8% 
(n=308/381) 
.334 .283 
< 11 years of 
education 
81.5%  
(n=53/65) 
88.0% 
(n=22/25) 
77.6% 
(n=294/379) 
.545 .317 
Family history of 
prostate cancer 
5.1%  
(n=3/59) 
4.0%  
(n=1/25) 
7.7% 
(n=27/350) 
1.00 1.00 
Ever diagnosed 
with cancer 
0%  
(n=0/65) 
0%  
(n=0/25) 
0.3%  
(n=1/380) 
----- 1.00 
Ever had 
Gonorrhea 
14.1%  
(n=9/64) 
16.0%  
(n=4/25) 
17.9% 
(n=66/369) 
1.00 1.00 
Ever had Syphilis 3.1%  
(n=2/64) 
4.3%  
(n=1/23) 
5.2% 
(n=19/366) 
1.00 1.00 
Prostatitis 
diagnosed 
0%  
(n=0/63) 
0% 
(n=0/24) 
1.4%  
(n=5/359) 
------ 1.00 
Benign prostatic 
hyperplasia (BPH) 
diagnosis 
6.2%  
(n=4/64) 
25.0%  
(n=6/24) 
5.1% 
(n=19/375) 
.022 .000 
Has taken 
Ibuprofen (in the 
past 12 months) 
6.3%  
(n=4/63) 
4.0%  
(n=1/25) 
5.1% 
(n=19/372) 
1.00 1.00 
Has taken Aspirin 
(in the past 12 
months) 
14.1%  
(n=9/64) 
4.0%  
(n=1/25) 
11.6% 
(n=44/378) 
.271 .338 
Smoke cigarettes 
(> 6 months) 
33.8% 
(n=22/65) 
40%  
(n=10/25) 
41.6% 
(n=158/380) 
.585 .877 
Note: PSA = prostate specific antigen, DRE = digital rectal examination, N and n = number of study participants,  
----- = p-value not determined, a = the p-value of the comparison between the incident cases groups, b = the p-value 
of the comparison between the incident cases and the controls in the sub-cohort 
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6.4.2 HHV-8 Seroprevalence 
HHV-8 seroprevalence was 16.8% (95% confidence interval [C.I.],13.2% - 20.9%), 19.3% (95% 
C.I., 14.6% - 24.7%), and 16.9% (95% C.I., 12.9% - 21.4%) among prostate cancer-free men in the sub-
cohort at the baseline visit, wave 2 visit, and wave 3 visit, respectively (Figure 19). For screen-detected 
incident prostate cancer cases in the sub-cohort, HHV-8 seroprevalence was 12.0% (95% C.I., 2.5% - 
31.2%), 9.1% (95% C.I., 1.0% - 29.2%), and 11.1% (95% C.I., 1.3% - 34.7%) at the baseline visit, wave 
2 visit, and wave 3 visit, respectively (Figure 19). HHV-8 seroprevalence was 20% (95% C.I., 11.1% - 
31.8%), 23.1% (95% C.I., 12.5% - 36.8%), 19.6% (95% C.I., 10.2% - 32.4%) in the screen-detected 
incident prostate cancer cases not in the sub-cohort at baseline visit, wave 2 visit, and wave 3 visit, 
respectively (Figure 19). HHV-8 seropositivity among these groups did not differ at any study visit (p-
values > 0.3).  
 
Note: n1 = the number of incident prostate cancer cases not in the sub-cohort, n2 = the number of incident 
prostate cancer cases in the sub-cohort, n3 = the number of prostate cancer-free men (controls) in the sub-
cohort, a = the p-value of the comparison between the incident cases groups, and b = the p-value of the 
comparison between groups in the sub-cohort 
Figure 19. Overall HHV-8 Seropositivity Rates by Prostate Cancer Status for all Study Visits 
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As for age, baseline HHV-8 seropositivity was the following for the prostate cancer-free men in 
the sub-cohort: 6.9% (n = 12/173) in men 40-49 years, 17.0% (n = 18/106) in men 50-59 years, 30.1% (n 
= 22/73) in men 60-69 years, and 40% (n = 12/30) in men 70-81 years (p-value trend = 0.000). For screen-
detected incident prostate cancer men in the sub-cohort, baseline HHV-8 seropositivity by age was the 
following: 0% (n = 0/2) in men 40-49 years, 0% (n = 0/6) in men 50-59 years, 11.1% (n = 1/9) in men 60-
69 years, and 25.0% (n = 2/8) in men 70-81 years (p-value trend = 0.498). Among screen-detected incident 
prostate cancer men not in the sub-cohort, baseline HHV-8 seropositivity by age was the following: 0% (n 
= 0/8) in men 40-49 years, 8.3% (n = 2/24) in men 50-59 years, 40.7% (n = 11/27) in men 60-69 years, 
and 0% (n = 0/6) in men 70-81 years (p-value trend = 0.005). There were no age-specific differences in 
HHV-8 seropositivity between screen-detected incident prostate cancer cases and prostate cancer-free 
men in the sub-cohort  (p-values > 0.4) and between screen-detected incident prostate cancer cases in the 
sub-cohort and screen-detected incident prostate cancer cases not in the sub-cohort (p-values  > 0.2). 
There was also no difference in HHV-8 seropositivity by the date of laboratory analysis (< = 
April 6, 2008 vs > April 6, 2008) for the prostate cancer-free men (p-values > 0.1) and screen-detected 
incident prostate cancer cases in the sub-cohort (p-values > 0.1) and screen-detected incident prostate 
cancer cases not in the sub-cohort at each study visit (p-values > 0.1) (Data not shown). When serum 
collected by study visits (baseline visit and wave 2 visit, baseline visit and wave 3 visit, and all study 
visit) was examined among prostate cancer-free individuals (N = 382), men who had blood collected at all 
study visits had a higher frequency of baseline HHV-8 seropositivity (21.9%) than men who had blood 
collected at baseline and wave 2 visit only (14.5%) and baseline and wave 3 visit only (10.2%) (p-value = 
0.020) (Table 22). As for screen-detected incident prostate cancer cases (N = 90), men who had blood 
collected at all study visits had a lower baseline HHV-8 seropositivity (15.5%) in comparison to men who 
had blood collected at only two study visits (18.8% and 25%); however, there was no significant 
difference among these groups (p-value = 0.676). After adjusting for age, the date of laboratory analysis, 
and prostate cancer status, there was no significant difference between baseline HHV-8 seropositivity and 
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the number of study visits blood was collected; however, this relationship was borderline non-significant 
(p-value = 0.088) (Table 22).  
Table 22. The Association between the Number of Study Visits Blood Collected and Baseline HHV-8 
Seropositivity among Tobago Men 
 4Percentage of 
HHV-8 
Seropositivity 
in Controls 
5Percentage of 
HHV-8 
Seropositivity 
in Cases 
1Unadjusted 
Odds Ratio 
(95% 
confidence 
interval) 
2Age-adjusted 
Odds Ratio 
(95% 
confidence 
interval) 
3Age-, Lab-, 
Prostate 
cancer - 
adjusted 
Odds Ratio 
(95% 
confidence 
interval) 
Baseline 
and Visit 2 
Only 
14.5%  
(n=9/62) 
25%  
(n=4/16) 
.780  
(.399 – 1.525) 
.611  
(.302 – 1.234) 
.621  
(.307 – 1.257) 
Baseline 
and Visit 3 
Only 
10.2% 
(n=12/128) 
18.8%  
(n=3/16) 
.488  
(.267 - .892) 
.523  
(.281 - .972) 
.527  
(.283 - .981) 
All Study 
Visits 
21.9% 
(n=42/192) 
15.5% (n=9/58) Reference Reference Reference 
Note: 1Wald’s p-value = 0.065, 2Wald’s p-value = 0.080, 3Wald’s p-value = 0.088, 4Pearson chi-square p-value = 
.020, 5Pearson chi-square p-value = 0.676, n = the number of study participants, age is continuous, and lab-
adjusted (<= April 6, 2008 in comparison > April 6, 2008) 
 
As for markers of prostate cancer and HHV-8 seropositivity, there were no significant differences 
in baseline HHV-8 seropositivity with abnormal DRE and serum PSA levels >= 4 ng/mL between screen-
detected incident prostate cancer cases not in the sub-cohort and screen-detected incident prostate cancer 
cases in the sub-cohort at each study visit (p-values > 0.6) (Table 23). There were also no significant 
differences in HHV-8 seropositivity with these prostate cancer markers between screen-detected incident 
prostate cancer cases and prostate cancer-free men in the sub-cohort, except for serum PSA level >= 4 
ng/mL at wave 2 visit. Prostate cancer-free men in the sub-cohort had a significantly higher frequency of 
serum PSA level of >= 4 ng/ mL at wave 2 visit (47.6%) in comparison to screen-detected incident 
prostate cancer cases in the sub-cohort (8.3%) (p-value = 0.027) (Table 23). 
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Table 23. The Comparison between Baseline HHV-8 Seropositivity and Markers of Prostate Cancer 
at Baseline, Wave 2, and Wave 3 Visits among Tobago Men 
 Incident Cases 
not in the Sub-
Cohort (N=65) 
Incident 
Cases in the 
Sub-Cohort 
(N=25) 
Controls in 
the Sub-
Cohort 
(N=382) 
P-valuea P-valueb 
Serum PSA 
>= 4 ng/mL at 
Baseline Visit 
18.2%  
(n=4/22) 
14.3%  
(n=1/7) 
37.5% 
(n=12/32) 
1.000 0.388 
Serum PSA  
>= 4 ng/mL at 
Wave 2 Visit 
19.2%  
(n=5/26) 
8.3% 
(n=1/12) 
47.6% 
(n=10/21) 
0.643 0.027 
Serum PSA 
>= 4 ng/mL at 
Wave 3 Visit 
28.6%  
(n=6/21) 
25.0%  
(n=2/8) 
21.4% 
(n=6/28) 
1.000 1.000 
Abnormal 
DRE at 
Baseline Visit 
23.5%  
(n=4/17) 
14.3%  
(n=1/7) 
23.9% 
(n=11/46) 
1.000 1.000 
Abnormal 
DRE at Wave 
2 Visit 
30.8% 
(n=4/13) 
22.2% 
(n=2/9) 
38.7% 
(n=12/31) 
1.000 0.453 
Abnormal 
DRE at Wave 
3 Visit 
18.5%  
(n=5/27) 
16.7%  
(n=1/6) 
35.5% 
(n=11/31) 
1.000 0.641 
Note: PSA = prostate specific antigen, DRE = digital rectal examination, N and n = number of study participants,  
----- = p-value not determined, a = the p-value of the comparison between the incident cases groups, and b = the p-
value of the comparison between the incident cases and the controls in the sub-cohort  
 
6.4.3 The Association between Baseline HHV-8 Seropositivity and Screen-Detected 
Incident Prostate Cancer 
There was an inverse but not significant association between baseline HHV-8 seropositivity and 
screen-detected incident prostate cancer, after adjusting for age (as a continuous variable) (H.R. = 0.517, 
95% C.I., 0.262 – 1.020) (Table 24). When the regression model was adjusted for age (as a continous 
variable) and baseline prostate cancer screening results (serum PSA >= 4 ng/mL or abnormal DRE results 
in comparison to normal serum PSA, normal DRE results, or no screening results), there was a significant 
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inverse association between baseline HHV-8 seropositivity and screen-detected incident prostate cancer 
(H.R. = 0.454, 95% C.I., 0.221 – 0.933) (Table 24). However, when the regression model (HHV-8 
seropositivity and screen-detected incident prostate cancer) was restricted to baseline screen-negative men 
(comparing 46 incident prostate cancer cases [13 sub-cohort members] and 288 controls), adjusted for age 
(as a continuous variable), a non-significant inverse association was found between baseline HHV-8 
seropositivity and screen-detected incident prostate cancer (H.R. = 0.547, 95% C.I., 0.213 – 1.403) (Table 
24). Inverse but not significant associations were also found between baseline HHV-8 seropositivity and 
screen-detected incident prostate cancer diagnosed at wave 2 visit (H.R. = 0.585, 95% C.I., 0.254 – 1.348) 
and wave 3 visit (H.R. = 0.373, 95% C.I., 0.131 – 1.062), after adjusting for age (as a continuous 
variable) (Table 24).  
Table 24.  The Association between Baseline HHV-8 Seropositivity and Incident Prostate Cancer 
   Yes Yes Yes No Case 
   No Yes All Yes Sub-
cohort 
 H.R. 95% 
C.I. 
N N N N  
Age-
adjusteda 
0.517 0.262 – 
1.020 
65 25 90 407  
Baseline 
screening 
resultsb,c 
0.454 0.221 – 
0.933 
65 25 90 407  
Incident 
at Wave 
2 Visitc 
0.585 0.254 – 
1.348 
65 25 90 407  
Incident 
at Wave 
3 Visitc 
0.373 0.131 – 
1.062 
65 25 90 407  
Baseline 
screen-
negative 
menc 
0.547 0.213 – 
1.403 
65 25 90 407  
Note: H.R. = hazard ratio, C.I. = confidence interval, N= # of study participants, a = age is continuous, b = serum 
prostate specific antigen (PSA) > = 4 ng/mL or abnormal digital rectal examination (DRE) in comparison to 
normal serum PSA, normal DRE results, or no screening results, c = age (continuous)-adjusted 
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In stratified analyses, there were inverse associations between baseline HHV-8 seropositivity and 
screen-detected incident prostate cancer with baseline screening results (positive and negative), age (< 55 
years and >= 55 years), the date of laboratory analysis (< = April 6, 2008 and > April 6, 2008), and BPH 
or prostatitis diagnosis (yes and no) (Table 25). Significant associations between baseline HHV-8 
seropositivity and screen-detected incident prostate cancer, controlling for age (as a continuous variable), 
were found among Tobago men >= 55 years of age (H.R. = 0.503, 95% C.I., 0.256 – 0.986) and the date 
of laboratory analysis after April 6, 2008 (H.R. = 0.281, 95% C.I., 0.097 – 0.810). There were no 
significant differences between the regression models in each stratified analysis (p-values interaction > 0.1) 
(Table 25). 
Table 25. The Association between Baseline HHV-8 Seropositivity and Incident Prostate Cancer 
based on Stratified Analysis 
   Yes Yes Yes No Case  
   No Yes All Yes Sub-
cohort 
 
 H.R. 95% C.I. N N N N  P-value 
(interaction) 
Baseline 
Screening 
Resultse 
       0.5192 
Positivea 0.449 0.172 – 1.175 31 11 42 81   
Negativeb 0.524 0.204 – 1.348 34 14 48 326   
Agec,e        0.3737 
<55 years 0.660 0.128 – 3.400 17 4 21 244   
>= 55 years 0.503 0.256 – 0.986 48 21 69 163   
Lab dated,e        0.1319 
<= April 6 0.866 0.348 – 2.156 36 13 49 210   
> April 6 0.281 0.097 – 0.810 29 12 41 197   
BPH or 
prostatitis 
diagnosise 
       0.3722 
Yes 0.226 0.028 – 1.848 4 6 10 25   
No 0.564 0.274 – 1.165 61 19 80 382   
Note: H.R. = hazard ratio, C.I. = confidence interval, N= # of study participants, BPH= benign prostatic 
hyperplasia, a = serum prostate specific antigen (PSA) > = 4 ng/mL or abnormal digital rectal examination (DRE), b 
= normal serum PSA, normal DRE results, or no screening results, c = categorized by median age, and d = the date 
of laboratory analysis, e = age-adjusted (as a continuous variable) 
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6.5 DISCUSSION 
In the present study, inverse but not significant associations were found between baseline HHV-8 
seropositivity and screen-detected incident prostate cancer, after adjusting for age (as a continuous 
variable). However, there was a significant inverse association between baseline HHV-8 seropositivity 
and screen-detected incident prostate cancer when age (as a continuous variable) and prostate cancer 
baseline screening results were considered. Also, significant inverse associations were found among 
Tobago men age >= 55 years (adjusted for continuous age) and the date of laboratory analysis conducted 
after April 6, 2008 (adjusted for continuous age). These inverse associations between HHV-8 
seropositivity and prostate cancer are consistent with other studies that have examined the relationship 
between prostate cancer and HHV-8 infection in U.S. populations, which included African-American 
men345, 347.  
At each study visit, there was no significant difference in HHV-8 seropositivity between screen-
detected incident prostate cancer cases not in the sub-cohort and screen-detected incident prostate cancer 
cases in the sub-cohort and between screen-detected incident prostate cancer cases and prostate cancer-
free men in the sub-cohort. Studies that examined the relationship between prostate cancer and HHV-8 
seropositivity also found no significant difference in HHV-8 seropositivity between men with and without 
prostate cancer345-347. In fact, lower HHV-8 seropositivity rates have been reported for the prostate cancer 
cases rather than for their controls. For example, 17.1% and 19.0% HHV-8 seropositivity were found 
among African-American men with benign prostatic hyperplasia and prostate cancer, respectively, in the 
Washington, D.C. area345. Among these men, there was no significant association between HHV-8 
seropositivity and prostate cancer (O.R. = 0.88, 95% C.I., 0.35 – 2.24)345. A similar pattern of HHV-8 
seropositivity was observed in African-American and White American men with and without prostate 
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cancer that were from four U.S. areas (Georgia, New Jersey, Detroit, and Washington D.C): 17.5% 
(cases) and 27.5% (controls) seropositivity in African-American men, and 18.7% (cases) and 24.4% 
(controls) seropositivity in White American men345. In this U.S. population-based case-control study, 
inverse but not significant associations between prostate cancer and HHV-8 seropositivity were found for 
both African-American (O.R. = 0.56, 95% C.I., 0.28 – 1.14) and White American men (O.R. = 0.71, 95% 
C.I., 0.36 – 1.43) 345. However, among men in the Pittsburgh, Pennsylvania area, a positive but not 
significant association was found between HHV-8 seropositivity and prostate cancer (O.R. = 1.65; 95% 
C.I., 0.77 – 3.54), with a seropositivity of 20% in cases and 13% in controls9. In addition, a positive but 
not significant association between HHV-8 seropositivity and prostate cancer was found among Italian 
men in the Bologna region (O.R. = 1.08, 95% C.I., 0.27 – 4.33), with a seropositivity rate of 40% and 
38.2% in prostate cancer men and benign prostatic hyperplasia men, respectively345. The reason for the 
difference in the positive but not significant association among Pittsburgh and Italian men from the 
Bologna region may be due to regional differences in HHV-8 seropositivity345. All of these prostate 
cancer/HHV-8 seropositivity studies used the same serological assay, mIFA, used in the present study13. 
Therefore, the reason for the patterns of lower seropositivity among prostate cancer cases compared to the 
controls in U.S. populations remains unclear. 
Despite the non-significant associations found in several study populations, a nested case-control 
study conducted among men in the U.S. Health Professional Follow-up Study found a significant inverse 
association between prostate cancer and HHV-8 seropositivity (O.R. = 0.70, 95% C.I., 0.52 – 0.95), with 
seropositivity of 13.5% and 18% for the cases and controls, respectively347. Sutcliffe et al. stated that their 
cases were composed of early stage disease347. For the present study, stages of prostate cancer were not 
collected unless radical prostatectomy was performed; however, majority of the screen-detected incident 
prostate cancers had a Gleason score of 6 and 7 (94.4%) which was the majority in Hoffman et al. study. 
Therefore, there may be differences between incident and prevalent prostate cancer that affect HHV-8 
seropositivity; however, these differences are unknown.   
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In the present study, screen-detected incident prostate cancer cases and prostate-cancer free men 
had lower HHV-8 seropositivity rates at each study visit in comparison to Hoffman et al. cases and age-
matched controls, respectively, at baseline visit. Hoffman et al. study found HHV-8 seropositivity rates of 
39.9% and 22.9% in the cases and controls, respectively9. In the present study, HHV-8 seropositivity was 
< 24% for the cases and < 20% for the controls at each study visit. One possible reason for these 
seropositivity differences may be that cases and controls in Hoffman et al. study were older men, mean 
age of 67 years, opposed to the cases and controls in the present study, mean age of 61 and 53 years, 
respectively. Studies have shown a relationship between HHV-8 seropositivity and age, in which 
seropositivity increases with age3, 5, 138, 145, 146, 153, 157. Even though the present study population was 
younger than Hoffman et. al cases and controls, HHV-8 seropositivity was shown to increase from 6.9% 
in 40-49 year olds to 40% in 70-81 year old prostate cancer-free men at baseline visit; this pattern of 
increase was also seen in screen-detected incident prostate cancer men. This increase in HHV-8 
seropositivity may be due to factors related to cumulative exposure to the virus, sexually or non-sexually; 
however, in Tobago, these factors are not yet known. As for other studies that have investigated the 
relationship between HHV-8 seropositivity and prostate cancer, seropositivity by increasing age was not 
examined.  
The inverse associations between screen-detected incident prostate cancer and HHV-8 
seropositivity in this present study were different from the results Hoffman et al. found with screen-
detected prevalent prostate cancer men and HHV-8 seropositivity (O.R. = 2.24; 95% C.I., 1.29-3.90) in 
Tobago9. A possible reason for this difference may be due to the selection of the study participants. The 
cases in Hoffman et al. study were screen-detected prevalent prostate cancer men at baseline visit. In the 
present study, the cases were men who had a screen-detected prostate cancer at a subsequent study visit 
from the baseline visit. Therefore, the cases in the present study were considered prostate cancer-free at 
baseline visit opposed to the cases in Hoffman et al. study. In addition, there was no significant difference 
in HHV-8 seropositivity between the incident and prostate cancer-free men at any study visit in the 
present study. A possible explanation for the lack of difference in HHV-8 seropositivity between incident 
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prostate cancer cases and prostate cancer-free men could be due to the difference in how the BCBL-1 
cells were prepared in the present study in comparison to Hoffman et al study. In the present study, the 
BCBL-1 cells contained a doxcycline-inducible RTA gene368 which was used for the purpose of reducing 
background on the mIFA slides when they were read. However, in Hoffman et al. study, this inducible 
gene was not used. Therefore, the introduction of this gene may have affected the sensitivity of the assay. 
Another possible reason for the lack of difference in HHV-8 seropositivity between the incident and 
prostate cancer-free men could be that the incident prostate cancer men were different from the prevalent 
prostate cancer men; and therefore, HHV-8 seropositivity may not be related to prostate cancer incidence. 
For the prevalent prostate cancer cases, chronic inflammation induced by the cancer may reactivate HHV-
8, therefore, increasing their likelihood of being HHV-8 seropositive in contrast to the incident prostate 
cancer cases. Therefore, HHV-8 may not be the factor that causes chronic inflammation that leads to the 
development of prostate cancer in Tobago men of African descent. Also, HHV-8 may cause an increase in 
serum PSA levels in a subject of men, therefore, improving the detection of prostate cancer at baseline 
screening. This improvement may explain why there was a positive association between screen-detected 
prevalent prostate cancer men and HHV-8 seropositivity in Hoffman et al. study opposed to the findings 
in the present study among screen-detected incident prostate cancer men. 
The examination of HHV-8 seropositivity up to a 9-year period provided important information 
on the relationship between screen-detected incident prostate cancer and HHV-8 infection in Tobago. 
However, there were some limitations in the present study. First, the incident prostate cancer men were 
screen-detected based on a serum PSA level of >= 4 ng/mL and/or an abnormal DRE. A study conducted 
among men in the Prostate Cancer Prevention Trial discovered that 15% of the men who had a serum 
PSA < = 4 ng/mL had a screen-detected prostate cancer252. In the present study, men who had a serum 
PSA < 4 ng/mL did not receive a prostate biopsy unless they had an abnormal DRE; therefore, prostate 
cancers identified at serum PSA < 4 ng/mL were missed in this group of men. A second limitation was 
that one study participant did not have a prostate cancer screening at baseline visit. This individual, 
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diagnosed with incident prostate cancer at wave 2 visit, may have had prostate cancer at baseline visit; 
therefore, misclassification of incident prostate status may have occurred for this individual. 
The variability of the serological assay used to test the participants’ serum for HHV-8 
seropositivity may be another limitation to the study. To examine this variability, participants’ serum 
specimens were tested on 2 different days in a blinded fashion. In the present study, stratified analysis by 
the laboratory date was used to compare days in which a consistent kappa statistic of > 0.85 was observed 
(before and on April 6, 2008) in comparison to days in which the kappa statistic ranged from 0.54 to 1.00 
(after April 6, 2008). Based on the stratified analysis, there was no significant difference in HHV-8 
seropositivity by the laboratory date.  A fourth limitation was that levels of HHV-8 antibody titers were 
not examined on HHV-8 seropositive men. HHV-8 antibody titers would have provided information on 
whether HHV-8 reactivation had occurred among Tobago men and whether this activity was responsible 
for the persistent seropositivity levels observed in this population.  
Another limitation in the present study was that the study participants in the Tobago Prostate 
Cancer Screening Study did not participate in all study visits and some men were excluded due to missing 
HHV-8 test results. Even though baseline and wave 2 visit and/or wave 3 visit serum specimens were 
available for 81.1%, 83.3%, and 75.6% of the prostate cancer-free men, screen-detected incident prostate 
cancer men in the sub-cohort, and screen-detected incident prostate cancer men not in the sub-cohort, 
respectively, men who were not part of the study due to missing HHV-8 test results were different. The 
prostate cancer-free men had significantly higher frequency of gonorrhea diagnosis and BPH diagnosis as 
well as a higher median age. The screen-detected incident prostate cancer men (all incident cases in the 
study) had a higher frequency of BPH diagnosis and they were more educated. As a result of these 
differences between men with missing and non-missing serum specimens, selection bias may have been 
introduced. And finally, based on a 2-sample binomial proportion (2-sided, alpha = 0.05), the present 
study did not have adequate power (2.66%) to observe a true difference in baseline HHV-8 seropositivity 
between prostate cancer-free men (16.8%, n = 382) and incident prostate cancer men (17.8%, n = 90). 
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The small sample size in the present study may explain the lack of significant seropositivity difference 
between screen-detected incident prostate cancer and prostate cancer-free men in Tobago. 
In this up to 9-year, population-based study among Tobago men of African descent, there were 
significant and not significant inverse associations between HHV-8 seropositivity and screen-detected 
incident prostate cancer, after adjusting  for  continuous age and baseline screening results and continuous 
age only, respectively. These inverse associations may suggest that HHV-8 seropositivity may not be 
related to prostate cancer incidence. Further studies are needed to investigate the difference in the 
relationship with HHV-8 seropositivity between screen-detected incident prostate cancer and screen-
detected prevalent prostate cancer among men of African descent in Tobago. 
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7.0  SUMMARY/CONCLUSION 
Human herpesvirus 8 (HHV-8) is widespread, geographically, with seroprevalence ranging from 
0.2% in Japan172 to 87% in Botswana, Sub-Saharan Africa2. HHV-8 has sexual and non-sexual modes of 
transmission in which all ages are affected by this virus. Because of its tropism to B cells, HHV-8 is the 
causal agent of B cell lymphomas like Kaposi’s sarcoma and primary effusion lymphoma and is 
associated with multicentric Castleman’s disease, in which these lymphoproliferative disorders usually 
develop in immunocompromised individuals. In addition, HHV-8 has been identified in prostatic 
epithelial cells; and, its DNA and protein expressions have also been identified in prostatic tissue15, 16, 332. 
In the Caribbean island of Tobago, a case-control study conducted among African-Caribbean men found 
prostate cancer to be associated with HHV-8 seropositivity, 39.9% and 22.9% in men with and without 
prostate cancer, respectively (O.R. = 2.24; 95% C.I,1.29-3.90)17. In a population where 11% prostate 
cancer prevalence was detected at initial screening9, this significant finding prompted an investigation to 
understand the relationship between HHV-8 and prostate cancer in Tobago. Therefore, examining HHV-8 
seropositivity among Tobago women, identifying possible modes of sexual transmission of HHV-8, 
studying the natural history of HHV-8 seropositivity, and investigating the relationship between HHV-8 
and prostate cancer risk were methods used to evaluate HHV-8 infection and its possible relationship with 
prostate cancer in Tobago.  
Three studies were conducted to understand the epidemiology of HHV-8 infection and the 
relationship between HHV-8 seropositivity and prostate cancer. Study 1 “Human Herpesvirus 8 
Seroprevalence among Tobago Women and the Role of Sexual Lifestyle Behavior” was designed to 
provide information on things not known in relation to HHV-8 seropositivity in Tobago, such as HHV-8 
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seropositivity among presumably healthy Tobago women, possible sexual modes of HHV-8 transmission 
among the women, and HHV-8 seropositivity differences between Tobago men and women of similar 
ages. Study 2 “The Natural History of Human Herpesvirus 8 Seropositivity in a Cohort of Tobago Men of 
African Descent, 1997-2007” was designed to study the patterns of change in HHV-8 sero-status over a 9-
year period among Tobago men at risk for prostate cancer, and to see whether HHV-8 seropositivity is 
persistent among HHV-8 seropositive men over this time period. Finally, Study 3 “Human Herpesvirus 8 
Seropositivity in Relation to Incident Prostate Cancer among Men of African Descent in Tobago” was 
designed to determine whether baseline HHV-8 seropositivity among men who were not screened-
positive for prostate cancer at baseline visit was associated with incident prostate cancer. These three 
studies allowed the evaluation of HHV-8 infection and its relationship to prostate cancer risk in Tobago. 
7.1 THE SEROPREVALENCE OF HHV-8 IN TOBAGO 
From these three studies, HHV-8 seroprevalence was the following at baseline: 14.1% among 213 
Tobago women, ages 18-65 years; 14.8% among 122 Tobago women, ages 40-65 years; 20.8% among 
159 Tobago men (controls in Hoffman et al.), ages 40-65 years; 16.5% among 407 Tobago men, ages 40-
81 years, at risk for incident prostate cancer; 16.8% among 383 Tobago men, ages 40-81 years, who were 
prostate cancer-free in the 9-year cohort; and, 17.8% among 90 men, ages 40-81 years, who developed 
prostate cancer (incident prostate cancer) in the 9-year cohort. These HHV-8 seropositivity rates were 
similar between genders and across study groups. However, the women had a lower HHV-8 seropositivity 
rate than the men. A possible reason for this gender difference could be that men have different sexual 
behaviors that increase their risk for acquiring HHV-8 infection. As shown in Study 1, this gender 
difference was not significant which this lack of difference in HHV-8 seropositivity is consistent to 
studies conducted in Sub-Saharan Africa3, Italy144, and the United States166.  
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The frequencies of HHV-8 seropositivity observed in Study 1, 2, and 3 were comparable to HHV-
8 seropositivity reported in the Mediterranean6, 7, 143, a region where KS, in particular classic KS, is 
common. As for Tobago, no cases of KS have been reported since the establishment of the cancer registry 
in 199410, 11. The lack of KS in a population that has moderate levels of HHV-8 seropositivity is puzzling. 
However, factors such as genetic make-up that prevents disease development/progression to clinical 
stage, diet, immune status, under-reporting of cases to health officials, or small sample size may explain 
the lack of KS cases reported in Tobago. 
In Study 3, screened-detected incident and prostate-cancer free men had lower HHV-8 
seropositivity levels at all study visits in comparison to Hoffman et al. cases and age-matched controls at 
baseline visit, respectively. In Hoffman et al. study, HHV-8 seropositivity of 39.9% and 22.9% was found 
among the cases and controls, respectively9. In Study 3, HHV-8 seropositivity was < 24% for the cases 
and < 20% for the controls at each study visit. One possible reason for these seropositivity differences is 
that the cases and controls in Hoffman et al. study were older men, mean age of 67 years, opposed to the 
cases and controls in the present study, mean age of 61 and 53 years, respectively. 
Studies have shown that HHV-8 seropositivity increases with age3, 5, 138, 145, 146, 153, 157. In all three 
studies, HHV-8 seropositivity increased with age. For example, in Study 1, HHV-8 seropositivity 
increased from 10.6% in women ages 30-39 years to 20.0% in women ages 60-65 years. As for women 
ages 18-29 years, a higher frequency of seropositivity (16.3%) was observed in comparison to women 
ages 30-49 years; this difference in seropositivity could be due to a cohort effect in which the younger 
women may have participated in activities (sexually or non-sexually) that increased their risk of acquiring 
HHV-8 infection. However, women ages 40-65 years had a higher antibody titer than the women < 40 
years of age. This higher antibody titer in the older women may be due to cumulative exposure to the 
virus or higher rates of HHV-8 reactivation. 
Among Tobago men, a similar increase in HHV-8 seropositivity was observed. In Study 1, HHV-
8 seropositivity increased in men who were the prostate cancer controls in Hoffman et al. study, from 
17.6% in men ages 40-49 years to 23% in men ages 60-65 years. In Study 2, among Tobago men at risk 
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for incident prostate cancer, HHV-8 seropositivity increased from 6.9% in men ages 40-49 years to 36.8% 
in men ages 70-81 years. As for Study 3, a similar pattern was seen when the men in Study 2 were 
examined by prostate cancer status: 6.9% to 40% in prostate cancer-free men ages 40-49 years and 70-81 
years, respectively, and 0% to 33.3% in screen-detected incident prostate cancer men (all incident cases) 
ages 40-49 years and 60-69 years, respectively. As for screen-detected incident prostate cancer men ages 
70-81 years, HHV-8 seropositivity of  14.3% was found; the reason for the lower seropositivity in 
comparison to men ages 60-69 years was probably due to the small sample size (n = 2/12) in this age 
group. In summary, higher HHV-8 seropositivity with increasing age again suggests that cumulative 
exposure to the virus, sexually or non-sexually, is occurring in the Tobago population. 
Study 2 demonstrated that HHV-8 seropositivity was persistent over time. In this study, HHV-8 
seropositivity was 16.5%, 18.5%, and 16.6% at baseline, wave 2, and wave 3 visits, respectively, among 
Tobago men at risk for incident prostate cancer. Among HHV-8 seropositive men, 88.1% remained 
seropositive from baseline visit to wave 2 and/or wave 3 visits. However, HHV-8 seroreversion (11.9%) 
did occur in this population. These seroreversions were probably attributed to low antibody titers at 
baseline visit that became undetectable by the serological assay, mIFA, at subsequent study visits. These 
moderate levels of HHV-8 seroreversion indicate that a more sensitive assay is needed for the detection of 
antibodies against HHV-8 antigens in populations. 
7.2 TRANSMISSION OF HHV-8 IN TOBAGO 
In Study 1, a minimal significant association between HHV-8 sero-status and age at first sexual 
intercourse was found among Tobago women. Tobago women who reported to have their first sexual 
intercourse at < 17 years of age were 2.51-folds more likely (95% C.I., 1.09-5.78)  to be HHV-8 
seropositive than women who reported to have their first sexual intercourse at > 18 years of age.  The 
minimal significant association between HHV-8 seropositivity and age at first sexual intercourse reported 
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suggests that sexual activity may not be a major contributor in acquiring HHV-8 infection. Plus, in Study 
1, several variables that assess sexual lifestyle behaviors were not associated with HHV-8 sero-status 
among the women. In addition, the detection of HPV DNA in oral or cervical cavity was not associated 
with HHV-8 seropositivity. The lack of associations between seropositivity and several sexual behavior 
variables may indicate that non-sexual transmission of HHV-8 may be a possible mode in acquiring this 
viral infection; however, evidence of this transmission remains not known. 
As for Tobago men, sexual lifestyle behaviors were not collected in the Tobago Prostate Cancer 
Screening Study. This lack of information was a limitation in understanding routes of sexual transmission 
of HHV-8 among Tobago men. Information on whether one has ever been diagnosed with gonorrhea or 
syphilis was collected in the Tobago Prostate Cancer Screening Study. In Study 2, the frequencies of 
gonorrhea and syphilis diagnosis at baseline visit were examined and compared between HHV-8 
seropositive and seronegative men at risk for incident prostate cancer. There were no differences in the 
frequencies of these STDs between these 2 groups. Examining STDs in HHV-8 seropositive men in 
comparison to HHV-8 seronegative men was one way Study 2 tried to assess whether sexual behavior 
was related to HHV-8 seropositivity. However, the lack of difference in the diagnosis of these STDs 
between HHV-8 seropositive and seronegative men did not provide information on whether sexual 
activity was one way of acquiring this viral infection in Tobago.  
In Study 2, low HHV-8 seroconversion (0.50 per 100 person-years) was observed among Tobago 
men, ages 40-81 years, at risk for incident prostate cancer. There was no significant difference in STDs 
diagnosis such as syphilis and gonorrhea between HHV-8 seroconverters and persistent seronegative men; 
manner of fact, none of the seroconverters reported that they were ever diagnosed with these diseases. 
Therefore, sexual transmission may not be the primary mode of acquiring HHV-8 infection for “HHV-8 
seroconverters” in this study population.  
In summary, evidence on whether sexual or non-sexual activity is the primary mode of HHV-8 
transmission among Tobago men remains to be seen. However, evidence that low seroconversion 
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occurred after the age of 40 years suggests that HHV-8 infection is probably acquired at younger ages, < 
39 years, among Tobago men. 
7.3 HHV-8 AND PROSTATE CANCER IN TOBAGO 
In Study 3, there were inverse associations between HHV-8 seropositivity and screen-detected 
incident prostate cancer when continuous age and baseline screening results (H.R. = 0.454, 95% C.I., 
0.221 – 0.933) and continuous age (H.R. = 0.517, 95% C.I., 0.262–1.020) were considered. These inverse 
associations were consistent with other studies that examined the relationship between prostate cancer and 
HHV-8 infection in U.S. populations345, 347. However, the inverse associations in Study 3 were different 
from the positive association Hoffman et al. found between HHV-8 seropositivity and screen-detected 
prevalent prostate cancer among Tobago men (O.R. = 2.24; 95% C.I., 1.29 - 3.90)9. One reason for this 
difference in association in Tobago may be that screen-detected incident prostate cancer men and screen-
detected prevalent prostate cancer men are different. Therefore, one may hypothesize that HHV-8 
seropositivity does not cause an inflammatory immune response that leads to the development of prostate 
cancer. However, an inflammatory response induced by prevalent prostate cancer may activate HHV-8, 
therefore, increasing men with prevalent prostate cancer likelihood of being HHV-8 seropositive. Also, 
HHV-8 may cause an increase in serum PSA levels in a subject of men, therefore, improving the 
detection of prostate cancer at baseline screening. In summary, HHV-8 may not be the factor that causes 
chronic inflammation that leads to the development of prostate cancer in Tobago men of African descent. 
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7.4 CONCLUSION 
HHV-8 infection is present among women and men of African descent in Tobago, with 
seroprevalence ranging from 14.1% to 20.8% in a presumably healthy population. There was no 
significant difference in HHV-8 seropositivity between Tobago women and men and between prostate 
cancer-free men and screen-detected incident prostate cancer men. Among women, age at 1st sexual 
intercourse was the only sexual lifestyle behavior associated with HHV-8 seropositivity. Therefore, 
sexual transmission may not be the predominate mode of HHV-8 transmission, and that non-sexual 
modes may be a major contributor in HHV-8 transmission among Tobago women. Among Tobago men, 
ages 40-81 years, a low seroconversion rate (incidence of 0.50 per 100 person-years, 95% C.I., 0.22 – 
0.99) was found; this low rate suggests that, HHV-8 is probably acquired before the age of 40 years. A 
moderate seroreversion rate (incidence of 2.52 per 100 person-years, 95% C.I., 1.09 – 4.96) was observed 
among Tobago men, which this rate was probably due to the sensitivity of the serological assay. 
However, a high frequency of persistent HHV-8 seropositivity was observed among HHV-8 seropositive 
men. And finally, there were significant and non-significant associations between HHV-8 seropositivity 
and screen-detected incident prostate cancer after controlling for continuous age and baseline prostate 
cancer screening results and continuous age only, respectively. These inverse associations between HHV-
8 seropositivity and screen-detected incident prostate cancer suggest that HHV-8 seropositivity may not 
be related to prostate cancer incidence. 
In conclusion, further studies are needed 1) to examine possible sexual and non-sexual modes of 
HHV-8 transmission in Tobago, 2) to examine the seroprevalence of HHV-8 among pre-pubertal children 
in Tobago, and 3) to study the relationship between HHV-8 seropositivity and prostate cancer (incident 
and prevalent cases) in Tobago. 
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APPENDIX A: THE PROTOCOL FOR ARRANGEMENT OF TOBAGO SAMPLES ON 
IFA SLIDES FOR HHV-8 AIM 2 (COHORT) AND AIM 3 (SUB-COHORT AND 
INCIDENT CASES) 
1. Alicia needs a list of Tobago serum samples that she will test by IFA in a day. This list will 
include 1) Tobago men at risk for incident prostate cancer, the cohort and sub-cohort (n = 501) 
from wave visit 1 to 3, and 2) men who developed incident prostate cancer, the cases that are not 
a part of the cohort (n = 86) from wave visits 1 to 3. The reason for testing these two study groups 
in an assay run is to reduce possible IFA slide variability between the groups. Since Alicia is 
limited on the number of samples she can test in a day, she will test an equal proportion of these 
two groups per lab run. Therefore, 50 out of 501 Tobago men from the cohort/sub-cohort list (list 
#1) and 8 out of 86 Tobago men from the case list (list #2) will be tested in a lab run. 
2. In order to test the reliability of the IFA results, serum samples will be tested on 2 different days, 
“lab day 1” and “lab day 2”.  However, the order of the serum specimens will be different for 
both days so that the slide reader is blinded to the serum specimen’s results (HHV-8 positive or 
negative). Therefore, Alicia will design two different maps indicating the location of the 58 
sample sets (one set equals all of 1 man’s wave samples) on the IFA slides for “lab day 1” and 
“lab day 2”. “Lab day 2" samples will be placed in a random order on the IFA slides by the 
statistical computer package SAS. An abbreviated study id number and its wave visits will be 
written on these maps for Alicia to have a record on what serum samples are being tested per lab 
run.  
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3. For each map, Tobago men’s samples for the wave visits (Wave 1, 2, and/or 3) will be plated on 
the same slide in order to reduce IFA slide variability among the wave visits; in addition, these 
samples will be placed in random order so that the slide reader is blinded to the order of the wave 
visits on the slides.   
4. For each lab run, this slide order of the specimens will be duplicated (slides A1 and A2 are 
duplicates) so that the slide reader can determine the sero-status of each sample. Also, each slide 
will be given an alphabet label (A1/A2 to ZZ1/ZZ2) so that Alicia will have a record of what 
samples were placed on what slide in a lab run. 
5. Six samples can be tested per slide. Therefore, the number of men per slide (a slide equals 6 rows 
which include 1:50 and 1:100 dilutions) will be the following ones in random order: (A positive 
HHV-8 result is a serum specimen that has a fluorescent at dilutions at 1:50 and 1:100) 
a. 3 men (only have 2 wave samples) per slide 
b. 2 men (have 3 wave samples) per slide 
c. 1 positive control, 1 negative control, and 2 men (only have 2 wave samples) per slide  
d. 1 positive control, 1 negative control, 1 man (have 3 wave samples), and 1 man (only 
have 1 wave, the other wave sample was not found) per slide 
e. 2 men (only have 2 wave samples), 1 man (have 3 wave samples), and 1 man (only have 
1 wave, the other wave sample was not found) per slide 
These sets of random order per slide are aimed at reducing possible IFA slide variability. 
Since a lot of serum specimens will be tested per lab run, at least 3 sets of positive and negative 
controls will be plated per lab run for quality control purposes. 
 
 142 
 
 
6. In order for the slider reader to be blinded to the serum samples’ study id, the sample order from 
the map for each lab run will be given an unique lab id; and, this order will be written on a lab 
result sheet for the slide reader to record the results (HHV-8 positive or negative). The samples 
that were run on “lab day 1” will have a different lab id than the samples run on “lab day 2” for 
blinding purposes. The lab result sheet looks like the following: 
                     Date:  
A1                    1:50    1:100        A2 
1. Positive  
2. Negative  
3. 0001  
4. 0002  
5. 0003  
6. 0004  
 
7. Results from the lab result sheet (HHV-8 positive, negative, or repeat) and its lab run date for 
“lab day 1” and “lab day 2” will be recorded in the HHV-8 Aims 2 and 3 database for data 
analysis. The final HHV-8 sero-status result will be based on 2 lab day runs’ agreement (this is 
the standard protocol requirement for IFA).  
A 1       2       3      4       5     6  
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a. If sample results from both lab day runs agree (day 1: positive, day 2: positive), the final 
HHV-8 sero-status result (positive) will be recorded in the database.  
b. If sample results from both lab day runs disagree (day 1: positive, day 2: negative), that 
sample (all its wave visits) will be repeated after all the samples on the list 1 and list 2 
have been tested. That sample will be recorded as “lab day 3”. The “lab day 3” result will 
determine whether the sample will be recorded positive or negative for the final HHV-8 
sero-status in the database (the majority rules; this action is based on the standard 
protocol of IFA).  
c. If Tobago samples have an R (repeat) written on the slide reader’s result sheet for only 1 
lab day run, that sample (all its wave visits) will be repeated after all the samples on the 
list 1 and list 2 have been tested. That sample will be recorded as “lab day 3”. The “lab 
day 3” result will determine whether the sample will be recorded positive or negative (the 
majority rules; this action is based on the standard protocol of IFA).  
d. For Tobago samples that have discrepant results, Alicia will continue to test these 
samples until 2 lab day runs agree in HHV-8 sero-status (“lab day 4”, “lab day 5”, etc.).  
8. After all Tobago samples from lists 1 and 2 have been tested, antibody titers will be performed on 
Tobago samples that have a final HHV-8 seropositive result in the database. Only positive 
samples will have antibody titers that are detectable by the IFA. 
e. Antibody titers (1:50 to 1:1600) will be performed (lab day 1). Lab results will be 
recorded by 2-folds on samples that are 1:100 to 1:800 dilutions. Samples that are marked 
as 1:1600 dilution may have a higher antibody titer; therefore, these samples will be 
tested again at higher antibody titers on another day. If a sample is not > 1:100 dilution, 
that sample will be marked as HHV-8 negative in database. Samples 1:50 or less are 
marked as HHV-8 negative. 
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f. If samples that have an antibody titer of dilution 1:1600 on lab day 1, antibody titers 
(1:50 to 1:102,400) will be performed on those samples at lab day 2. Lab results will be 
recorded in the database for data analysis. 
9. To ensure reliable data, lab results will be double-entered in Access and then transferred to SPSS 
or SAS; Alicia and another person will enter the data. If the data disagrees, Alicia will examine 
the lab result form and decide the final result in the database. 
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APPENDIX B: THE PROTOCOL FOR PULLING TOBAGO SAMPLES FROM 
FREEZER 
 
Tobago Biological File: > 1 more aliquots 
of sample available 
Go to assigned 
freezer to pull 1st 
aliquot sample 
Aliquot sample is not in 
assigned box in freezer 
 
Aliquot sample is in 
assigned box in freezer 
Check miscellaneous box in 
freezer for aliquot sample 
Aliquot is in 
miscellaneous box 
Aliquot is not in 
miscellaneous box 
 
Pull aliquot 
sample and put in 
new box 
Pull aliquot sample 
and put in new box 
For 1 aliquots of 
sample from Tobago 
biological file 
Go to assigned 
freezer to pull 2nd 
aliquot sample 
(repeat flowchart for 
k aliquots) 
For 2 or more aliquots of 
sample from Tobago 
biological file 
Stop here 
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